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ABSTRACT 
Pancreatic (PC) is the eleventh most common malignancy in the UK but it has the poorest 
prognosis of all human adenocarcinoma.  The autopsy, epidemiological and clinical 
studies have consistently identified PC as one of the most highly angiogenic and invasive 
malignancies, with the greatest prevalence and incidence of thrombo-embolism (TE).  
The incidence of TE in PC has been reported as high as 57%.  Tissue factor (TF) bearing 
microparticles (MP) have recently been shown to promote thrombosis.  The biological link 
between cancer haemostasis, cell invasion and angiogenesis remains unclear.  These 
three indices may be driven by PC cells directly, be a reflection of the individual tumour 
stromal microenvironment and/or a result of the inflammatory response of the host.  The 
hypothesis of the thesis is that factors directly attributed to the cancer promote the 
observed pathophysiology and that the removal of the tumour should result in reversal of 
these abnormalities. 
 
Flow cytometry was used for the evaluation of MP in plasma and quantification of 
surface-expressed TF, VEGFR-1 and-2 and EGFR.  Cellular TF activity and pro-coagulant 
activity (prothrombin time) of PC patients were measured using a coagulometer.  
MatrigelTM Invasion Chambers and Boyden chambers with collagen IV were used to 
measure cellular invasion. A two dimensional angiogenesis assay was used to evaluate 
tubule formation in vitro in response to PC sera.  Relative levels of protein expression of 
55 angiogenic markers in the sera of PC patients were evaluated using a human 
angiogenesis array kit.  Enzyme-linked immunosorbent assay was undertaken on VEGF, 
TF, TFPI, Leptin and annexin autoantibodies using sera or plasma from PC patients as 
appropriate.  Immunohistochemical analysis of key markers of angiogenesis and 
thrombosis was also undertaken on resected PC samples. 
 
The in vitro optimisation experiments revealed that the cell invasion was significantly 
correlated with TF antigen expression and activity on PC cell lines (MIA-PaCa-2, AsPC-1 
and CFPAC1) and that blocking TF on these cells decreased cell invasion.  In the same 
manner neutralising soluble TF in PC serum samples also significantly decreased cell 
invasion, as did spiking of the serum with low molecular weight heparin.  Analysis of sera 
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from patients showed that TF bearing MP, pro-coagulant activity, cell invasion and 
angiogenesis (total length and number of capillaries) of PC cases were significantly higher 
than the control.  Furthermore, the post-operative median number of TF bearing MP, 
procoagulant activity, cell invasion and angiogenesis (total length and total number of 
capillaries) were all significantly lower compared with pre-operative samples.  Out of 55 
angiogenic markers studied in 6 PC patients, pre- and post-operatively there was a 
significant decrease of angiopoietin-1, angiostatin/plasminogen, PDGF-AA, PDGF-
AB/PDGF-BB and VEGF post-operatively.  This result was supported by ELISA analysis of 
29 samples and 14 controls that also showed significantly higher levels of VEGF in 
pancreatic cancer sera versus control groups, and that there was a significant decrease 
observed post-operatively only in the cancer patients.  Furthermore both angiogenesis 
array and ELISA showed increased leptin levels post-operatively.   
 
Immunohistochemical analysis of the pancreatic tissue sections revealed that TF was 
expressed on 62 % of PC samples.  There was significant correlation between TF 
expression on the tissue and procoagulant activity.  Also, there was a significant 
correlation between tissue-expressed TF and in vitro angiogenesis, i.e. total length  and 
number of capillaries.  Furthermore, there was a significant correlation between TF 
expression on tissue with intratumoural microvascular density (MVD) and tumour-
expressed with VEGFR 2.  As expected, high levels of MVD correlated with high levels of 
tissue-expressed VEGF.  Finally serum from patients who showed a high level of tissue-
expressed VEGF also induced the greatest level of in vitro angiogenesis, i.e. number of 
capillaries. 
 
In summary, it was shown that TF expression on cell lines was significantly correlated 
with TF activity and cell invasion, and that TF expression in plasma and on tissue from PC 
patients was significantly correlated with procoagulant activity, cell invasion and 
angiogenesis.  PC tissue-expressed VEGF was significantly associated with the angiogenic 
activity of PC sera and tissue MVD.  Thus, the pathophysiology represented by a high 
procoagulant state, elevated cell invasion and angiogenic properties seen in PC patient 
sera appears to be driven by the malignant cells, as removal of the tumour causes a 
return towards the normal state. 
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CHAPTER ONE: INTRODUCTION 
1.1 Anatomy, Histology and Physiology of the Pancreas 
The pancreas is a relatively large gland about six inches in length, which lies in the superior part 
of the abdomen, just behind the stomach (Fig. 1.1A).  It consists of three parts: head, body and 
tail.  The hormones and digestive juices, which are secreted by the pancreas, flow into the 
duodenum via the pancreatic duct.  The lobular units of acini of the exocrine part of the 
pancreas drain into ducts of increasingly bigger size, and finally collect into the main pancreatic 
duct (Duct of Wirsung), which combines with the common bile duct and ends in the papilla of 
Vater.  Some people have an accessory pancreatic duct which ends in minor duodenal papillae 
(Fig. 1.1B).  Numerous anastomotic communications join the Wirsung and Santorini ducts 
(Delhaye and Cremer, 1992).  
  
 
Figure 1.1 Anatomy of the pancreas (Web reference 1). 
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Histologically, the pancreas consists of two main components: the endocrine and exocrine 
system (Fig. 1.2).  The endocrine portion is known as the Islets of Langerhans and although this 
structure receives 10-15 per cent (%) of the pancreatic blood flow, it comprises only 1-2% of the 
total pancreatic mass (Hoppener et al. 2008).  
 
 
Figure 1.2: Histology of the pancreas.  The endocrine part is indicated by red arrows, the 
exocrine part by orange arrows (x 100).  
 
There are four major types of cells in the Islets of Langerhans, each of which produce different 
endocrine products (Hoppener et al. 2008): 
 
1. Alpha cells produce glucagon which converts stored hepatic glycogen into glucose that is 
then released into the blood stream.  The cells are situated in the periphery of the Islet cells 
and form 15-20 %.  The secretory granules are characterised by an eccentric electron-dense 
core (Brelje et al., 1989). 
2. Beta cells produce insulin, which causes the body’s cells to take up glucose from the blood, 
storing it as glycogen in the liver and muscle and stopping the use of fat as an energy 
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source.  These cells are situated mainly in the centre of the Islet and form 65-80% of the cell 
mass.  The secretory granules typically have a crystalline appearance.   
3. Delta cells produce somatostatin which regulates the endocrine system and affects 
neurotransmission and cell proliferation via interaction with G-protein-coupled somatostatin 
receptors and inhibition of the release of numerous secondary hormones.  These cells are 
spread through the Islets and form 3-10 % of the total Islet cell number.   
4. Pancreatic Polypeptide-Secreting cells produce pancreatic polypeptide, a hormone that 
regulates appetite and food intake.  Pancreatic polypeptide-secreting cells are located at the 
periphery of the Islet cells and form 3-5 % of Islets cells (Hoppener et al., 2008). 
 
The main endocrine functions of the pancreas are mediated by insulin and glucagon which 
regulate blood glucose.  In addition to the hormonal function, the pancreas also secretes 
digestive enzymes such as proteases, amylase and lipase from the exocrine part and therefore 
plays a major role in the digestion of food (Mitropol'Skii, 1966).  Islet cell tumours are called 
pancreatic neuroendocrine tumours.  These tumours are divided into functional (which secrete 
hormones) and non functional.  The most common functional pancreatic neuroendocrine tumour 
is insulinoma which secretes an excess of insulin causing hypoglycaemia (Kimura et al. 2011).   
 
1.2 Prognosis and Mortality of Pancreatic Cancer 
Pancreatic cancer (PC) is the eleventh most common malignancy in the United Kingdom.  The 
male to female ratio is 1.6:1 and 63% of patients are over 70 years (Gold et al., 1985), while 
Jemal et al. (2010) reported the male to female ratio is 0.98:1.  Worldwide, more than 270,000 
people were diagnosed with PC in 2008 and 266,000 people died from this malignancy in the 
same year.  In comparison, 7690 and 7680 PC cases were diagnosed in 2007 and 2008 
respectively in the USA (Jemal et al., 2010).  
 
PC has the poorest prognosis of all adenocarcinoma in the human body (Jemal et al., 2003).  
Although most PC patients die within one year of diagnosis ( Jemal et al., 2010, Hillen, 2000, 
Olsen et al., 1989), recently it has been shown that the five year survival rates differ from one 
country to another: in England in the period of 2001-2006 the rate was 3%, compared with 6% 
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in the USA for a similar time period (1999-2005; Jemal et al., 2010).  Successful surgical removal 
of PC tumours improves five year survival rates, which can reach up to 40% when there is no 
lymph node.  However the five year survival rate drops to 20% when there is lymph node 
metastasis (Yao and Qian, 2010, Lieberman et al., 1995).  Unfortunately, surgical removal of the 
PC can only be performed in 20% of PC cases because of the presence of distant metastasis 
(Hackert et al., 2009).  Furthermore, approximately 30% of PC patients who submitted to the 
surgical removal of the tumour died in the first year following the operation and had the same 
prognosis as those who were treated by anti-tumour therapy alone (Kennedy and Yeo, 2007, 
Burris, 2005).   
 
1.3 Risk Factors of Pancreatic Cancer 
It has been reported that intraductal papillary mucinous neoplasm (IPMN) is a precancerous 
cystic type tumour that grows within the pancreatic ducts (intraductal).  This type of the tumour 
associated with mucinous secretion (Verbeke 2010).  Furthermore, there is a strong relationship 
between PC and tobacco usage, whether by cigarette/cigar smoking or chewing tobacco 
(Ahlgren, 1996).  Carcinogenic materials, in particular nitrosamines, are found in cigarette smoke 
(Potter, 2002).  PC is also increased among people who regularly consume foods containing high 
levels of sugar, fat, large quantities of red meats and low levels of fresh fruit, vegetables and 
vitamin C (Olsen et al., 1989).   
 
Chronic pancreatitis increases the risk of PC, but chronic pancreatitis that is due to alcohol 
consumption does not increase the risk as much as other types of chronic pancreatitis like 
idiopathic pancreatitis and pancreatitis that has been caused by taking steroid and anti-
inflammatory drugs (Kalapothaki et al., 1993).  Moreover, genetic factors may also play a role in 
PC, because some PC occurs more frequently in certain families (Hruban et al., 1998).  Although 
the risk of PC increases among diabetic patients, diabetes mellitus in PC might be the result of 
the cancer rather than the cause (Gullo et al., 1994).   
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1.4 Histopathology of Pancreatic Cancer 
Exocrine tumours are the commonest type of PC and adenocarcinoma represent 90% of exocrine 
PC (Morohoshi et al., 1983).  PC can be classified into three main types (Tanase et al., 2006, 
Yamasaki et al., 2002, Terada et al., 1998): 
1. Low papillary:  This type is characterised by low papillary projections and the lack of a fibro-
muscular core.  It forms about 39% of all PC. 
2. Tubular:  This includes tubular and solid types.  It forms 56% of all PC. 
3. Mixed:  This consists of malignancies containing both low papillary and tubular types and 
composes a maximum of 5%. 
There are three grades of pancreatic carcinoma: well, moderately and poorly differentiated 
(Morohoshi et al., 1983).  The number of intraductal carcinoma foci is correlated with tumour 
grading (Yamasaki et al., 2002).   
Staging of PC depends on Tumour/Node/Metastasis (TNM) classification (Rindi et al., 2006).   
1.4.1 TNM Classification  
T- Tumour:  
T0: Tumour in situ / dysplasia (0.5 cm).       
 T1:Tumour invades lamina properia or subserosa and the size is less than 1 cm.   
 T2:Tumour more than 1 cm in diameter and invades muscularis properia or subserosa.  
 T3:Tumour penetrates serosa.          
 T4:Tumour invades the adjacent structure.  
N-Regional lymph node:  
N0: No involvement of regional lymph nodes.        
 N1: Involvement of regional lymph nodes.  
M-distant metastasis: 
M0: No distant metastasis         
 M1: There is distant metastasis.  
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1.4.2 Staging:  
Stage I = T1 N0 M0           
 Stage IIa=T2 N0 M0           
 Stage IIb =T3 N0 M0          
 Stage IIIa=T4 N0 M0          
 Stage IIIb = any T N1 M0         
 Stage IV = any T any N M1  
 
1.5 Symptoms and Signs of Pancreatic Cancer 
The early symptoms of PC are usually non-specific and are commonly ignored by the patient and 
doctor.  Such symptoms include epigastric discomfort, vomiting, diarrhoea, general malaise and 
flatulence.  The late signs and symptoms include painless jaundice, abdominal pain and weight 
loss (DiMagno, 1999).  The presence of jaundice depends on the location of the tumour, as 
jaundice in patients with body and tail carcinoma tends to be later than the jaundice caused by 
the cancer of the head of the pancreas; the latter is usually associated with inoperability because 
of liver metastasis (Takhar et al, 2004). 
 
1.6 Treatment of Pancreatic Cancer 
Pancreaticoduodenectomy (Fig. 1.3), with or without preservation of the pylorus, is the 
procedure of choice for tumours in the head of the pancreas.  In contrast the most common 
operation for malignant tumours of the tail or body of the pancreas is a distal pancreatectomy 
with splenectomy (Fernandezdelcastillo et al., 1995).   
 
In the Whipple’s operation, described by Allen Whipple in 1935, the head of the pancreas, a 
portion of the bile duct, the gallbladder, the duodenum and occasionally a portion of the stomach 
are all removed (Whipple et al., 1935).  After removal of these structures the remaining 
pancreas, bile duct and the intestine are sutured into the intestine to direct the gastrointestinal 
secretions back into the gut (Rivera et al., 1996, Fernandezdelcastillo et al., 1995).  Biliary 
and/or gastric bypass is recommended in patients with obstructive jaundice. 
. 
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Figure 1.3: Picture showing total pancreatectomy with total duodenectomy,  
splenectomy and cholecystectomy (Hackert et al., 2009). 
 
Chemotherapy is routinely given after a surgical operation (Lillemoe, 1995) and it is 
recommended as a palliative treatment with unresectable tumours.  In the absence of an 
available clinical trial, gemcitabine is the evolving standard treatment (Nakchbandi et al., 2008, 
Fernandezdelcastillo et al., 1995, Lillemoe, 1995) and is used widely in the treatment of PC.  
Gemcitabine has replaced 5-Fluorouracil (5FU) as the preferred drug due to its efficacy and lower 
side effects.  Although the median survival improvement in favour of gemcitabine compared with 
5FU is slight (5.7 vs. 4.4 months), the one-year survival rate is more encouraging (18% vs. 2%), 
and most importantly the toxicity is relatively mild and clinical response has been found to be 
better (24% vs. 5%, respectively) (Burris et al., 1997).  The potential benefit of combining 
gemcitabine with other drugs such as low molecular weight heparin (LMWH) and/or anti-
angiogenic drugs shows a slight improvement in the survival rates.  This will be described later 
(section 1.17).   
 
1.7 Tissue Factor 
Tissue factor (TF), designated cluster of differentiation (CD) -142; thromboplastin or factor III is 
a 47 kilo Dalton (KDa) glycoprotein receptor (Spicer et al., 1987).  In addition to its principal role 
in the initiation of the extrinsic pathway of coagulation (Nemerson, 1988, Paborsky et al., 1989, 
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Gouaulthelimann and Josso, 1979, Fig.1.4), TF also has a major role in angiogenesis, tumour 
growth (Khorana et al. 2007, Rak et al., 2006, Kim et al., 2004, Nemerson, 1988) and 
embryogenesis (Carmeliet et al., 1996).  It has been shown that TF plays an essential role during 
embryo formation as a deficiency of TF in transgenic mice causing death by day 10.5 due to 
impaired vascular function and abnormal development of the yolk sac (Carmeliet et al., 1996).  
 
TF is expressed in a number of vital organs including the brain (meninges and cerebral cortex), 
lung (bronchial mucosa, alveolar epithelial cells, aleveolar macrophages and alveolar septa), 
heart (myocardium), kidney (glomeruli), placenta and blood vessels (advential cells surrounding 
the blood vessel walls (Drake et al., 1989).  TF expression on these organs has a prophylactic 
effect to inhibit and/or stop bleeding which has dangerous sequellae for these organs.  
Furthermore it has been reported by Drake et al. (1989) that TF is also expressed in a number of 
non vital organs such as skin (epidermis), gut (mucosa), spleen (trabeculae and capsule) and the 
peripheral nerve (Schwan cells).  Moreover, TF is also expressed normally in host cells such as 
endothelial cells, monocytes, macrophages and fibroblasts but only in response to inflammatory 
stimuli or remodelling signals in malignant cases (Ruf et al., 2000).  The plasma of healthy 
individuals contains relatively minor amounts of biologically active TF (Wada et al., 1995), but 
this increases in various conditions including cancer (Rak et al., 2006).  PC shows high plasma TF 
concentration which is positively correlated with the incidence of thromboembolism (TE) 
(Khorana et al., 2008).  See section 9.6 for details.   
 
TF consists of 295 amino acids (AA): a 32 AA leader sequence (264-295; Paborsky et al., 1989) 
which is cleaved to produce the protein, 263 AA which is formed of three domains (extra-cellular, 
transmembrane and cytoplasmic) that have distinct roles (Nemerson, 1988).  The extra-cellular 
N-terminal domain (AA 1-219) comprises two fibronectin type III domains, which interact with 
FVIIa to initiate the coagulation cascade and bind factor VIIa and factor Xa (Coughlin, 2000, 
Martin et al., 1995).  The transmembrane domain contains 23 AA (220-242), and the short C-
terminal cytoplasmic domain (21 AA 243-263) contains three serine residues (Nemerson, 1988, 
Neuenschwander and Morrissey, 1992, Fig. 1.5).  
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Figure 1.4: Coagulation cascade. Both extrinsic and intrinsic pathways lead to the activation  
of factor X which combines with activated factor V in the presence of calcium and phospholipid  
(PL) to produce thrombin.  Anticoagulant pathway (fibrinolytic pathway) will be activated after  
vessel integrity has been restored. 
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Figure 1.5: Schematic representation of tissue factor adapted from (Nemerson, 1988).  The 
three intracellular serine residues are highlighted.   
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TF shows similarity to a class II cytokine receptor (Bazan, 1990).  However, TF does not exhibit 
all the classical features of a cytokine receptor; firstly its C-terminal intra cellular domain is short 
and lacks the membrane proximal motif for binding of the non-receptor Janus kinases (JAKs) 
(Kotenko and Pestka, 2000, Ruf, 1999).  Under the effect of phorbol ester, the cytoplasmic 
domain can become phosphorylated (Zioncheck et al., 1992).  The synthetic cytoplasmic domain 
has been phosphorylated at multiple sites when incubated with cell lysate (Mody and Carson, 
1997).  Furthermore, it has been shown that serine 253 (Dorfleutner and Ruf, 2003) and serine 
258 may be phosphorylated via a mechanism involving protein kinase (Dorfleutner and Ruf, 
2003, Mody and Carson, 1997; Zioncheck et al., 1992).  These phosphorylations are necessary 
for cancer metastasis (Bromberg et al. 1999) due to involvement of the cytoplasmic domain of 
TF in TF-VIIa signalling which increases the chemotaxis ability of malignant cells (Bromberg et 
al., 1999).   
 
The tendency for aberrant expression of TF on the tissue alters the behaviour of cells through 
FVIIa/TF signalling (Peppelenbosch and Versteeg, 2001).  Furthermore, it has been noted that 
high TF expression is associated with more growth of primary PC (Kakkar et al., 1999) and 
sequentially more FVIIa/TF signalling (Peppelenbosch and Versteeg, 2001).  It has been 
postulated that there is an aberrant expression of TF on tumour cells, particularly those of 
epithelial origin (Callander et al., 1992), one of which is PC.  In the latter study, Callander et al., 
(1992) studied 61 epithelial tumours, 3 of which were pancreatic adenocarcinoma, 19 non 
epithelial malignant cases and 6 benign cases.  The authors postulated that there is an aberrant 
TF expression on tumour cells, particularly those of epithelial origin and they noted that 41 
(68%) cases out of 60 epithelial malignant cases, 3 (16%) cases out of 19 non-epithelial 
malignant cases and 1 of 6 benign tumours expressed TF.  The three PC cases showed the 
highest level of TF staining.  Callander and his colleagues used rabbit polyclonal anti human 
antibody but most of the specimens were frozen tissues; some samples were taken on the day of 
surgery and others from autopsy.  All the samples were embedded in optimum cutting 
temperature compound and stored in liquid nitrogen and stored at -70oC in air-tight bags which 
has less effect on masking of the antigen.  Furthermore it has been noted that the increase of 
lymphatic and vascular cell invasion of the pancreatic cancer cells is correlated with the 
histological grade (Nitori et al., 2005).  In the latter study paraffin embedded tissues were used. 
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Moreover, it has been noted that positive expression of TF has been found in glioma (Guan et 
al., 2002) as well.  In this study 34 glioma cases were involved, of which 10 were grade IV, 12 
were grade III, 7 grade II and 5 were grade I.  The authors evaluated expression of TF antigen 
and von Willebrand factor using immunohistochemistry.  They found that 90 % of grade IV cases 
strongly expressed TF, 58 % of grade III cases strongly expressed TF, 43% of grade II cases 
strongly expressed TF and 20% of grade I cases strongly expressed TF.  Positive TF expression 
has been reported in breast cancer as well.  Contrino et al. (1996) noted that TF was expressed 
in the endothelial and tumour cells of breast cancer while it was not in 10 cases of breast 
fibrocystic disease.  Nakasaki et al. (2002) reported that TF expression was correlated to the 
Ducke’s stage and the clinical staging in colorectal cancer.  The authors noted that TF expression 
was positive in 57% of all cases.   
 
It has been reported that normaly some of circulating TF is potentially active and the TF that 
come from leukocytes and monocytes are completly encrypted (Giesen, et al. 1999).  More 
growth of primary PC and an increase of procoagulant activity of the tumour cells correlates with 
the histological grade (Kakkar et al., 1999).  The details are discussed in section 8.6.  Another 
source of TF in the blood is circulating microparticles (MP, Yu & Rak, 2004) and this will be 
discussed in section 1.8.  Under the effect of cytokines and inflammatory molecules such as 
bacterial lipopolysacharide, endothelial cells (Parry and Mackman, 1995) and monocytes 
(Mackman, 1996) express TF.  
 
1.8 Microparticles 
1.8.1 Definition of Microparticles 
MPs are membrane vesicles of approximately 0.1-1 μm in diameter shed from the plasma 
membrane of healthy, apoptotic and stimulated cells (Freyssinet, 2003, VanWijk et al., 2003).  
MPs were discovered by Wolf in 1967 but he regarded them as “platelet dust” (Wolf, 1967). 
 
1.8.2 Origin and Structure of MP 
MP originate from different types of cells including monocytes (Satta et al., 1994), platelets 
(Pasquet et al., 1996), granulocytes (Berckmans et al., 2002), endothelial cells (Combes et al., 
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1999), smooth muscle cells (Leroyer et al., 2007) and tumour cells (Yu and Rak, 2004).  The 
latter are considered as a major source of TF-bearing MP (Yu & Rak, 2004).  It appears that MPs 
differ in their size, phospholipid (PL) and protein content, depending on their origin (Morel et al., 
2004).  The MP is composed of a cytoplasmic component and membrane elements such as PL 
and cell surface receptors.  Following stimulation, the plasma membrane is rearranged resulting 
in an outer leaflet rich in phosphatidylserine, essential for TF activity (Fig. 1.6).  This is followed 
by release of MP into the circulation.  Furthermore, p-selectin dependent interaction among 
platelets, macrophages and granulocytes determines expression of TF activity (Scholz et al., 
2002).  Moreover, MP express antigenic markers distinctive of the parent cell (Abid Hussein et 
al., 2003).    
 
              
 
Figure 1.6: Schematic Presentation of Microparticle. 
 
MP might express P-selectin glycoprotein ligand-1 on their surfaces (Lopez et al., 2005, 
Vandendries et al., 2004).  Endothelial MP (EMP) are also known to contain matrix 
metalloproteinases (MMP) in addition to procoagulants that are involved in angiogenesis 
(Taraboletti et al., 2002).  MMP play an important role in the cell invasion processes.  MMP 
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degrades the basement membrane allowing the invasion of the interstitial stroma by migrating 
endothelial cells (Taraboletti et al., 2002). 
Furthermore, CD-62P (P-selectin), CD-42a (GPIX), CD-42b (GPIb), CD-41 (GPIIb/IIIa, αIIbβ3) 
and CD-61 (GPIIIa) are expressed on platelet derived MP (Baj-Krzyworzeka et al., 2002); CD-4, 
CD-8 and CD-3 are expressed on MP derived from leukocytes (Martin et al., 2004), CD-14 
(Endotoxin receptor) is expressed on monocytes derived MP (MoMP) and CD-62P, CD-31 
(PECAM-1), CD-51 (Vitronectin receptor, αvβ3); CD-54 (ICAM-1); CD-62E (E-selection), CD-105 
(Endoglin); CD-144 (VE-Cadherin); CD-146 (MeICAM) and CD-106 (VCAM-1) are expressed on 
endothelial cell derived MP (Nomura et al., 2008).  These characteristics allow individual sub-
populations of MP to be enumerated by flow cytometry. 
 
In vitro, MP induction has been induced by chemical stimuli, such as incubation with tumour 
necrosis factor alpha (TNF-α), Interleukin 1 (IL-1) and bacterial polysaccharides and by external 
causes such as hypoxia, oxidative injury and chemotherapy due to the damage to endothelial 
cells (Lechner et al., 2007).  
 
1.8.3 Pro-coagulant Activity of MP 
The pro-coagulant activity in cancer patients depends mainly on numbers of circulating TF and 
PL bearing MP (Debaugnies et al., 2010, Zwicker et al., 2009, Del Conde et al., 2007, Tilley et 
al., 2008) as both these factors (TF and PL) are important to convert FVII to FVIIa which is 
essential for extrinsic pathway of coagulation.  Furthermore, there is accumulating evidence of a 
correlation between TF activity expressed on MP and thromboembolism (TE) in cancers (Tilley et 
al., 2008).  It has been reported by some investigators that TF bearing MP (TF+MP) involved in 
coagulation result in an increase of blood clot size rather than initiating coagulation (Giesen et 
al., 1999), because the TF within the MP is thought to be either at too low a level to trigger clot 
formation itself or encrypted; other investigators, however, suggest that TF+MP initiate 
coagulation and have an effect on vascular function (VanWijk et al., 2003).  The TF bearing MP 
might have both, initiating and increasing the clot if there is a high level of TF bearing MP.   
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1.8.4 Clinical Experience of MP Number and Activity in Pancreatic Cancer 
Madden et al., (2008) suggested the existence of a circadian variation of TF-bearing MP in 
normal individuals and postulated a role in haemostasis.  Furthermore, MPs have been detected 
in the blood of healthy individuals but their level is increased in malignant cases where the risk 
of thrombosis is increased (Biro et al., 2003).   
 
The suggestion that the tumour may be the main source of TF+MP comes from the 
demonstration that TF+MP reduce substantially after successful surgery to remove tumours 
(Zwicker et al., 2009) and the fact the correlation between the level of TF+MP activity and 
incidence of thrombosis in cancer has been demonstrated (Khorana et al., 2007).  It has also 
been demonstrated that tumour growth, metastasis, and angiogenesis can be stimulated by 
TF+MP (Debaugnies et al., Yu and Rak, 2004).  Furthermore, increased levels of MP can be 
found in patients with a number of cancer types but the highest levels of TF activity are those in 
PC patients (Tesselaar et al., 2009, Tilley et al., 2008).  Tesselaar et al., (2007) reported that 
34% of PC patients and 29% of advanced breast cancer cases involved in this study had TF 
activity above the upper limit of the normal range.  Furthermore, it has been noted that vascular 
functions in particular processes involved in cardiovascular diseases can be affected by TF 
expression; this is mainly due to apoptotic, survival, remodelling, pro-coagulant and pro-
inflammatory effects of microparticles (Wada et al., 1995).  In conclusion, a review of the 
literature on MP supports the idea that there is an increase of MP number and activity in some 
types of cancer including PC.  
 
1.9 Angiogenesis 
Angiogenesis is defined as new blood vessel formation from the pre-existing vascular network, 
consisting of three stages: migration, proliferation and differentiation.  It can be physiological as 
in wound healing, tissue remodelling, regeneration and the menstrual cycle or patho-
physiological as in cancer, rheumatoid arthritis and atherosclerosis.  Tumours can only grow up 
to 1-2 mm3 independent on angiogenesis.  For growth bigger than this size, angiogenesis is 
necessary (Folkman, 1995a).   
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Recently, Lomberk (2010) suggested that PC is one of the more angiogenesis-driven tumours, as 
he showed that rapid tumour growth with a poor prognosis was positively correlated with 
increased angiogenesis.  There are two principal mechanisms for promotion of angiogenesis; 
clotting dependent and clotting independent (Rickles et al., 2003, Shoji et al., 1997).   
 
1.9.1 Clotting Dependent Mechanism of Angiogenesis   
The extrinsic pathway of the coagulation cascade and clotting dependent mechanism of 
angiogenesis is initiated by activation of TF receptors via ligand binding; TF binds with FVIIa to 
form the TF/ FVIIa complex (Coughlin, 2000, Martin et al., 1995).  This complex triggers the 
coagulation cascade (Fig. 1.4) which involves activation of FX to FXa in the presence of Ca2+ and 
PL, followed by the conversion of prothrombin to thrombin (Gilbert and Arena, 1995) which is 
crucial in clot mediating formation due to fibrin formation and platelet activation (Falanga and 
Rickles, 1999) (Fig. 1.4).  TF-FVIIa has also been reported to induce activation of all three 
mitogen-activated protein kinase (MAPK) pathways, p44/42 (Poulsen et al., 1998), p38 and c-Jun 
N-terminal kinases/stress activated protein kinases (JNK/SAPK) (Camerer et al., 2000) in 
different cell types.  TF-FVIIa also promotes the activation of the src family of proteins (Versteeg 
et al., 2008).  The src family proteins are known to increase phosphatidylinositol 3 kinase (PI3K) 
activities, which in turn activates protein kinase B.  Activated platelets can then promote 
angiogenesis by releasing a number of pro-angiogenic factors such as vascular endothelial 
growth factor (VEGF), beta fibroblast growth factor (β-FGF) and platelet derived growth factor 
(PDGF) (Battinelli et al., 2011, Fig. 1.7).  
 
1.9.2 Clotting Independent Mechanism of Angiogenesis  
In addition to its role in the clotting dependent mechanism, thrombin also has a role in the 
clotting independent mechanism of angiogenesis through proteolytic cleavage of protease-
activated receptors (PAR).  There are four PAR of which PAR1, PAR3 and PAR4 are cleaved by 
thrombin while the proteases trypsin, tryptase, TF-FVIIa and FXa can activate PAR2 (1998, 
Ishihara et al., 1997, Nystedt et al., 1995).  There are several different pathways for clotting 
independent mechanisms of angiogenesis (Fig. 1.7), including a direct effect of TF-FVIIa that is 
dependent on phosphorylation of the cytoplasmic domain of TF, as mediated by PAR2.  TF 
cytoplasmic domain may contribute to cell signalling by regulating TF-FVIIa signalling.  
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In fact, the activation of PAR2 and PAR1 by TF-FVIIa-FXa induces the phosphorylation of the 
cytoplasmic tail (Ahamed and Ruf, 2004).  In support of the co-operative involvement of the 
cytoplasmic domain with PAR signalling, a study demonstrated that PAR2 dependent 
angiogenesis is tightly controlled by the TF cytoplasmic domain (Belting et al., 2004).  Other 
pathways are mediated by FVIIa and FXa activation of PAR (Camerer et al., 2000).  For example 
the TF/FVIIa complex reacts with FXa to form TF/FVIIa/FXa, and this complex triggers protease-
activated G protein-coupled receptors, through PAR1 and PAR2 (Camerer et al., 2000).  
Furthermore, thrombin increases cell invasion by its direct effect on the integrins or indirectly 
through increase of proangiogenic markers through clotting dependent and independent 
mechanisms.  All of these mechanisms could contribute to the control of angiogenesis.  
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Figure 1.7: Representation of clotting dependant and clotting independent mechanism of 
angiogenesis. EMT: Endothelial Mesenchymal Transition. 
 
1.9.3 Capillary Formation and Angiogenesis  
To study angiogenesis in vitro, different types of endothelial cells as well as cells that have 
endothelial characteristics and behaviours have been utilised.  One of the characteristic features 
of these endothelial cells is a cobblestone appearance in culture medium supported by growth 
factors, but on removal of these growth factors or when the endothelial cells are seeded on or 
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embedded in the collagen and fibrin, they form tubes which are similar in nature to capillaries 
(Smith and Staton 2006).   
 
In vitro, the number, length and diameter of these capillaries can be measured, which therefore 
provides a quantitative method to evaluate the angiogenic activity in PC sera.  This method is 
employed in the thesis as described in section 2.2.7.2.  Although three dimensional (length, 
width and depth) capillary formation is more closely similar to in vivo angiogenesis than two 
dimensional (length and width) capillary formation and their analysis takes a longer time 
compared with two dimensional (length and width) tubule formation (1-3 days vs. more than 7 
days; 1 day vs. 5-15 days, respectively).  Moreover, tubule analysis of three dimensional 
methods is more complicated as the gel should be fixed with 10% formaldehyde, dehydrated 
with graduated alcohol and imbedded in paraffin block.  The block should be then sectioned 
horizontally and vertically in 3-5 micro metre (µm) thickness using microtome and stained with 
anti CD 31 and analysed using a digital analysis software (Smith and Staton 2006).   
 
1.10 Relationship between Cancer and Thrombosis   
In 1865 Trousseau described thrombosis as a major complication of cancer (Trousseau, 1865), 
the risk of thrombosis being increased 2-7 fold in patients with cancer compared with a non-
cancer population (Stein et al., 2006, Blom et al., 2005, Heit et al., 2002).  Furthermore, 
Prandoni et al. (2002) noted that the rate of recurrence of TE is higher in cancer patients than in 
non-cancer patients (1.9% vs. 5.4%).  Aberrant coagulation is commonly detected in many 
patients with malignancy, especially in advanced or disseminated stages (Kirwan et al., 2003).  
The higher the prevalence of abnormalities in coagulation, the greater the likelihood a 
recognisable haemostasis-related clinical syndrome will occur.  The most common coagulation 
abnormalities observed in solid malignancies are TE and disseminated intravascular coagulation 
(Kakkar et al., 2003).  A seminal post-mortem study reported in 1938 showed that TE is a major 
complication of PC with the highest incidence being found in pancreatic tail tumours (Sproul, 
1938).  Many recent studies have verified that PC is one of the malignancies (Khorana and Fine, 
2004, Ogren et al., 2006a, Shah and Saif, 2010) with the highest prevalence of TE (up to 57% of 
PC cases, Khorana and Fine, 2004) and that a patient’s risk of developing thrombosis is further 
increased with chemotherapy treatment (Khorana et al., 2008, Ogren et al. 2006b, Moore et al., 
2005, Heit et al., 2000b, Wall et al., 1989).  
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The presence of TE in PC patients is correlated with a shorter survival period (Mandala et al., 
2007) and the associated early mortality may be directly related to the incidence of TE (Sgouros 
and Maraveyas, 2008).  There are three, non-mutually exclusive, explanations for the 
relationship between thrombosis in PC and reduced survival.  The first is that the thrombosis 
itself is a potentially lethal event that causes mortality (Maraveyas and Johnson, 2009) and the 
use of many of the conventional therapies, including chemotherapy (Heit et al., 2000a, Wall et 
al., 1989), anti-angiogenic drugs (Nalluri et al., 2008, Heit et al., 2000a) and erythropoietin 
(Bennett et al., 2008) directly increases this risk.  Secondly malignant cells exhibiting enhanced 
ability to shed MP and promote thrombosis are inherently or phenotipically more aggressive 
(Khorana et al., 2007) and finally the targeting of an aberrant coagulation exacerbates the 
malignant phenotype by sustaining a continuous loop of factors that promote trafficking and 
anchoring, invasion, tumour growth and metastasis, or a combination of one or more processes.   
 
1.11 Regulation of Tissue Factor 
There are several mechanisms that control TF activity; however the TF pathway inhibitor (TFPI) 
(Fig. 1.4), a serine protease inhibitor (Broze, 1995), acts as the principal endogenous regulator 
of TF (Sandset, 1996).  TFPI is produced mainly by the microvascular endothelium and up to 
85% of it is bound to these cells (Bajaj et al., 1990).  Ten percent is associated with lipoprotein 
in plasma and the remainder is stored within platelets.  Small amounts of TFPI are released from 
platelets (Novotny et al. 1991).  It has been reported that the median concentration and range 
of TFPI in 35 healthy people was [90 (75-120) ng/ml] while the median concentration of TFPI 
and range in 22 patients with solid malignancy was [128 (47-286) ng/ml].  However, the median 
TFPI concentration and the range of 52 patients with haematological malignancies was [68 (23-
133), Iversen et al., 1998].   
 
TFPI is composed of three Kunitz type protease inhibitor domains and a C-terminal polybasic 
motif.  The first domain reacts with and inhibits FVII in the TF-FVIIa complex; the second 
domain reacts with and inhibits FXa in the TF-FVII-FXa complex (Sevinsky et al., 1996, Broze, 
1995, Girard et al., 1989) and the third domain has an unknown function at this time.  However 
Sameera et al. 2011 (Conf reference 1) suggested the Kunitz 3 has a role in inhibition of FXa. 
Therefore, TFPI reacts with TF and inhibits its pro-coagulant activity (Bach and Moldow, 1997).  
In addition to the anti-coagulation effect, recombinant TFPI (rTFPI) has been shown to decrease 
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cell proliferation (Hamuro et al., 1998) and to induce apoptosis of human umbilical endothelial 
cells (HDMEC) due to its inhibitory effect on TF (Hamuro et al., 1998).  Furthermore, Ahamed et 
al. (2004) noted that the TFPI could prevent the PAR1 signalling pathway in Chinese hamster 
ovary cells.  However the concentration of TFPI used to prevent the PAR1 signalling is 30-fold 
higher than the concentration of TFPI for anticoagulation.  In phase III clinical studies, TFPI 
modified the coagulation system but it had disappointing results in improving the survival rate in 
patients with sepsis (Polderman and Girbes, 2004, Abraham et al., 2003).  There was no clear 
explanation for these results.   
 
It is reported that TF expression can also be regulated signalling via the epidermal growth factor 
receptor (EGFR1) through nuclear factor kappa B (NF-κB), loss of E-cad and subsequent EMT 
(Fig. 1.7, Milsom et al., 2008).  It has been noted recently that LMWH may impact on TF level 
through NF-κB by EGFR1.  Furthermore It has been noted that the LMWH effect on NF-κB may 
be mediated via effects on growth factor signalling (Ettelaie et al., 2011b).  The signals through 
these pathways enhance activation of TF.  Another mechanism that controls TF is FXa, which has 
a negative feedback effect on the regulation of TF (Ettelaie et al., 2007, Fig. 1.4).  Furthermore, 
there are some biological changes which are responsible for the up-regulation of growth factors 
in general, including TF.  These include phosphatidylinositol kinase  (PI3K) which controls cellular 
activities and properties including proliferation, survival, motility and morphology , p38 and 
Extracellular Signal-Regulated Kinases-1/2 (Erk-1/2) Mitogen-Activated Protein Kinase (MAPK) 
which have a critical role in chemo-attraction and angiogenesis (Schett et al., 2008).  In tumour 
cells, the activity of PI3K is decreased; in contrast p38 and Erk-1/2MAPK are increased (Blum et 
al., 2001).  Consequently, apoptosis will decrease and proliferation and angiogenesis will 
increase.  Thrombin can activate PAR signalling directly and some transcription factors such as 
specific protein-1 , activator protein-1 and NF-kB bind to corresponding sites in TF after cell 
activation (Martin et al., 1995).  As a conclusion, there are several signalling pathways that could 
control TF. 
  
21 
 
1.12 Vascular Endothelial Growth Factor 
VEGF is a 40 kDa glycoprotein critically important in controlling angiogenesis.  The VEGF family 
includes VEGF A, B, C, D, E, G and the placental growth factor (Ogawa et al., 1998).  VEGF A 
and B are two of the most angiogenic proteins, whereas VEGF C and D have been shown to act 
principally as lymphangiogenic factors.  Placental growth factors control angiogenesis in ischemic 
heart and limb (Autiero et al., 2003, Nagy et al., 2002).  VEGF ligands bind to two main groups 
of receptors, tyrosine and non tyrosine kinase receptors.  There are three types of tyrosine 
kinase receptors: VEGFR 1, also called Flt-1 (fms-like tyrosine kinase-1), VEGFR 2 also called 
KDR (Kinase insert domain-containing receptor) and VEGFR-3, also called Flt-4 (fms-like tyrosine 
kinase-4).  Angiogenesis is mainly controlled by signalling through VEGFR 2 (Autiero et al., 2003) 
and its ligands (Milkiewicz et al., 2004) which depends on many factors such as hypoxia, 
hypoglycaemia stress and the presence of transcription factors such as signal transducer and 
transduction of transcription-3 (Stat-3).   
 
VEGF A, B and placental growth factor bind to VEGFR 1 receptor.  VEGF A and VEGF E bind to 
VEGFR 2.  VEGF C and D bind to VEGFR-3 (Olsson et al., 2006).  VEGF A has an important role 
on vascular-angiogenesis, while VEGF C has an important role on lymph-angiogenesis (Eriksson 
and Alitalo, 1999).  VEGF A and VEGF C are commonly expressed by malignant pancreatic cells.   
 
There is a direct link between VEGF and TF expression.  High expression of TF is associated with 
raised expression of VEGF (Abe et al., 1999, Nakasaki et al., 2002).  In an immunohistochemistry 
study Nakasaki et al. (2002) noted a significant correlation between expression of TF with VEGF 
and microvascular density.  The data is described in relation to this thesis work in section 9.4.  It 
has been noted that VEGF upregulation can be controlled by the cytoplasmic domain of TF in a 
mechanism that is independent of FVIIa (Abe et al., 1999).  Abe et al. (1999) reveal that 
tansfection of HT144 a (low TF and VEGF producing melanoma cell line) with a TF cDNA 
containing the full-length sequence produce increased levels of both TF and VEGF on the HT144 
while transfection with a cytoplasmic deletion TF cDNA produced an increase of TF with little or 
no increase in VEGF.   
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In summary, VEGF is an important signalling protein involved in angiogenesis. As its name 
implies, VEGF activity is restricted mainly to cells of the vascular endothelium, although it does 
have effects on a limited number of other cell types (e.g. stimulation monocyte/macrophage 
migration) and it seems to be a direct line between VEGF and TF expression.   
 
1.13 Angiogenic Markers Commonly Studied with Relevant Pancreatic Cancer  
The angiogenic markers are divided into two groups; proangiogenic and antiangiogenic markers.  
It has been postulated that angiogenic markers play a major role in angiogenesis, as the up-
regulation of proangiogenic markers enhance angiogenesis and is associated with poor 
prognosis.  It has been hypothesised that a tumour is the main source of the serum angiogenic 
markers.  Furthermore, evaluation of these markers in the serum is a rapid, relatively non-
invasive and convenient method in comparison to surgical resection and diagnostic pathological 
techniques, such as taking a fine needle aspirate (Poon et al., 2001).  Increased expression of 
several angiogenic markers such as VEGF (Chang et al., 2008, Pistol-Tanase et al., 2008), EGFR 
(Yamanaka et al., 1993) and platelet-derived endothelial cell growth factor (Ikeda et al., 1999) 
has been noted in PC tissue and or in the serum of PC patients.  Furthermore, clinical and 
laboratory studies suggest that high expression of pro-angiogenic markers is associated with an 
increase of angiogenesis and poor prognosis (Lomberk, 2010, Fujioka et al., 2001).  It has been 
reported that pro-angiogenic factors enhance angiogenesis due mainly to decrease of apoptosis, 
increase of survival and cell proliferation (Herbst, 2004, Neutzner et al., 2007).  Although the 
mechanism by which pro-angiogenic factors control survival and apoptosis is not clear, it is 
thought that the binding of these factors results in PI3K/Akt, Ras/MAPK up-regulation (Suhara et 
al., 2001), and p38 MAPK-dependent apoptosis pathways down-regulation (Nicholson and 
Anderson, 2002, Gratton et al., 2001,Yu and Sato, 1999).   
 
Furthermore, VEGF can regulate αvβ3 integrin which enhances cell migration and survival when 
it is associated with VEGF receptor-2 (VEGFR 2) and defective tyrosine phosphorylation resulting 
in impaired adhesion, spreading, and migration (Mahabeleshwar et al., 2006, Hood et al., 2003).  
Other contributing mechanisms could include the Ras/MAPK, phosphatidylinositol 3 kinase (PI3K) 
/Akt, Janus kinase (JAK)/Stat and phospholipase C /protein kinase C pathways which are the 
main signalling pathways activated by EGFR 1, resulting in the activation of genes that cause 
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over-expression of angiogenic factors, increased cell proliferation, migration, adhesion, 
differentiation and apoptosis (Yu et al., 2005). 
 
The families of molecules studied to-date are briefly reviewed with investigations of particular 
relevance to PC being highlighted (Tables 1.1 and 1.2).   
Table 1.1: Pro-angiogenic factors.   
Proangiogenic 
Factor 
Main Functions  
Amphiregulin  
In normal tissue, amphiregulin is expressed in the nuclei, while in normal PC 
is expressed in the cytoplasmic part of the cells (Yotsumoto et al., 2008, 
Ebert et al., 1994,).  
Angiogenin 
Over expression of angiogenin is related to aggressive PC, bad prognosis 
(Shimoyama et al., 1996) and increased angiogenesis by inducing nitric 
oxide (NO) through PI-3 and Akt Kinase (Trouillon et al., 2010).  In a series 
of 100 cases of lung cancer, high nuclear expression of angiogenin was 
found in 67% of cases (Yuan et al., 2009).  Furthermore, it has been 
postulated that angiogenin increases in the advanced stage of breast cancer 
(Duranyildiz et al., 2009) and melanoma (Vihinen et al., 2007) and high 
expression is linked to poor prognosis.  
Ang-1 
 
Angiopoetin-1 plays an important role in endothelial cell survival and inhibits 
apoptosis (Papapetropoulos et al., 2000).   
Artemin 
Artemin belongs to Glial cell line-derived neurotrophic factor (GDNF).  It 
promotes cell survival and differentiation and down regulates apoptosis 
(Dong et al., 1996).  
TF 
Also called coagulation factor III or CD 142, induces angiogenesis through 
clotting dependent and clotting independent mechanisms (Rickles et al., 
2003, Shoji et al., 1997). 
CXCL 16 
Chemokine (C-X-Cmotif) ligand 16.  It induces a strong chemotactic 
response and it guides migration of activated T-cells into inflamed tissue 
(Abel et al., 2004).  
DPP-IV 
Di-peptidyl peptidase-4 or CD-26.  It is an intrinsic membrane glycoprotein 
and a serine exopeptidase that cleaves X-proline di-pepides from the N-
terminus of polypeptides (Yazbeck et al., 2009). 
EGF 
Epidermal growth factor regulates cell proliferation, differentiation and 
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growth by binding to its receptor (EGFR) (Camaj et al., 2009).   
EG-VEGF 
Endocrine gland–derived VEGF, it is restricted to the steroidogenic glands, 
ovary, testis, adrenal and placenta (Hoffmann et al., 2009).  
Endoglin-1  
Also called CD-105.  It is involved in cytoskeletal organisation, affecting cell 
morphology and migration (Duff et al., 2003, Cheifetz et al., 1992).  In a 
series of 30 cases, endoglin was detected in all cases and it was expressed 
mainly in small blood and lymphatic vessels (Yotsumoto et al., 2008) 
FGF 
Fibroblast growth factors-acidic, basic, 4-7 play a role in angiogenesis; 
wound healing, cell proliferation (Gospodarowicz et al., 1989) and 
differentiation of cells and tissues.  Wang et al. (2009b) suggested that 
bFGF is a negative regulator of angiogenin and the expression of angiogenin 
decreases when bFGF is over-expressed.   
GFL 
Glial family ligands play a role in cell survival, cell growth, cell differentiation 
and cell migration (Lieu et al., 2011).  
GM-CSF 
Granulocyte-macrophage-colony—stimulating factor is a cytokine that has a 
major role in the production of white blood cells, particularly macrophages, 
granulocytes and megakaryocytes (Uchida et al., 2007).  
HB-EGF 
Heparin-binding epidermal growth factors act on EGF receptor in smooth 
muscle cells and fibroblast cells but not endothelial cells.  It has a major role 
in cell tumourgenesis and survival (Takemura et al., 1999) and wound 
healing (Homma et al., 1995). 
HGF 
Hepatocyte growth factor stimulates mitogenesis, cell motility, matrix 
invasion and tissue regeneration (Otte et al., 2000). 
IGFBP 
Insulin-like growth factor binding proteins -1, -2, -3, are made up of six 
distinct subgroups of protein, IGFBP-1 to IGFBP-6. IGFBPs play a chief role 
in the regulation of the autocrine/paracrine and endocrine functions of IGF.  
Furthermore, IGFBPs play a role as a growth factor independent of IGF 
(Conover et al., 1993, Conover, 1992).  
IL-1B 
Interleukin-1B has role in white blood cell aggregation, cell proliferation, 
differentiation and apoptosis (Liu et al., 2009). 
IL-8 
Interleukin-8 a chemokine (IL-8) that acts as a chemo-attractant and potent 
pro-angiogenic marker (Waugh and Wilson, 2008).  
Lep 
Leptin regulates energy intake and expenditure (Brennan and Mantzoros, 
2006). 
MCP1 
Monocyte chemotactic protein-1 acts as a white blood cell chemo-attractant 
agent, and inhibits stem cell proliferation (Cook, 1996).   
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MMP 
Matrix metalloproteinases 8, 9 have a vital role in metastasis due to the role 
they play in breaking down the cellular matrix (Page-McCaw et al., 2007).  
NRG-B1 
Neuregulin-1-B1 EGF has an important role in increasing the level of tyrosine 
phospherlisation of focal adhesion kinase (Ritch et al., 2003). 
PD-ECGF 
Platelet-derived endothelial cell growth factor plays a role in angiogenesis 
(Fujimoto et al., 1999).  In immunohistochemistry study, Ikeda et al. (1999) 
noted that an immunohistochemistry that 75% were positive to platelet 
derived endothelial growth factor (PD-ECGF) and 25%. 
PDGF 
 
Platelet derived growth factor plays an essential role in capillary formation 
and in vascular ageing process of the tumour and also has role in cell 
growth, division and angiogenesis. PDGF is composed of two chains, so has 
3 forms (AA), (BB), or (AB) (Turner et al., 2009, Fruttiger et al., 1996). 
PIGF 
Phosphatidylinositol-glycan has a major role in protein synthesis and 
enhancement of angiogenesis (Fox et al., 1987). 
Prolactin 
Stimulating proliferation of oligodendrocyte precursor cells (Web reference 
2, 2011).  
VEGF  
Acts as a general activator to the endothelial cells (Ferrara et al., 2003). 
26 
 
Table 1.2: Anti-angiogenic factors.* means factors have been reported to have pro- and anti- 
angiogenic factors  
 
Anti-
angiogenic  
Factors  
Main Functions 
 
Activin A * Decrease of pancreatic cell (Zhang et al., 2004) and endothelial cell survival 
(Chen et al., 2002)).  Also shown to regulate cell differentiation cell 
proliferation, and apoptosis (Galloway et al., 2000, Dong et al., 1996). 
ADAMTS-1 A Disintegrin and Metalloproteinase with ThromboSpondin motif-1 has an 
inhibitory effect on VEGF (Turner et al., 2009, Vazquez et al., 1999).  Higher 
expression has been noted in lymph nodes and peritoneal secondary of 
pancreatic primary origin (Masui et al., 2001). 
Ang-1 
 
Angiopoietin-1 (Ang-1) plays an important role in endothelial survival and 
inhibits apoptosis (Papapetropoulos et al., 2000).  However, other reports 
have shown that it prevents hepatic growth, vascular permeability and 
angiogenesis (Stoeltzing et al., 2003). 
Ang-2 Angiopoietin -2 is a natural antagonist of Ang-1 binding to the same 
receptor but not causing a signal (Davis et al., 1998, Maisonpierre et al., 
1997). 
Angiostatin Angiostatin is a protein that acts as an inhibitor of angiogenesis (Kirsch et 
al., 1998, Oreilly et al., 1994). 
Endostatin/ 
CollagenXVIII 
Has an anti-angiogenic activity and tumour growth inhibitory effect (Oreilly 
et al., 1997). 
LAP (TGF-B1)* Latency Associated Peptide (Transforming growth factor beta ) acts as a 
pro-angiogenic factor in low doses because it up-regulates angiogenic 
factors and proteinases, while in high doses it acts as an angiogenic 
inhibitory factor because it prevents endothelial cell growth, stimulates 
differentiation of smooth muscle cells and enhances formation of the 
basement membrane ( Pardali and ten Dijke, 2009, Carmeliet, 2003). 
Endothelin Acts as a vasoconstrictor and inhibitor of angiogenesis.  It suppresses 
growth and metastasis of cancer including PC (Weydert et al., 2009). 
PTX3 Pentraxin 3 (PTX 3) impedes endothelial cell proliferation and 
vascularisation that depends on bFGF because it has a high binding affinity 
for bFGF receptors (Davis et al., 1998, Maisonpierre et al., 1997).  
PF4 Platelet factor 4 is released from alpha granules of platelets during platelet 
aggregation and promotes clotting.  PGF 4 has an inhibitory effect on 
endothelial cell proliferation and angiogenesis (Gupta et al., 1995, Kolber et 
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al., 1995, Luster et al., 1995)). 
Serpin B5, E1 
and F1 
Serpins are a group of proteins that inhibit chymotrypsin-like serine 
proteases.  They have an anticoagulant, anti-tumour and anti-angiogenic 
activity (Web reference 3, 2011). 
TIMP-1, -4 Tissue inhibitors of metalloproteinase 1-4 are glycoproteins which act as 
natural inhibitors of the MMP (Hornebeck 2003 and Green 1996). TIMP4 
regulates platelet aggregation and recruitment and may play a role in 
hormonal regulation and endometrial tissue remodelling (Greene et al., 
1996). 
TSP-1 Thrombospondin-1 is a natural inhibitor of neovascularisation, 
tumourigenesis, and angiogenesis (Rastinejad et al., 1989). 
TSP-2 Thrombospondin-2 is a matrix glycoprotein and has a potent function 
against tumour growth and angiogenesis (Strieter et al., 2006). 
Vasohibin Acts as an anti-angiogenic marker (Kaya et al., 2004). 
 
1.14 Factors Influence Thrombosis in Pancreatic Cancer 
There are two groups of factors that affect the thrombosis; extrinsic and intrinsic.   
1.14.1 Extrinsic Factors 
Increased TE in PC is associated with the appearance of distant metastases (Blom et al., 2006).  
Superimposed risk factors such as acute medical conditions (e.g., concurrent infection, heart 
failure and chronic obstructive pulmonary disorders (Offord et al., 2004) and surgery can further 
exacerbate this risk of TE (Bergqvist et al., 2002).  Moreover, the systemic treatments used in PC 
patients may also have a significant prothrombotic effect; chemotherapy for example increases 
the incidence of TE in PC up to 4.8 fold (Moore et al., 2005).  There are distinct mechanisms 
which may be responsible for increase TE occurrence in cancer treated with chemotherapy: 
platelet activation (Togna et al., 2000), decrease of the natural inhibitor factors (such as 
antithrombin III, protein S and protein C; (Feffer et al., 1989), increase of cell adhesion 
molecules (Sgouros and Maraveyas, 2008, Mandala et al., 2007) and damage of the blood vessel 
wall/endothelium (Mandala et al., 2006).  Any number of these factors may be acting in 
combination of two or more.  More recently it has been postulated that chemotherapy increases 
apoptosis in PC (Yao and Qian, 2010).  The latter process would lead to apoptotic cells and 
cellular fragments being increased within the circulation, both having a generally pro-coagulant 
surface due to TF and PL/Phosphatidylserine (PS) exposure.   
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1.14.2 Intrinsic Factors 
PC cells secrete mucin which then enters the circulation.  Although most of the mucin that enters 
the blood circulation is cleared by the liver, some of it remains in the circulation and can react 
with P-selectin on platelets, L-selectin on leukocytes and P- and E-selectin on the vascular 
endothelium leading to formation of platelet-rich thrombi (Wahrenbrock et al., 2003).  Therefore, 
pancreatic tumour cells could directly activate the host cells (endothelial cells, platelets, 
leukocytes) by mucin secretion.   
 
Furthermore, in a 23796 autopsies from general population studied between 1970 and 2006 
(Ogren et al. 2006a) reported that the incidence of portal thromboemolism was in 254 (1%), of 
which 44% were associated with malignancy, 28% with liver cirrhosis and 10 % with abdominal 
infection and inflammatory disease.  In another study using the same data Ogren et al. (2006b) 
reported that association between cancer and thrombosis depends on the histological type as the 
incidence of thrombosis was more with adenocarcinoma and metastatic cancer.   
 
1.15 Epidermal Growth Factor Receptor in Haemostasis and Angiogenesis  
It has been noted that over-expression of EGFR 1 was seen in 43% of human PC cases (Friess et 
al., 1999) and its expression appears to be correlated with poor prognosis, increased tumour 
aggressiveness and enhanced angiogenesis (Fujioka et al., 2001, Friess et al., 1999).  EGFR 1 
expression on PC differs according to the part of the pancreas that is cancerous.  For example, 
cancer of the papilla of Vater did not show an over-expression of EGFR 1 compared with a 
normal control, while cancer of other parts of the pancreas showed over-expression of EGFR 1, 
reaching up to 60% (Friess et al., 1999).  A range of expression for EGFR2 has also been 
reported in PC (Koka et al., 2002, Dergham et al., 1997); however, no association with prognosis 
was observed.   
 
Milson et al. (2008) postulated that TF expression could be regulated by EGFR, controlled at 
least in part via NF-κB signalling.  Kinase suppressor of Ras1 (KSR1) is involved in the control of 
both pro-coagulant and aggressive phenotypes of cancer cells by the up-regulation of TF and 
downstream of Erb (EGFR) oncogenes (Yu et al., 2010).  Therefore the use of KSR1 targeting 
agents is being explored as a therapeutic strategy (Mostefai et al., 2008a, Zhang et al., 2008, 
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Xing et al., 2003).  Furthermore it has recently been reported that LMWH downregulation of the 
transcriptional activity of NFκB and interfere with the function of growth factor and sequentially 
down-regulates TF expression (Ettelaie et al., 2011b).  Based on these studies, EGFR-driven up-
regulation of TF (and therefore targeting of EGFR receptor directly or indirectly through KSR1) is 
a potential target for the treatment of PC. 
 
1.16 The Clinical Experience of Targeting Growth Factor Receptors in Pancreatic Cancer  
From a clinical perspective two recently completed trials of antiangiogenic agents (bevacizumab 
or Avastin®) and axitinib (S1005 and AG-013736), when used as a first line treatment for PC 
combined with standard therapy yielded disappointing results.  Firstly, gemcitabine in 
combination with axitnib resulted in a median overall survival of 7.4 months, compared to 8.2 
months for gemcitabine alone, in 630 patients (Kindler et al., 2009).  Secondly, gemcitabine in 
combination with bevacizumab also failed to confer any significant increase in overall survival 
(5.8 months) when compared to gemcitabine alone (5.9 months) in a study of 535 patients 
(Kindler et al., 2009).   
 
Furthermore, in a large (607 patients) randomised phase III clinical trial, where a triple 
combination of bevacizumab, Tarceva® (erlotinib ) and gemcitabine was compared to 
gemcitabine, Tarceva® and placebo, no statistical difference in the median overall survival rate 
was found (7.1 vs. 6.0 months respectively; p = 0.209) (Van Cutsem et al., 2009b).  A concern 
remains that these agents also drive thrombosis and whatever potential benefit from anti-cancer 
treatments may exist may be lost through excess thrombotic events (Maraveyas and Johnson, 
2009).   
 
However, a large randomised clinical trial of Tarceva® and gemcitabine vs. gemcitabine alone 
produced one of the few positive results in APC (Moore et al., 2005).  In this series of 569 cases, 
the median overall survival was significantly prolonged with Tarceva® (100 mg/ daily) and 
gemcitabine compared with gemcitabine only (6.24 vs. 5.91 months, p = 0.038); a marginal 
clinical improvement that was seen only in the stage IV patients.  There was no significant 
difference in the objective response rate and there were many grade I and II side effects in the 
group treated with Tarceva® plus gemcitabine, such as rash, diarrhoea, stomatitis and infection 
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(Moore et al., 2005).  However, one recently concluded trial of anti-EGFR agent [cetuximab 
(Erbitux), (IgG1 monoclonal antibody (mAb)], in a larger randomised clinical trial of cetuximab 
and gemcitabine vs. gemcitabine alone was negative.  In this randomised controlled trial of 745 
patients with APC, gemcitabine and cetuximab did not demonstrate a survival prolongation 
compared to gemcitabine alone (6.3 months for gemcitabine plus cetuximab v 5.9 months for 
gemcitabine alone; p = 0.23, Philip et al., 2010).  To date therefore, there is little positive 
support for the targeting of growth factor receptors in PC. 
 
1.17 Clinical Evidence of Benefit from Direct Interference with the Coagulation Apparatus 
Natural heparin (unfractionated heparin) is a highly-sulfated glycosaminoglycan that has varying 
molecular weights (3-40 kDa) (Weitz1997).  Low molecular weight heparin (LMWH) is defined as 
heparin salts having an average Molecular Weight of less than 8 kDa and a mean MW of about 5 
kDa.  Clinically, LMWH has been used for treatment and prevention of thrombotic disorders 
(Linhardt and Gunay, 1999) with a lower risk of bleeding tendency, thrombocytopenia and 
osteoporosis than natural heparin (Linhardt and Gunay, 1999, Weitz, 1997).  One of the most 
widely used forms of LMWH is dalteparin (Fragmin), which is a nitrous acid depolymerised type 
of heparin with mean MW of 6 kDa (Fig. 1.8, Weitz, 1997).  
 
Heparin can potentially act as an anti-cancer agent via a variety of mechanisms.  It inhibits 
several coagulation factors such as thrombin, FXa, FIXa, FXIa, FXIIa (Palumbo et al., 2000) and 
inhibits cell proliferation, particularly of those cells that over express PAR1 (Balzarotti et al., 
2006).  Heparin also interacts with VEGF-165 and VEGF-189 expressed on malignant cells (Yu et 
al., 2002) and could inhibit angiogenesis via blocking of P- and L-selectin (Borsig, 2010).  It has 
been recently shown that LMWH can decrease the angiogenic and chemo-attractant activity of 
PC patients’ sera (Maraveyas et al., 2010a).  A recently completed randomised phase IIb study in 
APC of gemcitabine vs. weight-adjusted dalteparin (WAD), a type of LMWH, demonstrated a 
significant decrease in the overall incidence of venous TE from 31% to 12%, with a reduction of 
recorded lethal TE and sudden death from 9% to 0%.  These differences were significant but the 
trial was too small to demonstrate an overall survival advantage (Maraveyas et al., 2010b) . 
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Figure 1.8: Schematic representation of dalteparin structure adapted from European 
Pharmacpoeia.  
 
In a second larger randomised trial, Riess et al. (2010) studied 312 APC patients receiving 
chemotherapy randomised into two groups, those with enoxaparin (Clexane which is another 
type of LMWH have MW of 4.5 KD and the ratio of anti-Xa/anti-IIa activity is 3.9 while the MW of 
dalteparian is 6 KD and the anti-Xa/anti-IIa activity is 2.5) those without.  Similar to Maraveyas 
et al. (2010a), a significant decrease of clinical TE was found, 15% vs. 5%, respectively in the 
group treated with LMWH.  However, once again no overall survival benefit was documented 
(Riess et al., 2010).  Most recently, Epstein et al. (2010) studied 6870 PC cases of which 19% of 
patients suffered TE.  Ninety five percent of PC patients that developed TE were treated with 
chemotherapy and LMWH and the survival time of PC patients who developed thrombosis at the 
time of the diagnosis was 6.2 months, while those with secondary thrombosis after PC diagnosis 
was 13.7 months (Epstein et al. (2010). 
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1.18 Pancreatic Cell Invasion: 
Although there have been advances in surgical techniques (Hines and Reber, 2009) and 
chemotherapy (Hines and Reber, 2009, Willett and Czito, 2009), still PC has very poor prognosis, 
due mainly to cell invasion.  Tumour cell metastasis depends on stages that precede the actual 
invasion, which are self-sufficiency in growth signals, insensitivity to growth-inhibitory (ant-
igrowth) signals, evasion of programmed cell death (apoptosis), and limitless replicative potential 
sustained angiogenesis.   
 
The first step of invasion is loss of cell to cell adhesion (Kominsky et al., 2003), often followed by 
impairment of intercellular connection (Czyz, 2008).  The most common changes in cell-
environment interaction in malignancy are loss of E-cadherin (E-cad) function (Kominsky et al., 
2003, Christofori and Semb, 1999) and E-cad expression changes to other integrins such as α3β1 
and αVβ3 that bind the degraded stromal materials (Varner and Cheresh, 1996).  Furthermore, 
neural cell adhesion molecule (CAM, CD-56) decreases either in its level, as in PC and colorectal 
cancer (Fogar et al., 1997) or in activity, as in Wilms’ tumour and neuroblastoma (Johnson, 
1991).  The aggressiveness of the cells depends on the presence of abnormal mitotic activity in 
the nucleus of invaded cells.  Integrin β1 regulates several aspects of mitosis in centrosome 
function cells and cytokinesis (Revert Carlos et al. 2006) and the disruption of this integrin 
inhibits pancreatic cell invasion (Lee et al. 2011).  On genetic bases, erythropoietin-producing 
human hepatocellular carcinoma (Eph receptors) with their ephrin ligands (Eph family receptor 
interacting proteins) form an important cell-cell communication system capable of bi-directional 
signalling (Heroult et.al. 2006, Kullander and Klein, 2002).  It has been reported that Eph genes 
play an important role in control of growth factors and their receptors which are involved in the 
regulation of cell proliferation.  They also play a key role in oncogenesis (Hirai et al.1987).  There 
are two subclasses of Eph family receptor and ligands; the ephrin A ligands bind to EphA 
receptors, while ephrin B ligands bind to EphB receptors (Heroult et.al, 2006).  Although the bulk 
of research has studied the EpH & Ephrin role in development, new evidence suggests strong 
involvement in tumourigenesis, including cell invasion and angiogenesis (Wimmer-Kleikamp and 
Lackmann, 2005; Dodolet and Pasquale, 2000).  Through the use of multiple cell lines, including 
PC cells, it was demonstrated that the C-terminus of ephrin B1 was responsible for conferring the 
increased invasive properties through activation of matrix metalloproteinase-8 secretion (Tanaka 
et. al., 2007b).   
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It has been postulated that there are several oncogen mutations and their signalling pathways 
play an essential role in PC, of which K-RAS, which is a member of the RAS family of GTP-
binding proteins, mediates several cellular activities including cell survival, proliferation and 
differentiation (Malumbers and Barbacid 2003).   
 
The next step of cell invasion is degradation and destruction of the extra-cellular matrix 
(Ellenrieder et al., 1999, Mignatti and Rifkin, 1993 Clark, 1979).  ECM proteinases, such as 
tryptase or thrombin, act on PAR.  This interaction releases a blocking peptide, allowing the 
internal ligand to bind and activate a G protein–coupled signalling cascade.  When the GPI-
anchored uPA-R binds uPA, it interacts with integrins and activates signalling pathways mediated 
by growth factor receptor-bound protein 2 (Grb2).  The transmembrane A disintegrin and 
metalloproteinases (ADAM) proteinases target substrate such as receptors in the plasma 
membrane.  Proteolysis of ECM proteins alters integrin-mediated anchorage, focal adhesions, 
cytoskeletal architecture, and signalling molecules.  Binding of cleaved ECM fragments by 
integrins also activates different pathways than binding of intact molecules.  Proteolysis can 
activate growth factors, such as TGFb, by liberating them from binding proteins in ECM. The 
growth factors then can bind to and activate their plasma membrane receptors, and initiate the 
downstream signalling cascades (Werb 1997, Fig. 1.9).  
 
It has been noted that the thrombophilic state of PC patients may be an accelerant of this 
process.  One of the most important steps is up regulation of proteases, which have an 
important role in membrane degradation (Ellenrieder et al., 2000, Koshiba et al., 1998, Werb, 
1997, Sporn, 1996).  TF-FVIIa-PAR2 signalling regulates αvв3 integrin which enhances cell 
migration and survival when it is associated with VEGFR 2.  Furthermore the chemo attractive 
activity of pro-angiogenic factors plays an important role in enhancement of cell invasion  
(Mahabeleshwar et al., 2006, Hood et al., 200).  Furthermore, protease inhibitor is down 
regulated, protease is unregulated and the inactive form of protease converted to the active 
form of the enzyme.  Protease binds its protease receptor on the surface of the membrane or 
interacts with integrins ( Werb, 1997, Sporn, 1996).  High levels of active MMP-2 have been 
associated with metastasis and the aggressiveness of PC (Ellenrieder et al., 2000, Koshiba et al., 
1998).  
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Figure 1.9 Signalling pathways involving in cell invasion (adapted from Werb 1997)  
 
Thrombin stimulates adhesion of PC cells to endothelial cells and extracellular matrix (Rudroff et 
al., 1998) and also stimulates gelatinase matrix metalloproteinase-2 (MMP-2), which is a collagen 
type IV degrading enzyme (Page-McCaw et al., 2007), therefore enhancing invasion of the 
basement membrane.  In addition, thrombin mobilises adhesion molecules like CD-40 ligand, P-
selectin and αIIbβ3 integrin to the cell surface of endothelial cells.  Furthermore, it has been 
reported that substitution of the three serines of TF the cytoplasmic domain and substitution of 
key residues of the extracellular domain decrease cell invasion (Bromberg et al., 1999). 
 
TF-FVIIa-PAR2 signalling that is produced by the clotting-dependent mechanisms induces the 
production of pro-angiogenic factors including VEGF (Albrektsen et al., 2007).  VEGF is produced 
by clotting-dependent mechanisms and by clotting- independent mechanisms through TF-FVIIa-
PAR2 signalling regulates αvв3 integrin which enhances cell migration and survival when it is 
associated with VEGFR 2 (Hood et al., 2003, Mahabeleshwar et al., 2006).  Furthermore, 
thrombin mobilises adhesion of molecules like CD-40 ligand, P-selectin and αIIbβ3 integrin to the 
cell surface of endothelial cells.  Moreover, endothelial cells (Haralabopoulos et al., 1997) 
platelets, tumour cells and the extra-cellular matrix are adhered to each other by thrombin 
(Maragoudakis et al., 2001).  
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Fibrin clots coat TF expressing tumour cells.  This coat could allow the tumour cells to escape 
surveillance (Palumbo et al., 2000) and would also aid the adhesion of metastatic cells to the 
endothelium (Biggerstaff et al., 1999), leading to colonisation of a new site in the body.  
Metastasis will start when malignant cells adapt to the microenvironment away from the primary 
tumour cells (Gupta and Massague, 2006).  Furthermore, vascular permeability is increased in 
cancer to cover the nutritional demands (Utoguchi et al., 1996) facilitating blood and lymphatic 
vessel invasion (Ellenrieder et al., 1999, Fig. 1.10).  
 
 
Figure 1.10:  Schematic representation of the process of cell invasion (adapted from Martin and 
Jiang 2009). 
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In summary, the autopsy, epidemiological and clinical studies identified pancreatic cancer as one 
of the most highly invasive and angiogenic cancers.  There is a significant correlation between 
pancreatic cancer and TE.  Furthermore, the incidence of thrombosis significantly correlated with 
TF bearing MP.  However, the link (s) between cell invasion, angiogenesis and haemostasis are 
still unclear.  The hypothesis of the thesis is that factors directly attributed to the cancer promote 
the observed pathophysiology and that the removal of the tumour should result in reversal of 
these abnormalities. 
 
1.19 The Aims of the Study 
1- To optimise and standardise the methodology for the clinical part of the study.   
2- To study the expression levels of angiogenic soluble markers pre-and post-operatively in 
patients with operable PC.  
3- To study whether increased levels of these soluble angiogenic markers are associated with 
in vitro motility and chemotaxis of cancer cells (cell invasion assays) or increased haptotaxis 
of endothelial cells (tubule angiogenesis assays).  Also to correlate the cell invasion with 
angiogenic results to see how these change.   
4- To study the levels of pre-operative MP in plasma by flow cytometry and investigate 
changes to these (quantitative) before and after surgery and correlate the results with cell 
invasion and angiogenesis.   
5- To evaluate the procoagulant activity of PC patients pre- and post-operatively and correlate 
the results with TF-bearing MP.   
6- To correlate serological findings with immunohistochemical parameters such as VEGF, 
VEGFR1, VEGFR2, TF, EGF and EGFR. 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 Materials 
All the reagents and chemical used in this thesis were of cell culture grade as appropriate.   
2.1.1 Reagents  
Reagents were obtained from the companies described in Table 2.1 
Table 2.1: Materials used in the study.  
Companies Reagent Catalogue 
Number 
abcam plc, Cambridge, 
UK 
Goat F (ab)2 Poyclonal (Po) Antibody (Ab) anti  
Rabbit IgG (Biotin) 
Rabbit PoAb to human CD-34 
Rabbit PoAb to human EGF 
Rabbit PoAb to human EGFR 
Rabbit PoAb to human TF 
Rabbit PoAb to human VEGF  
Rabbit serum (sterile) 
ab6111 
 
ab64480 
ab9695 
ab2430 
ab62251 
ab46154 
ab7487 
AbD Serotec Ltd., 
Oxford, UK 
Mouse anti-human CD-31: FITC  
Mouse anti-human CD-42b: RPE 
Mouse anti-human CD-14 : RPE  
Mouse anti-human tissue factor: FITC  
Mouse IgG1 Negative control: FITC 
Mouse IgG1 Negative control : RPE 
Rabbit anti mouse HRP 
Rabbit anti rat FITC 
MCA1738F 
MCA740PE 
MCA2185PE 
MCA2548F 
MCA928F 
MCA928PE 
STAR13B 
STAR17B  
 
American diagnostica 
Inc, Stamford, USA   
FITC mAb mouse anti-human tissue factor 
Rabbit PoAb anti-human tissue factor IgG (1 mg) 
4507CJ 
4502 
Aniara, Mason,  
Germany 
Zymuphen MP-Activity  A521096 
ATCC, Teddington, UK  AsPC1 
CFPAC1  
MIA-PaCa-2 
Iscove’s Modified Dulbecco’s Medium  
CRL-1682™ 
CRL-1918™   
CRL-1420™ 
30-2005 
AXIS-SHIELD  
diagnostics Ltd,  
Dundee, UK 
Gluteraldehyde (70%) 
Tween®20  
 
G7776 
P1379 
 
BD Bioscience, Oxford, 
UK 
 
BD MatrigelTM invasion chamber 24- well plate 8 
Micrones.   
Collagen type I   
354480 
 
354236 
Biocytex, Marseille – 
France 
Megamix beads  7801 
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BD Pharmingen TM , 
Oxford, UK 
PE Annexin V apoptosis detection kit I 
 
559763 
 
Biosera East, Sussex,  
UK 
Foetal Bovine serum  S1870 
Caltag Laboratories, 
Buckingham UK 
Caltag Counting Beads PCB-100 
Dade Behring, Milton 
Keynes, UK 
Dade R Innovin  B421-50 
eBioscience, Hatfield, 
UK 
Human anti-annexin V platinum ELISA  BMS247 TEN 
GE Healthcare, Bucks, 
UK 
Chemiuminescent (ECL western blotting detection 
reagent and analysis)  
RPN2106 
GIBCO Invitrogen 
Corporation, Paisley  
UK 
MEM 10x with + Earle’s with -L-Glutamine and  
NaHCO3 
21430 
Helena Bioscience 
Europe, Tyne and  
Wear , UK 
Normal-Trol 1 Coagulation Control  5186 
Hyphen BioMed, 
Versailles, Germany  
Zymuphen MP-Activity 521096 
Invitrogen Ltd, Paisley, 
UK 
AccuCheck counting beads for count & pipetting 
accuracy   
PCB 100 
National diagnostics,  
Georgia, USA 
Histoclear II HS-200 
PAA the cell culture 
company, Yeovil, 
Somerset, UK 
 
 
Bovine serum albumin 
DMEM High Glucose  Without  L-Glutamine 
HEPES Buffer Solution (1M) 
L-glutamine  
Medium 199 With Earle’s Salts and L-Glutamine 
Penicillin/Streptomycin 100X 
RPMI 1640 
K45-001 
E15-009 
S11-001 
M11-004 
E15-834 
P11-100 
E15-840 
Pharmacia Ltd., kent,  
UK 
Fragmin P10229 
Promega Corporation, 
UK 
CeII Titer 96 Aqueous One Solution Cell Proliferation 
Assay 
G3581 
Promo Cell, Heidelberg, 
Germany  
 
 
 
Endothelial Cell Growth Medium(MV) 
Free Freezing Medium (Cryo-SFM) 
HDMEC  
Hepes Buffer Saline  
HUVEC 
Trypsin/EDTA 
Trypsin Neutralising SolutionTNS 
C-22020 
C-29910 
C-12210 
C-40010 
C-12200 
C-41010 
C-41110 
R&D system Europe,  
Ltd. Abingdon UK 
Human angiogenesis array (proteome profilerTM 
antibody arrays) 
Human leptin immunoassay 
Human VEGF immunoassay 
Human VEGF R1/Flt-1 
ARY007 
 
DLP00 
DVE00 
AF321 
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Human VEGF R2/KDR/Flk-1 antibody 
Monoclonal anti h-VEGFR-RPE 
Mycoplasma detection kit  
TF ELISA 
TFPI ELISA 
AF357 
FABSP3P 
CUL001B  
DCF300 
DTFP10 
Scientific laboratory 
supplies LTD 
BD cell falconTM culture insert   
 
 
 
353097 
 
 
Sigma-Aldrich  
Company, Poole, 
UK 
Accustatin® Harris (Haematoxylin solution) 
Bovine serum albumin 
Collagen, type IV; from human placenta, Acid 
Diamino benzidin  (DAB) 
Dimethyl sulphoxide (DMSO) 
Ethanol 
Magnesium sulphate   
Methanol  
Sodium Chloride (NaCl) 
Potassium bicarbonate 
Sodium pyruvate  
Soluble Phosphate Buffered Saline  
Trypan blue solution (0.4%) 
Trypsin  
HHS 
A2153-50G 
S3014 
D4293-50SET 
D2650 
32221 
M7506-500G 
24229 
C5533-5MG 
P9144-500G 
S8636 
P4417-100TAB 
T8154 
T7168-50TAB 
Trizma Sigma, Poole,  
UK 
Tris T 1503 
Vector laboratories,  
Inc., Burlingame U.S.A  
Antigen unmasking solution 
Avidin/Biotin Blocking kit 
Biotinylated anti-goat IgG (H+L)  
TMB Substrate kit for peroxidise 
Vectostatain ABC kit 
H-3300 
SP-2001 
BA-9500 
SK-4400 
PK-6200 
VWR International, 
Leicestershire, UK 
Calcium chloride 2-hydrate  
Methylene blue 
100704Y 
3019270 
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2.1.2 Equipment  
Equipment and Materials used are described in Table 2.2.   
Table 2.2: Equipment used in the study.  
Companies Equipment and Materials  
 
 
Axis-Shield Diagnostics Ltd,  Cuvettes 500 pieces 
Gluteraldehyde (70%) 
Steel balls  
BD Bioscience 25 cm2 flasks with red cup  
75 cm2 flasks with red cup  
150 cm2 flasks with red cup  
Flow cytometry (FACSCaliurTM), CellQuest software  
version 3.3 
24-well plates 
8 µm pores Boyden chambers 
Plasma tubes 
Serum tubes 
BD Vacutainer, Franklin Lakes,  
UK 
Serum tubes  
Sodium citrate tube  
Biotek Instrument, Winooski,  
USA 
ELISA plate reader 
Epi Chemi II,Cambridge, UK Transmission mode scanner / UVP gel doc system /  
Darkroom Analysed on Labimage Aquisition and software/ 
version 4.6 / Cambridge, UK) 
ELWD 0.3 T1-SNCP- Nicon JP Imaging RTTIGA 2000R, Camira attached to Leitz Labrluxs 
Heraeus centrifuge,   
Buckinghamshire, UK 
Centrifuge 
Fishe Thermo Scientific,Roskilde, 
DK  
Freezing container (Mr Frosty) 
Progen, Mexborough, UK Gen Fuge Ultracentrifuge 
Sarstedt, Leicester, UK  25 cm2 flasks with yellow cup 
75 cm2 flasks with yellow cup 
Tissue Culture Plate 24-Well Flat Bottom with Lid 
Sartorrius stedim, biotech,  
Aubagne, FR 
0.10 µm filter  
Scientific laboratory supplies  
Ltd, East, Yorkshire, UK    
BD falconTM cell culture insert   
pH meter 
Thermo Shandon Ltd, Cheshire,  
UK  
Sequenza rank 
Weber Scientific International  
Ltd., Teddington, UK 
Haemocytometer 
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2.2 Methods  
2.2.1 Culture of the Cell Lines 
All experiments and procedures were carried out in a sterile environment in a class II biological 
safety cabinet.  Ethanol [70% volume/ volume (v/v)] was used for cleaning all surfaces before 
commencing work.  Only sterile plastics were used and all media were pre-warmed by placing in 
a 37 degree Celsius (oC) water bath for 30 minutes before use. 
 
2.2.2 Endothelial Cell Lines Used in the Study 
A panel of cell lines were used in this study.   
2.2.2.1 ECV 304  
2.2.2.1.1 Maintenance and Adaptation to Serum Free Medium  
ECV 304 cells are a human bladder cancer cell line initially used as a model for studying 
endothelial angiogenesis.  ECV 304 is a cell type characterised by a typical cobblestone 
monolayer growth pattern and a high degree of proliferation without requirement of any specific 
growth factors (Takahashi et al., 1990).  ECV 304 has been used previously to provide insight 
into the mechanisms governing angiogenesis under both physiological and pathological 
conditions (Hughes, 1996).  ECV 304 was used in this study to evaluate methods of angiogenesis 
assay as these cells have some similarity to endothelial cells.  ECV 304 cells were kindly supplied 
by Dr C Ettelaie (Department of Biological Science, University of Hull). 
 
ECV 304 cells were cultured in M199 medium supplemented with foetal bovine serum [FBS, 10% 
volume/volume (v/v), 100 units/ml penicillin 1% weight/ volume (w/v), 100 µg /ml streptomycin 
(1% w/v) and 2 mM/L-glutamine].  These cells were incubated in a humidified environment at 
37 ºC; in the presence of 5% CO2 (the medium was replaced every 2-3 days).  ECV 304 cells 
were propagated as a monolayer until approximately 95% confluent and then the cells were 
scraped and sub cultured at a ratio of 1:3.  In all experiments, cells were treated with test 
reagents at 70% confluence.  For angiogenesis experiments, the cells need to be adapted to 
serum free medium by progressive reduction of the serum concentration.  The medium was 
replaced with M199 medium supplemented with FBS (5%; v/v) and antibiotics as listed 
previously for 48 hours (h) at 37 oC / 5% CO2.  Finally, cells were cultured in 2% (v/v) FBS plus 
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antibiotic at 37 oC / 5% CO2 for 48 h.  Then cells were washed three times with phosphate buffer 
saline (PBS) and transferred to serum-free medium (SFM) and incubated for 24 h, at 37 oC / 5% 
CO2 before harvesting.   
 
2.2.2.1.2 Passaging 
The medium was removed from the flask and washed with 5 ml of PBS, to remove traces of 
remaining serum.  Trypsin/Ethylene Diamine Tetra Acetic acid (Trypsin/EDTA; 4 ml) was added 
to the flask which was then incubated for 3 minutes to allow the detachment of cells.  Complete 
medium was then added (4 ml) to neutralise the trypsin.  The suspension was centrifuged at 320 
g for 5 minutes, and the supernatant discarded.  The cell pellet was resuspended in an 
appropriate volume of medium and the cell density determined using a haemocytometer.  Cell 
suspension (10 μl) plus 10 µl of 0.2% (w/v) trypan blue stain were mixed together and 10 µl of 
mixture were loaded onto the haemocytometer.  The concentration of cells per ml was 
determined using the average total cell count (colourless and blue colour cells) multiplied by 2 x 
104.  The cell viability was determined per ml using the average of colourless cell count 
multiplied by 2 x 104.  ECV 304 cells were used at passage 10. 
 
2.2.2.1.3  Storage and Recovery of ECV 304 
Cells taken from the flask were centrifuged (320 g for 5 minutes), the supernatant was aspirated 
and the cells re-suspended in complete M199 medium supplemented as described in 2.2.2.1.1 
with the addition of 10% (v/v) Dimethyl Sulphoxide (DMSO).  One ml of the medium containing 
0.5 x 106 of cells was kept in 1.5 cryovials labelled with ECV 304 cell type, number and date.  
The vials were transferred into a freezing container (Mr Frosty) and placed into a -80 oC freezer 
overnight.  It is critical to get a repeatable -1 °C/minute cooling rate, which is required for 
successful cell cryopreservation and recovery.  This was achieved by adding 100% isopropanol to 
the freezing container.  After at least 24 h, vials were transferred to liquid nitrogen and the 
location was recorded.  This methodology has been used by many researchers (Meads and 
Schroer, 1995, Ihrke et al., 1993, Cassio et al., 1991).  When required, cryovials containing the 
cells were thawed by placing them in a 37 oC incubator.  Once defrosted, the cells were 
transferred immediately to pre-warmed 199 M medium, washed three times to removes traces of 
DMSO and seeded out into a 25 cm2 cell culture flask at the required density.   
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2.2.2.2  Human Dermal Microvascular Endothelial Cells (HDMEC)  
2.2.2.2.1  Maintenance and Adaptation to Serum Free Medium 
HDMEC are isolated from the dermis of juvenile foreskin and adult skin (Kubota et al., 1988). 
Since the dermis contains blood and lymphatic capillaries, HDMEC comprise blood and lymphatic 
micro vascular endothelial cells.  HDMEC were purchased from Promo cell.  A small sealed flask 
(25 cm2) was obtained from the Promo Cell Company.  On arrival the flask was incubated for 2 h 
at 37 oC (the lid remained completely closed).  The cells were maintained in endothelial cell 
growth medium (MV type) supplemented with 2% (v/v) FBS, 10 ng /ml EGF provided by the cell 
provider and antibiotics at the same concentration as described for ECV 304.  All HDMEC were 
used as flasks and became approximately 95 % confluent below passage 6.  A similar strategy to 
that described for ECV 304 was used; the FBS and EGF were depleted to 1% and 5 ng/ml 
respectively for 48 h and then to 0.5% to 2.5 ng/ml respectively for the next 48 h to adapt them 
to SFM.   
 
2.2.2.2.2  Passaging 
The flask was carefully opened in a class II biological safety cabinet, the medium aspirated and 
the cells washed with 2 ml of Hepes buffered saline. Trypsin/EDTA solution (2ml) was added for 
3-5 minutes, then the trypsin was inactivated by adding 2 ml trypsin neutralising solution.  The 
cells were re-suspended and centrifuged at 320 xg for five minutes.  The pellet was re-
suspended and the cells transferred to a 75 cm2 yellow cup cell tissue culture flask made from 
high-quality polystyrene with a positively charged growth surface, created by imitating the amine 
functional group of proteins.  HDMEC were used at passage 5.   
 
2.2.2.2.3  Storage    
The old medium was aspirated; the cells were washed with Hepes buffered saline (3 ml), then 
pre-warmed trypsin/EDTA (3 ml) was added for 3-5 minutes and trypsin neutralising factor (3 
ml) was added to neutralise enzyme activity.  The cells were pelleted at 320 xg for five minutes, 
and then were resuspended in Cryo-SFM (1 m).  Cryovials with HDMEC were labelled as 
described for ECV 304.  Cryo-SFM is a commercial formulation for cryo-preservation of animal 
and human cells; it contains DMSO, methylcellulose and SFM.  Long term freezing and storage 
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were as described in 2.2.2.1.3.  The density and viability were determined as described for ECV 
304.  
 
2.2.3 Pancreatic Cell Lines  
2.2.3.1 Maintenance and Adaptation of AsPC1 to Serum Free Media  
AsciticPC cells-1 (AsPC1) are PC cells derived from asciticfluid (Chen et al., 1982).  AsPC1 cells 
were purchased from American Type Cell Collection (ATCC).  AsPC1 cells were maintained in 
RPMI 1640 medium supplemented with Hepes buffer [final concentration 10 nanomolar (nM)]; 
sodium pyruvate [final concentration 1millimolar (mM)]; 2 mM/L-glutamine, FBS and an 
antibiotic with concentration as described for ECV 304 (section 2.2.2.1.1).  A similar strategy for 
adaptation to SFM was followed to that described for ECV 304.  For Hepes buffer and sodium 
pyruvate, the final concentration was depleted to 5 nM and 0.5 mM respectively for 48 h.  It was 
then depleted to 2.5 nM and 0.25 mM respectively in the following 48 h. Other steps were 
identical to those followed with ECV 304.  AsPC1 cells were used at passage 10.   
 
2.2.3.2 Maintenance and Adaptation of CFPAC1 to Serum Free Media 
Cystic Fibrosis Pancreatic Adenocarcinoma-1 cell line (CFPAC1) is derived from the liver 
(McIntosh et al., 1988).  The original source of these cells was from a patient with cystic fibrosis 
and adenocarcinoma of pancreas.  CFPAC1 cells were purchased from ATCC.  CFPAC1 cells were 
maintained in Iscove’s modified Dulbecco’s medium supplemented with FBS and antibiotic as 
described for ECV 304 (2.2.2.1.1).  The growth of CFPAC1 was relatively slow when the cells 
were cultured in a red cup flask, i.e. the ordinary flask, but when yellow cup tissue culture flasks 
were used, the growth of CFPAC1 was substantially faster.  SFM adaptation of CFPAC1 was 
similar to that described for ECV 304 (section 2.2.2.1.1).  CFPAC1 cells were used at passage 10 
 
2.2.3.3 Maintenance and Adaptation of MIA-PaCa-2 to Serum Free Media 
The MIA-PaCa-2 cell line is a cell line from primary pancreatic tumour.  MIA-PaCa-2 cells were 
maintained in Iscove’s Modified Dulbecco’s Medium supplemented with 2.5% (v/v) horse serum, 
FBS and antibiotics as described for ECV 304 in section 2.2.2.1.1.  The growth of MIA-PaCa-2 
was similarly slow when ordinary flasks (with red cup) were used.  Therefore, cells were 
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transferred to yellow cup tissue culture flasks for the same reason as described in 2.2.2.2.2.  
MIA-PaCa-2 cells were used at passage 10.   
Enzymatic detachment of adherent cells, determination of cell density and subculture of CFPAC1 
and MIA-PaCa-2 cells were as described for ECV304 (section 2.2.2.1.2).  For horse serum, the 
final concentration was depleted to 1.5% for 48 h.  It was then depleted to 0.5% v/v for 48 h.  
Other steps were similar to those followed with ECV 304 for SFM adaptation. 
 
2.2.4 Mycoplasma Testing 
The principle of this technique is detection of hybridisation of 16S ribosomal RNA.  The eight 
most common mycoplasma types are M.orale, M.pirum, M.hominis, M.salivarium, A.laidlawii, 
M.hyorhinis, M.arginini, M.fermentans in the cell culture supernatant with biotin-labelled capture 
oligonucleotide probe and dioxigenin-labeled detection probes.  The solution containing 
rRNA/probe hybrid was then added to streptavidin-coated microplate and the rRNA/probe hybrid 
was captured.  The plate was washed to remove unbound material.  An anti-digoxigenin alkaline 
phosphatase conjugate, substrate solution and amplifier solution were then added and the colour 
developed in proportion to the amount of mycoplasma rRNA.  Cell culture supernatant was 
collected from cell lines over a period of five weeks. Samples from the medium of each cell line 
were collected weekly and kept in a freezer at -80 oC.  The manufacturer’s method was carried 
out as follows: all reagents were brought to the room temperature.  Concentrated (10X) Cell lysis 
diluent was diluted with sample diluents to form 34 ml of Cell Lysis Diluent.  Capture probes (1 
ml) were mixed with detection probes (1 ml) and sample diluent (4 ml).  Wash buffer 
concentrate (10X) was diluted with distilled water to form 1L of wash buffer.  Lyophilized 
substrate was reconstituted with substrate diluents to form the working substrate solution.  
Lyophilized amplifier was reconstituted with 6 ml of amplifier diluents to form the working 
amplifier solution.    
 
The hybridisation plate was washed with wash buffer twice and the excess wash buffer was 
removed by inverting the plate against clean paper towel.  Diluted probes (50 µl) were added to 
the designated wells.  A hundred and fifty µl of positive control (in triplicate), negative control 
(fresh medium, in triplicate) and samples (duplicate) were added to designated wells.  A float 
collar was applied to the hybridisation plate and the plate was incubated at 65 oC for 60 minutes 
in a water bath.  The streptavidin plate was washed twice and the excess wash buffer was 
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removed by inverting the plate against clean paper towel.  Then, 150 µl from each well of the 
hybridisation plate was transferred to the washed streptavidin plate and incubated for 60 
minutes at room temperature, on a horizontal orbital shaker set at 500 rounds / minute.  Finally 
the plate was washed four times with wash buffer.  
 
Anti-digoxigenin conjugate (200 µl) was added to each well and the plate was covered with a 
new sealer; the plate was incubated for 60 minutes on the shaker at room temperature.  The 
plate was washed six times with wash buffer and the excess buffer was removed as described 
before.  Substrate solution (50 µl) was added to each well and the plate was incubated for 60 
minutes on the shaker at room temperature.  Then, amplifier solution (50 µl) was then added to 
each well and the plate covered with a new sealer and incubated for 30 minutes on the shaker at 
room temperature.  Stop solution 2 N sulphuric acid (50 µl) was added to halt the reaction and 
the optical density was measured using an ELISA reader at 490 nm wave length.  A correction 
reading was measured at 650 and subtracted from the 490 reading to correct for optical 
imperfections in the polystyrene micro-plate.  
 
2.2.5 Flow Cytometry Detection of Growth Factor Receptors  
For detection of growth factor receptor, the same principles were used to detect receptors on all 
cell types.  The cells were centrifuged at 320 xg for five minutes and washed three times in 
PBS/bovine serum albumin (BSA)/Azide.  At a concentration of 2 x 106 /ml, an aliquot (100 µl) of 
the cell suspension was mixed with test antibody or negative control for 30 minutes.  For the 
experiments with unlabelled test antibodies, samples were washed three times and then 
secondary fluorochrome conjugated antibody was added, mixed and incubated at dark for 30 
minutes.  Labelled (fluorescent) test antibodies were added and incubated in the dark for 30 
minutes.  The cells were then washed three times as previously described to remove excess of 
unbound antibody.  Finally, the cells were re-suspended in 300 µl of PBS/BSA Azide and were 
analysed by flow cytometry.  Antibodies used for detection of TF, VEGFR 1-3, EGFR and their 
negative controls are summarised in Table 2.3. 
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Table2.3: Antibodies used for detection of growth factor receptors.  
Cell Receptor 
 
Antibody  Negative control  
TF  
Mouse anti – human TF antibody 
fluorescein isothiocyanate (FITC) - 1 
µg/ml.   
Mouse IgG FITC-1 µg/ml-5 µl  
VEGFR 1 
VEGFR 2 
VEGFR 3 
 
Mouse anti-human VEGFR 1, VEGFR 2 
and VEGFR 3 respectively 
Phycoerythrin (PE) labelled- µg/ml-10 
µl. Incubation was at 2-8oC  
Mouse IgG PE-1 µg/ml-5 µl  
EGFR  
Rat anti-human EGFR- 5µg/ml-5 µl 
(unconjugated).  
 
Rabbit anti rat (FITC labelled)- 1 
µg/ml-5  µl (Secondary conjugated)  
Rat monoclonal IgG- 5  µg/ml-5 µl  
 
 
Rabbit anti rat (FITC labelled)- 1 
µg/ml-5  µl (Secondary conjugated)  
 
2.2.6 In Vitro Model of Angiogenesis  
Two-dimensional assay of angiogenesis is a simple and common method that enables in vitro 
study of the formation of capillaries (tubule-like structures).  Capillaries develop on an 
extracellular matrix and are a convenient method for evaluation of the pro-angiogenic activity.  
2.2.6.1 Gel Preparation   
For reproducibility and optimisation, gel was prepared by two methods.  
2.2.6.1. A  Method A 
All materials were kept on ice. Collagen type I, from rat tails, was mixed with acetic acid (0.02 N) 
to give 3.41 mg/ml concentration was used as a stock concentration.  The gel was diluted (1:8) 
with cold distilled waster (DW).  Further dilutions are not recommended because this decreases 
the rigidity of the gel.  To prepare 1 ml of gel, 10X PBS (100 μl) was added to sterile ice cold 
NaOH (3 μl) and mixed well using a Whirly Mixer, then 10X PBS/NaOH was added to ice cold DW 
(771 ml), and the volume was adjusted to 1 ml with diluted collagen type I (1:8, v/v) and mixed 
thoroughly.   
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2.2.6.1. B Method B 
Collagen type I (0.1% (w/v) in 0.1 M acetic acid ), 10 X MEM, neutralised buffer (260 mM 
Sodium bicarbonate, 1 N sodium hydroxide) in respective proportion 9:1:1. The gel was 
incubated for 1 h at 37 oC (Ettelaie et al., 2008, Pradier and Ettelaie, 2008, James et al., 2002, 
Watanabe et al., 1999). 
 
2.2.6.2  Two-dimensional Assay of Angiogenesis  
To set up the assay, the gel (0.5 ml) from either method was added to the wells of 24 well 
plates and allowed to set at 37 oC, 5 % CO2 for 1 h.  The cells that were previously adapted in 
SFM (2 x104 cells/100 µl) were seeded sparsely on the top of gel.  After 3 h, PC serum (100 µl) 
and if require 2-10 µl as appropriate, the volume was adjusted to 0.5 ml with sterile PBS.  After 3 
days incubation capillary formation was observed.  The gels were stained after fixation with 3% 
glutaraldehyde for 15 minutes.  This method was used successfully by many previous groups 
(Ettelaie et al., 2008, Pradier and Ettelaie, 2008, Staton et al., 2004b, Zimrin et al., 1995, Madri 
and Williams, 1983).  Immediate fixation is essential to prevent detachment of capillaries from 
the matrix due to the release of protease enzymes of the cells.   
 
2.2.6.3  Staining of Capillary Formation 
After fixation of the gel, the cells were stained with (0.25 µg/ml) mouse anti human CD-31 
antibody for 15 minutes (Pradier and Ettelaie, 2008).  The collagen gel was washed twice with 
PBS 0.05% (v/v) tween 20, then incubated for 1 h at room temperature with rabbit anti-mouse 
horse radish peroxidase (20 µg/ml).  The gel was washed twice with 0.05% (v/v) PBS-tween and 
incubated with tetramethylbenzidine (TMB) substrate for peroxidase, prepared a maximum of 
five minutes before use, at room temperature for five minutes.  TMB substrate was used to stain 
membranes allowing visualisation of a blue precipitate.  The gel was then observed by 
microscopy (the number and the length of capillaries were assessed) using an Imaging RETIGA 
2000 R camera attached to a LeitZ Laborlux S fluorescence microscope.  Images were analysed 
using the Image – pro plus program (The software is Image pro-plus version 6, Medium 
Cybernetics).  All experiments were carried out in duplicate and 10 fields of high power (x400) 
view were assessed for each test.  
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2.2.7 Cell Invasion  
2.2.7.1 Types  
Two methods were used to assess cell invasion: a BD biocoatTM matrigelTM invasion chamber 
(Khan et al. 2009, Kakkar et al., 1999) and a Boyden chamber coated with collagen IV (Ettelaie 
et al. 2011a, Staton et al., 2004b, Hagan et al., 2003, Miao et al., 2000).  The matrigel chamber 
was covered with a thin layer of basement membrane matrix, mimicking the nature of the in vivo 
basement membrane.  The BD matrigel matrix consists of collagen IV mixed with materials 
extracted from engelbreth-holm-swarm (EHS) mouse sarcoma which contains many pro-
angiogenic factors that enhance cell invasion such as heparin sulphate protoglycan, laminin, FGF 
basic and TGF beta.  Therefore, the cell motility does not depend only on the biological factors of 
malignant pancreatic cells and the chemotaxis effect of angiogenic markers in the sera, but also 
depends on the effect of those factors in the matrigel matrix.   
 
Boyden chambers coated with collagen type VI were used to evaluate the chemotaxis effect of 
PC sera without enhancement of the PC cells motility by angiogenic factors.  Boyden chambers 
coated with 50 µl collagen IV [1 mg/ml (w/v)] were placed into a 24-well plate and the excess 
collagen was then discarded after overnight incubation at 37 oC in 5% CO2.  
 
In both methods, pancreatic cell lines (8 x 105/ml) adapted previously to grow in SFM as 
described in sections 2.2.3.1-2.2.2.3, in an aliquot of 250 µl medium were seeded into the upper 
compartment of each chamber.  Medium in the base of the well was supplemented with patients’ 
serum (10% v/v; 250 µl total volume).  The plates were incubated at 37oC under 5% CO2 for 24 
h. Following incubation, the medium was removed from the upper compartment of each 
chamber and the cells on the upper side of the filter chamber were scraped off, using a sterile 
cotton swap. Non-invasive cells cannot infiltrate the membrane, therefore will remain in the 
upper part of the membrane while invasive cells can detach from the membrane and pass 
through the pores (Fig. 2.1).  The principles of cell migration have been described by several 
groups (Ettelaie et al. 2011a, Staton et al., 2004b, Hagan et al., 2003, Miao et al., 2000).  
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Figure 2.1: Schematic representation of Boyden chamber.  
 
2.2.7.2 Measurement of Cell Invasion  
2.2.7.2.1 Cell Titre Aqueous One Reagent (CTAOR) Method 
The number of cells that had migrated through the collagen-coated pore was measured by 
adding CTAOR (40 ml) to the medium in the lower chamber of the plates.  A control containing 
only medium was included.  All samples were incubated at 37 oC for 4 h.  Finally, 240 µl of each 
sample was diluted with 360 µl of DW in a plastic cuvette and the absorption values measured 
against the control samples (known numbers of cells) at 490 nm using an ELISA plate reader.  
The absorption values were converted to number of cells using a standard curve.  CTAOR 
contains a tetrazolium compound, which is reduced by cells into a coloured formazan product 
that is soluble in tissue culture medium.  The quantity of the formazan product is directly 
proportional to the number of living cells (Ettelaie, et al., 2011, Maraveyas et al., 2010a). 
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2.2.7.2.2 Staining Method 
Staining was also used to evaluate the cell invasion.  The membranes were fixed with 100% 
ethanol for 2 minutes, stained with methelyne blue for 2 minutes, washed with DW and left to 
dry.  A small drop of immersion oil was placed on the slide, the membrane was put on the slide 
and then another drop of immersion oil was put on the membrane.  The membranes were 
covered by a cover slip and gentle pressure was applied to expel any air bubbles.  Cells were 
counted in non-overlaping 5 high-power fields of view (x 400) covering the whole membrane.  
The mean number of these 5 fields was used as a measure of cell invasion.  This methodology 
has been used successfully by many researchers (Tang et al., 2010, Staton et al., 2004a, 
Koshiba et al., 2000, Kakkar et al., 1999, Miao et al., 2000).  
 
2.2.8 Flow-cytometric Analysis of MP 
Blood samples were collected in 5 ml sodium citrate tubes (tubes with a blue top which contain 
buffer tri-sodium solution and citrate concentration of 0.109 mol/L  (3.2%).  The details of blood 
sample collection will be described in section 6.2.  Aliquots (50 μl) of platelet poor plasma (PPP) 
were mixed with target-specific FITC and PE antibodies (1 µg/ml, 5 μl) in polypropylene tubes 
and incubated at room temperature in the dark for 30 minutes.  Filtered PBS (0.1 µm filter) was 
then added before assay by flow cytometry.  An anti-TF conjugated FITC antibody was used to 
determine the total number of TF bearing MPs; anti-CD-14 PE was used to determine monocyte-
derived MP (MoMP), anti-CD-42b PE and anti-CD-31 FITC antibody were added to platelet 
derived MPs (PMP) and EMP as PMP were positive for both of them and EMP was positive for 
anti-CD- 31 and negative for anti-CD-42b antibodies.  Negative control FITC (mouse IgG) and PE 
were used to identify the positive expression of the factors mentioned above.   
 
To determine the size of 0.1-1 µm MP, megamix beads (20 μl with 180 μl distilled water; DW) 
were used.  These are a mixture of fluorescent beads with diameter in the range of 0.5 and 0.9 
and platelet size that ranged from 0.9-3 µm.  This allows the setting of the cytometer to study 
MPs within a fixed size region and to get reproducible MP counts (Robert et al., 2009, Vince et 
al., 2009).  MP were identified initially according to their scatter properties and further analysed 
according to provenance into MP by selective antibody labelling measured by flow cytometry.  A 
known volume of counting beads was mixed with the same known volume of PPP.  Since the 
concentration of MP was unknown, the number of MP/µl (the absolute count) was obtained by 
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relating the number of MP counted to the total number of fluorescent bead events.  The MP 
number was then multiplied by the number of total fluorospheres per unit of volume.   
 
For annexine MP, Two aliquots (25 μl) of PPP were mixed with target-specific PE Annexin V 
antibody (1 µg/ml, 5 μl) in polypropylene tubes and incubated at room temperature in the dark 
for 30 minutes, 1X annexin V binding buffer (400 μl) and counting beads (25 μl) were added to 
one tube (test) and filtered PBS (400 μl) was added to another (control) before assay.  Megamix 
beads were used to identify the site of MP and counting beads were used to count the absolute 
number of MP as described in section 2.2.8.2. 
 
2.2.9  Measurement of One Stage Prothrombin Time 
One stage prothrombin time (PT) time assay can be defined as a measurement of the time in 
seconds (S) which is required for a plasma sample to clot using a coagulometer.  In the current 
study a modified one-stage PT assay was performed using a Thrombotrank SOLO Coagulometer.  
A modified one stage PT assay was used in this study as described by other groups (Ettelaie et 
al., 2008, Ettelaie et al., 1998).   
 
TF concentration used for measurement of samples PT was determined according to the TF 
concentrations that produce CT of 90 ± 10 when NormTrol control plasma (which has all the 
clotting factors except TF) was added.  For the latter experiment, the coagulometer was 
switched on 15 minutes before starting the experiment to allow the test chambers to reach 37 
oC.  The materials were also all equalibrated at 37 oC prior to addition of the reagents.  A steel 
ball was put in the central cuvette of the coagulometer.  CaCl2 (25 mM; 100 μl) and NormTrol 
control plasma (100 μl) were incubated together at 37 oC for two minutes in the central cuvette, 
then the coagulation was initiated by the addition of TF (100 μl, 10 U/ml).  Serial dilutions of the 
recombinant TF (1000-1 U/ml) were carried out and the PT assay was performed on several 
dilutions.  The experiments were repeated three times for each dilution to generate a standard 
curve.  A CT of 90 S was recorded when 10 U/ml of TF was used and this level of TF was used 
as standard when PT of test samples was measured.   
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The samples as described previously were collected in 5 ml sodium citrate tubes (Blue lids).  The 
PT was performed within 4 h of venesection to be sure the integrity of TF-bearing MP.  PT assay 
was performed when blood samples filled the vacuntainer completely as marked on the tube 
and, which indicates an accurate 1:9 dilution of one part sodium citrate to 9 parts of the blood.  
One stage PT relies on the activity of the recombinant tissue factor to initiate the coagulation 
mechanism, whereas the low activity of the 10 U/ml TF allows the values to be altered by the 
presence of any TF in the added samples.  Furthermore, adding of 10 U TF allows the clotting 
quicker.  The preparation of the coagulometer was performed as described in the measurement 
of CT with NormTrol control plasma.  Fresh PPP (100 µl) and recombinant TF (100 µl, 10 U/ml) 
were added to the central cuvette and incubated at 37 oC for two minutes, then coagulation was 
initiated by the addition of 25 mM CaCl2 (100 µl).  The experiment was repeated three times for 
each sample and mean of these readings was recorded.   
 
2.2.10 Human Angiogenesis Array (proteome profilerTM antibody arrays) 
2.2.10.1 Principles 
The measurement of levels of expression of angiogenic markers is a key step to understanding 
the role of these markers in angiogenesis.  This was done using serum from PC patients using a 
human angiogenesis array kit.  Detection of relative expression of 55 angiogenic markers 
simultaneously was achieved with this kit.  It is a rapid and economical method when compared 
with other methods such as ELISA, in which the protein expressions are assessed individually; 
however the latter would give quantitative values.  Captured antibodies were spotted in duplicate 
on nitrocellulose membrane.  Diluted serum was mixed with a cocktail of labelled of antibodies 
specific for angiogenic factor and then incubated with nitrocellulose membrane which contained 
capture antibodies to bind the antibody/antigen complex.  Streptavidin-HRP and 
chemiluminescent (ECL, which is a western blotting detection reagent and analysis) reagents 
were added to visualise binding.  Bound proteins are detected by the light emitted, which is 
proportional to the amount of antibody/antigen complex captured from the samples.  
 
The human angiogenesis array kit contains four nitrocellulose membranes; each membrane 
contains 55 antibodies, six identical positive control antibodies containing protein standards and 
two negative controls.  All antibodies are spotted in duplicate.  The membranes were handled 
with gloved hands and flat-tipped tweezers to avoid contamination.  The detection antibody 
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cocktail was reconstituted with 100 µL of DW.  The 25X wash buffer was diluted to 1X wash 
buffer (40 mL of 25X wash buffer was diluted with 960 ml of distilled water).  Array buffers 4, 5 
and 7 were ready for use.  Streptavidin-HRP was diluted in 1:2000 with buffer 5.  The developer 
and fixative were diluted with distilled water 1:4.  All assay reagents were brought to room 
temperature and the patients’ samples were thawed and kept on ice before use.  
 
2.2.10.2  Method  
Array buffer 7 (2 ml) was added into each well of the four-well multi-dishes for blocking of non 
specific protein reaction and incubated for one hour on a rocking platform.  At the same time, 
serum (100 µL) was added to 0.5 mL of array buffer 4 and the volume was adjusted to 1.5 mL 
with array buffer 5 (i.e. adding 0.9 mL of array buffer 5), then 15 µL of reconstituted labelled 
antibody cocktail was added to the mixture and incubated for one hour at room temperature.  
Buffer 7 was aspirated from the wells and the sample/antibody mixture was added to the 
membrane.  The lid was put on the plate, which was then incubated overnight at 2-8 oC on a 
rocking platform.  The membrane was removed from the well to individual plastic containers and 
washed three times for ten minutes each. Finally, the membranes were removed and the lower 
edge was gently blotted on absorbent paper to allow excess buffer to be drained off.  The 
membranes were moved to wash out 4-well multi dish plates and were incubated with 1.5 ml of 
diluted streptavidin-HRP for 30 minutes.  The membranes were moved to individual containers 
and washed with wash buffer three times for ten minutes for each wash.  Again the membranes 
were carefully removed from the individual containers and blotted on absorbent paper to remove 
excess buffer.   
 
ECL western blotting detection agents (3 ml) were added to each membrane for three minutes.  
A transmission mode scanner (UVP gel doc system / Epi Chemi II Darkroom) running on 
Labimage Acquisition and software/ version 4.6. / Cambridge, UK) was used to detect the light 
emitted from the spots; the scanner captured four pictures, one picture every five minutes up to 
20 minutes.  As the time of exposure increases, the density of spots increased (5, 10, 15, 20 
minutes).  The first picture was chosen for analysis (Fig. 2.2). 
. 
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Figure 2.2: Diagrammatic representation of angiogenesis protocol.   
 
 
 
Samples are diluted and mixed with biotinylated antibodies to form sample / 
antibody complex (1 hr at room temperature).   
Captured antibodies have been spotted in duplicate on nitrocellulose membranes.   
Antibody complex present is bound by its cojugate immobilized captured antibody on 
the membrane (over night at 2 oC – 8 oC). 
Incubate with Streptavidin-HRP and chemiluminescent detection reagents are 
added sequentially (30 min) 
Light is produced at each spot in proportion to the amount of analyte bound.  
(0-20 min) 
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2.2.11 MP Activity 
To avoid measuring platelet MP PL, frozen PPP samples were used in this experiment.  The MP 
activity kit was removed from 4 oC storage and kept at room temperature for 30 minutes.  
Sample diluent (containing FIIa and Xa and Ca2++ inhibitor, 380 µl) was added to 20 µl of 
calibrators, controls and samples.  Lyophilised Calibrator was prepared from lysed platelet 
concentrate and was reconstituted before use in 2 ml of sample diluent.  The stock concentration 
of PS was 2.8 nM.  A dilution curve of 2.8, 1.4, 0.7, 0.28, 0.05 and 0 nM was obtained using 
sample diluent.   
 
Normally prothrombin is converted to thrombin in the presence of calcium, Xa, PL and Va.  
Bovine Xa, Va, calcium and human prothrombin were added so the reaction depended primarily 
on the sample PL.  The samples (100µl) were then added to the microtitere plate and incubated 
for 1 h at 37 oC.  The plate was washed five successive times with 50 µl of washing solution.  R1 
which is bovine FXa-FVa mixture containing calcium (100 µl) and then R2 which contains human 
prothrombin (50 µl) were added, and then the plate was incubated for 10 minutes at 37 oC.  R3 
which is a thrombin specific chromogenic substrate (50 µl) was added, the plate then incubated 
for three minutes and the reaction was stopped with 3% (v/v) citric acid. The plate was 
incubated at room temperature for 10 minutes to allow colour stabilisation and then the 
absorbance was measured at 405 nm using the plate ELISA reader (Fig. 2.1). The samples Xa 
and IIa were inactivated by the sample diluents.  Therefore the limiting factor was PS.   
 
2.2.12 ELISA 
2.2.12.1 VEGF ELISA  
The plates were coated with monoclonal antibody specific to VEGF.  Sera and standards VEGF 
are then bound with the antibody.  Polyclonal antibody and the substrate are then added.  The 
reaction is then stopped and the VEGF concentration which is proportional to the colour intensity 
was measured.    
 
All reagents were brought to room temperature before use.  Wash buffer (20 ml) was diluted 
with DW to prepare a total volume of 500 ml.  VEGF standard was reconstituted with 1 ml of 
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calibrator diluent to form a stock solution (2000 pg /ml) which was then diluted with calibrator 
diluent to give a range of standards: 1000; 500; 250; 125; 62.5, 31.2 and 15.6 pg/ml.  Assay 
diluent (100 µl) was added to each well.  Standards and samples (100 µl) were added and the 
plate was incubated for 2 h, followed by three washes with 400 µl wash buffer to remove any 
unbound VEGF.  Then VEGF conjugate (200 µl, a polyclonal antibody against VEGF conjugated to 
horseradish peroxidase) was added and the mixture incubated for two h.  The wash was then 
repeated 3 times as described before.  Substrate solution [colour reagent A (stabilized hydrogen 
peroxide) and reagent B (stabilized chromogen) were mixed together in equal volumes, 200 µl] 
was added and incubated for 25 minutes at room temperature in the dark.  During this time a 
blue colour appeared in proportion to the amount of polyclonal antibody.  Then stop solution [(2 
N sulphuric acid) (50 µl)] was added to each well and the blue colour changed to yellow.  The 
concentration of TFPI was measured using an ELISA plate reader at 450 nm wave length with a 
540 nm wavelength correction.  
 
2.2.12.2 TFPI ELISA  
The plasma samples were used throughout.  Due to a high endogenous TFPI concentration, 
plasma TFPI required a 100-fold dilution before assay (20 µl of plasma was added to 180 µl of 
diluents).  All reagents were brought to room temperature before use.  Wash buffer (20 ml) was 
diluted with DW to prepare a total volume of 500 ml.  TFPI standard was reconstituted with 1 ml 
of calibrator diluent to form a stock solution (20000 pg /ml) which was then diluted with 
calibrator diluent to give a range of standards: 2000; 1000; 500; 250; 125; 62.5 and 31.2 pg/ml.  
Colour reagents A and B were mixed together in equal volumes a few minutes before use.   
 
Assay diluent (100 µl) was added to each well.  Standards and samples (50 µl) were added and 
the plate was incubated for 2 h, followed by four washes with 400 µl wash buffer.  Then TFPI 
conjugate (200 µl, which is polyclonal antibody against TFPI conjugated to horseradish 
peroxidase) was added and the mixture incubated for one h.  The wash was repeated four times 
as described before.  Substrate solution [colour reagent A (stabilized hydrogen peroxide) and 
reagent B (stabilized chromogen) were mixed together in equal volumes, 200 µl] was added and 
incubated for 30 minutes at room temperature in the dark.  During this time a blue colour 
appeared.  Then stop solution [(2 N sulphuric acid) (50 µl)] was added to each well and the blue 
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colour changed to yellow.  The concentration of TFPI was measured using an ELISA plate reader 
at 450 nm wave length with a 650 nm wavelength correction.  
2.2.12.3 TF ELISA 
To evaluate plasma TF, samples were diluted with calibrator diluents (150 µl of plasma + 150 µl 
calibrator diluent).  The TF standard was reconstituted with 1ml of DW to produce a 5000 pg/ml 
stock solution. The stock solution was diluted with calibrator diluents to form a series of 
concentrations: 500, 250; 125; 62.5; 31.3; 15.6 and 7.8 pg/ml.  The remaining methodology was 
similar to that with TFPI, except that the standard and sample volumes were 100 µl instead of 
50 µl.  It has been noted that 1000 U/ml of TF equal 5 ng/ml.   
 
2.2.12.4 Leptin ELISA 
The leptin standard was reconstituted with 1 ml DW to produce a stock solution (10000 pg/ml).  
This was successively diluted to yield concentration of 1000, 500, 125, 31.2 and 15.6 pg/ml.  
Calibrator diluent served as the zero standard (0 pg/ml).  The remaining methodology was 
similar to VEGF as described in section 2.2.12.1. 
 
2.2.12.5 Human anti-Annexin V platinum ELISA  
Annexins are a family of calcium-dependent PL-binding proteins.  The in vivo function of annexin 
is still unclear, but it does have a binding site for protein kinase C (Imai et al. 1995). Annexin V 
binds to the PS-exposing apoptotic cells and inhibits the procoagulant and pro-inflammatory 
activities of these dying cells.  The standards reconstituted in 1 ml assay buffer to form 800 
ng/ml concentrations, followed by five repeated serial dilutions to form 400, 200, 100, 50, 25, 
12.5, 6.3 ng/ml.  The remaining methodology was similar to that of TFPI ELISA as described in 
section 2.2.12.2.  
 
2.2.13 Haematoxylin and Eosin Staining of Paraffin Sections 
Paraffin blocks containing pancreatic tumour samples were sectioned (4 µm) in the Department 
of Pathology in Hull Royal infirmary.  The sections were labelled with pencil and placed in a 
warm histoclear II (60 oC) pot 1 for 10 minutes for deparaffinization.  The sections were then 
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deparaffinised with the Histoclear II three times using 3 pots of histoclear, for 1 minute each 
time to ensure that slides were deparaffinised completely.  The sections were then rehydrated 
through graded alcohols 100%, 90%, 70% (v/v) for 2 minutes each, before being transferred 
into a pot of tap water.  The pot was placed under a running tap for 1 minute, without allowing 
the running water to fall directly onto the sections.  The idea behind rehydration was to allow 
water to enter inside the cells and the latter would react with different types of stain that 
coloured different cellular architectures (Cook, 2006). 
 
The sections were rinsed under running tap water for 2 minutes.  Slides were stained with Harris 
haematoxylin for 20 S because this formulation contains mercuric oxide, which stains the nucleus 
a darker blue.  The slides were rinsed in running tap water for one minute.  Then the sections 
were differentiated with acid alcohol (10 dips) because acid alcohol removes the excess 
haematoxylin.  The sections were rinsed in tap water and transferred to Scott’s tap water 
substitute for 1 minute to increase the blue intensity.  The sections were then counter stained 
with eosin yellow (0.5% v/v), which stains the cytoplasm a red colour.  The sections were rinsed 
in running tap water for one minute. Then, the sections were dehydrated with 70%, 90% and 
100% ethanol for 60 S for each ethanol concentration to get rid of water outside the cells.  Then 
the sections were transferred to three Histoclear II pots (1, 2 and 3) for 60 S before mounting 
using Histomount (Cook, 2006).  
 
2.2.14 Immunohistochemistry on Paraffin Embedded Sections  
Endogenous biotin may be present in these sections.  This may cause non-specific background 
staining, particularly when using a biotin containing detection system.  This blocking step is 
achieved through sequential incubations with avidin and biotin.  Normal serum blocking is 
performed in order to prevent non-specific hydrophobic background staining; an unlabelled 
protein antibody of the same species as the secondary antibody is used to block the hydrophobic 
binding sites, which minimises the secondary antibody binding non-specifically. 
 
For protein visualisation, the avidin-biotin complex (ABC) method was used.  This method 
produces a complex with the antibodies which is very stable.  Avidin is an egg white glycoprotein 
which conjugates readily and strongly to biotin which is a vitamin.  The primary antibody will be 
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bound to the target antigen as in the direct technique but then a secondary antibody which has 
been raised against the primary antibody in a different species of animals will be bound.  It is the 
secondary antibody which has the label attached to it.  Advantages of using secondary 
antibodies include higher sensitivity, because only one primary antibody can be bound to any 
one antigen but numerous secondary antibodies can be bound to the primary antibody.  As the 
label will be present on the secondary antibody in the indirect method, the intensity of the 
visualisation will be amplified compared to the direct method.  This means that a smaller level of 
antigen can be detected and this can be achieved with antibody solutions of lower concentration.  
A further cost saving advantage to the indirect method is that not every antibody needs to be 
bound in order to visualise the antigens.  The avidin-biotin complex can have the label attached 
to the avidin and the biotin section will bind to the secondary antibody producing an extremely 
stable complex with high sensitivity (Cook, 2006).   
 
This visualisation method requires a chromogen step.  The enzyme which labels the antibodies 
catalyse a change of the substrate.  Diamino Benzidine (DAB) is one of the most common 
chromogens; it produces a brown end product. The protocol for immunohistochemistry staining 
was adapted from Cawkwell (1999).  
 
2.2.14.1 De-wax and Rehydrate  
The methodology of deparaffinisation and rehydration was similar to that described in section 
2.2.13. 
2.2.14.2 Endogenous Peroxidase Blocking  
The endogenous peroxidase activity was blocked by placing the slide rank into a pot containing 
360 ml methanol and 40 ml of hydrogen peroxide (H2O2) for 15 minutes. This solution was made 
fresh each use. 
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2.2.14.3 Antigenic Site Retrieval 
Heat induced-epitope retrieval (HIER) was used for antigen unmasking.  During incubation with 
hydrogen peroxide, the retrieval buffer (1600 ml DW with 15 ml Vector Antigen unmasking 
solution) was boiled and shaken in a pressure cooker.  When the retrieval buffer was boiling 
vigorously, the slides were added. The lid was fastened quickly and the mixture boiled for three 
minutes at pressure according to the recommendation of the supplier.  The pot was then 
removed from the heat and run under cold water.  The lid was opened when the internal 
pressure had dropped sufficiently (approximately 2-3 minutes).  The sections were rinsed in 
running tap water as before.  Protease induced-epitope retrieval (PIER) was used by incubation 
of the slides with solution of 1 mg trypsin/ml DW containing 4 mM CaCl2, 200 mM Tris, pH 7.7 at 
25°C for 30 minutes.  The sections were rinsed under running tap water for 2 minutes. Then 
slides were transferred to a pot of tris buffered saline (TBS), pH 7.6 for 5 minutes.  
 
2.2.14.4 Normal Serum Blocking  
The slides were assembled into the Sequenza ranks by dipping the cover plate in TBS and 
placing the section faces to cover the plate. The reservoir was filled with fresh TBS and washed 
for 5 minutes.  The sections were incubated for 20 minutes with 3 drops of diluted blocking 
serum (provided in the Vectorstain).  The diluted blocking serum was prepared by adding one 
drop of stock approximately (50 µl) to 5 ml TBS.  The blocking serum was prepared from the 
species in which secondary antibodies were made.  
 
2.2.14.5 Endogenous Biotin Block 
The non-specific binding of the avidin/biotin system reagents was blocked immediately by adding 
3 drops of Avidin D solution to the slides and the reagents incubated at room temperature for 15 
minutes.  The slides were rinsed in TBS for 5 minutes, three drops of biotin solution were added 
to each section from the same kit, and after this the sections were rinsed in TBS for 5 minutes.  
 
2.2.14.6 Primary Antibody Incubation 
The waste was emptied from the bottom of the Sequenza rank.  Three drops of diluted primary 
antibody were added to all except the negative slides.  These slides were incubated for one h (or 
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overnight at 4 oC if recommended by the supplier) except the negative slides.  After the 
incubation with primary antibody, the slides were rinsed in TBS for 5 minutes.  A negative control 
was included in each batch of slides, in which the primary antibody was omitted and replaced by 
TBS or 1:5000 dilution of rabbit serum for those antibodies raised in rabbit (VEGF, EGF, EGFR, 
TF and CD 34) and 1:5000 dilution of goat serum for those antibodies raised in goat (VEGFR 1, 
VEGFR 2).  Primary antibody concentration, diluent, incubation time, and temperature all impact 
the quality of staining.  These variables needed to be optimised for each antibody and sample to 
achieve specific staining with low background.  Often optimisation is approached by maintaining 
a constant incubation time and temperature, whilst varying the antibody concentration to 
determine when an optimal signal is achieved with low background noise.  For example, if a high 
affinity antibody was used, then the antibody can be applied at a relatively low concentration for 
a shorter incubation time.  Alternatively, a lower affinity antibody will be applied at higher 
antibody concentration for a longer incubation time.  Longer incubation durations were employed 
to ensure penetration throughout tissue sections.  To minimise non specific staining, longer 
incubation periods are often conducted at lower temperatures (i.e. 4 oC versus room 
temperature). The optimisation of antibodies is summarised in Table 2.4.   
 
2.2.14.7 Antibody Labelling  
The slides were incubated with diluted secondary antibody for 30 minutes (provided with the 
Vectastatin Elite universal kit).  For the rabbit anti-human PoAb , two drops (100 µl) of normal 
blocking serum were added to 5 ml TBS buffer in mixing bottle and then 2 drops (100 µl) of 
biotinylated stock antibody were added.  For the goat anti-human PoAb, biotinylated antibody 
horse anti-goat was used in 1:150 dilutions.   
 
2.2.14.8 Antibody Visualisation  
Further amplification of the signal (Fig. 2.3) was achieved by taking advantage of the strong 
affinity of avidin and streptavidin to bind biotin.  Streptavidin is purified from the bacterium 
Streptomyces avidinii, is not glycosylated, and exhibits lower non-specific binding than avidin.  
Streptavidin bind four biotins per molecule.  Because biotinylated secondary antibody was 
employed, the signal was significantly amplified by subsequent incubation with an avidin-biotin 
complex (ABC Method).   
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During the incubation with antibody labelling, Vectastain Elite ABC reagent (supplied with the kit) 
was prepared (two drops reagent A to 5 ml buffer in the ABC reagent large mixing bottle).  Then 
two drops of reagent B were added to the same bottle and mixed immediately, and then the 
mixture was allowed to stand for 30 minutes before use.  The sections were rinsed in TBS for 5 
minutes.  Vectastatin Elite ABC reagent (100 µl) was added to each section and incubated for 30 
minutes.  The slides were rinsed with TBS for 5 minutes.  One “gold” tablet of DAB and one 
“silver” tablet of urea hydrogen peroxide were added to 5 ml of DW and left to dissolve.  
Boundaries were drawn around the sections using an isolator pen to keep the reagent covering 
the section only and prevent spread of the reagent to unwanted areas of the slide.  DAB solution 
was added to the sections (50 µl) for approximately 5 minutes or until the brown colour was 
sufficiently developed (Fig. 2.3).   
 
2.2.14.9 Enhance, Counterstain and Differentiate 
Slides were stained with Harris haematoxylin for 20 S. The slides were rinsed in running tap 
water for one minute.  The sections were transferred to Scotts tap water substitute for 1 minute 
to increase the blue intensity. 
 
2.2.14.10 Dehydrate, Clear and Mount 
The methodology of dehydration, clearing and mounting was similar to that described in section 
2.2.13.  Several primary markers were used in this part of this study.  
 
Type, concentration and duration of primary antibody incubation, type and dose of secondary 
antibodies and the type of antigen retrieval are summarised in Table 2.4. 
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A                                                                  B     
Figure 2.3: Schematic representation of immunohistochemistry technique, A- Indirect method 
of imunohistochemistry B- Amplification of the signals using ABC method Antigen , primary 
antibody , secondary antibody  , label ,  avidin , biotin  , diamino benzidine 
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Table 2.4: Summary of Immunohistochemistry Methodology.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: [RPoAB: rabbit polyclonal antibody, GPoAB: goat polyclonal antibody, Heat induced-
epitope retrieval (HIER), Protease induced-epitope retrieval (PIER)].   
Marker Primary antibody 
Secondary 
antibody 
Antigen 
retrieval 
Type Dilution 
Used 
Range Duration of  
Incubation 
Dilution 
Used 
VEGF RPoAB 1:120 1:100-1:200 1 h  1:50 HIER 
VEGFR 1 GPoAB 1:20 1:20-1:100 Overnight  1:150 HIER 
VEGFR 2 GPoAB 1:20 1:20-1:100 Overnight 1:150 HIER 
EGF RPoAB 1:100 1:500 1 h  1:50 PIER 
EGFR RPoAB 1:30 1:30-1:200 1 h  1:50 HIER 
TF RPoAB 1:50 1:50-1:100 1 h  1:50 HIER 
CD34 RPoAB 1:100 1:100-1:500 Overnight 1:50 HIER 
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2.2.15 Components of Materials used in This Study  
1- Acid Alcohol (1% concentration hydrochloric acid in 70% methanol) 
 
Methanol (700 ml) 
DW (290 ml) 
Concentrated HCL (10 ml) 
 
2- 0.5% (w/v) Eosin Y 
 
Eosin Yellow powder (2.5 g) 
DW (500 ml)  
 
3- PBS  (isotonic buffer solution, pH 7.3).  
1 tablet of PBS 
500 ml DW 
To form PBS containing 0.14 M NaCl; 0.01 M Phosphate and 0.003 M potassium chloride 
concentration).   
 
4- PBS/BSA Azide 
 
PBS (1 L) 
BSA (2.9 g) 
Sodium azide (224 mg) 
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5- Scotts Tap Water  
 
Potassium bicarbonate (2g) 
Magnesium sulphate (20 g)  
DW (1 L). (Elangbam et al., 1997) 
 
6- Tris Buffer saline (TBS 20x pH 7.6) 
 
Tris [hydroxymethyl aminomethan] 1 M (121 g) 
NaCl  3 M (170 g) 
1L DW 
pH was adjusted to 7.6 with 80 ml concentrate HCL.  
TBS 20x was diluted twenty times to give: 
TBS X1 (50 mM Tris, 150 mM)  
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OPTIMISATION PART 
CHAPTER THREE: CELL INVASION  
3.1 General Introduction  
The following series of experiments was designed to optimise the methodology planned to be 
used in the analysis of clinical study.  Three pancreatic cell invasion experiments were used to 
evaluate cell invasion and procoagulant activity.  A series of stimulation experiments were 
conducted using extraneous factors to amplify signal.  A number of cell invasion experiments 
were performed to look at the robustness of the assays and the effects of blocking of TF by 
antibody and LMWH.  Different methodologies and different ways of evaluating of cell invasion 
were investigated.   
 
3.2 Correlation of Tissue Factor Expression and TF Activity with Cell Invasion 
3.2.1 Introduction  
TF is well known as a principal initiator of the extrinsic pathway of coagulation (Paborsky et al., 
1989, Nemerson, 1988, Gouaulthelimann and Josso, 1979) and the relatively high expression of 
TF on the primary PC is thought to be one of the underlying mechanisms giving rise to the 
hyper-coagulable state associated with this malignancy (Peppelenbosch and Versteeg, 2001).  
Therefore, it was postulated that TF expression correlated directly with TE (Khorana et al., 2007) 
and was associated with an increase of cell invasion and angiogenesis (Nitori et al., 2005, Zhang 
et al., 1994).  The correlation between TF expression and invasion has also been noted with 
other types of malignancy such as non small cell lung carcinoma (Sawada et al., 1999) and 
colorectal cancer (Seto et al., 2000).  This suggests that the aggressive course, cell invasion and 
thrombosis may be related to the high expression of TF.  In this study three PC cell lines were 
investigated: MIA-PaCa-2 (low/no TF expression); AsPC1 (low/moderate TF expression) and 
CFPAC1 (high TF expression).  
 
The one stage PT assay was used to evaluate plasma pro-coagulant activity, dependent on seven 
coagulating factors [X, VII, V, III (TF), II (prothrombin), I (Fibrinogen), PL, Fig. 3.1].  In the 
current study, the PT was used to measure the pro-coagulant activity and TF activity of cells.  
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There are 5 factors [X, VII, V, III, II (prothrombin), I(Fibrinogen)] were present in the fixed 
concentration within the control plasma but there is no TF.  Therefore additional TF present on 
cells or accelerate clotting.  A modified one stage PT for evaluation of procoagulant and TF 
activity of the cells was used by several researchers (Hobbs et al., 2007, Silberberg et al., 1989).   
                      
 
Figure 3.1: Diagrammatic representation of the clotting mechanism .  In the assay used in this 
part of thesis TF is the limiting factor.   
 
The main aim of this study was to evaluate the role of TF expression and activity on PC cell 
invasion.  Before evaluation of the procoagulant activity and cell invasion, all cells were checked 
for mycoplasma infection and TF receptor expression.  
 
3.2.2 Assay for Mycoplasma Infection  
Mycoplasma contamination does not produce visible changes in the medium and resists 
antibiotics because mycoplasma do not have a cell wall.  The incidence of mycoplasma infection 
in cell culture lines was varied over wide range from 5 up to 94% (McGarrity, 1979).  The eight 
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most common mycoplasma types are M.orale, M.pirum, M.hominis, M.salivarium, A.laidlawii, 
M.hyorhinis, M.arginini, M.fermentans.  Mycoplasma and other bacterial infections affect the 
biological activities and behaviour of the cells.  For example mycoplasma infection might change 
the expression of receptors.  Therefore all cell lines were tested for the presence of mycoplasma 
using a commercial kit which covers the eight most common mycoplasma species listed above.  
 
Cell culture supernatant samples were collected weekly (week 1- week 6) from AsPC1, CFPAC1, 
MIA-PaCa-2, HDMEC and several other types of cells lines available in the laboratory at the date 
of experiment and stored at -80 oC.  Samples were analysed as explained in section 2.2.2.7.  A 
representative plate is shown in Fig. 3.2.  The mean optical density of six positive controls was 
1.7 (yellow box) , the six negative controls (medium only) was 0.6 (black box ) and the mean OD 
of duplicates for week 1-6 culture of AsPC1, CFPAC 1, MIA-PaCa-2 and HDMEC were  0.5 - 0.6 
(blue box).  The results were considered negative compared to the negative control values 
(Table 3.1).  
 
Figure 3.2: Mycoplasma test.  Culture medium samples in duplicate from Week1-Week6 (from 
left - right) were marked with a blue box.  Positive controls were repeated six times and marked 
with a yellow box and negative controls were repeated six times and marked in black.  Other cell 
lines in the laboratory were investigated in other well on the plate. 
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Table 3.1: Mycoplasma test results.   
Note: The test samples were performed in duplicate, positive and negative controls were 
performed in triplicate.  Average absorbance values are shown.   
 
3.2.3 Growth Factor Receptor Expression of Pancreatic Cell Lines 
Cell culture, growth and harvesting of 3 pancreatic cell lines were described in sections 2.2.3.1, 
2.2.2.3.2 and 2.2.3.3 respectively.  Flow cytometric detection of TF and EGFR was detailed in 
section 2.2.5.  The highest TF expression was noted on the CFPAC1 and no TF expression on 
MIA-PaCa-2.  There was slight TF expression on AsPC1 (4%).  Furthermore, the highest EGFR 
expression was noted on CFPC1, followed by AsPC1 and there was slight expression of TF on 
MIA-PaCa-2 (Fig.3.3). 
.  
Sample Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 
AsPC1  0.6 0.6 0.5 0.5 0.4 0.4 
CFPAC1 0.4 0.5 0.6 0.6 0.6 0.5 
MIA-PaCa-2 0.5 0.5 0.5 0.4 0.6 0.6 
HDMEC 0.5 0.4 0.6 0.5 0.3 0.6 
Positive control 1.7 ( mean of 6 positive controls) 
Negative control 0.6 ( mean of 6 negative controls) 
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Figure 3.3: Expression of TF (A) EGFR (B) on MIA-PaCa-2, AsPC1 and CFPAC1. Data are 
representative of three repeats.  Blue colour was the negative control. Green colour was the 
EGFR and TF 
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3.2.4 Methodology of Procoagulant Activity Cell Invasion  
Aliquots of PC cells (2x105) in 100 µl of PBS were incubated at 37 oC with and without 5µl (5 
µg/ml) of rabbit PoAb anti human TF for 20 minutes.  These aliquots of treated cells were 
subsequently used in clotting and cell invasion experiments.  The one stage PT assay was used 
to measure the TF activity of PC cell lines using an Axis shield coaguolometer.  The limiting 
factor in the assay was TF on the surface of the cells; more TF expression will lead to shorter CT.  
The coagulometer and the materials were equilibrated to 37 oC before starting the experiment.  
A steel ball was put in the central cuvette of the coagulometer and mixed with the cell lines and 
CaCl2 (100 μl, 25 mM).  Clotting was induced by the addition of NormTrol control plasma (100 
μl), and then CT was recorded.   
 
For invasion experiments, a BD BiocoatTM MatrigelTM Invasion Chamber was used to evaluate the 
motility of MIA-PaCa-2, AsPC1 and CFPC1 that had previously been adapted to grow in SFM as 
described in section 2.2.3.1 - 2.2.3.3 in response to sera from patients with advanced PC from a 
clinical trial investigation (Maraveyas et al., 2010a).  In this study, the staining method with 
methylene blue was used (section 2.2.7.2.2, Staton et al., 2004a, Miao et al., 2000).  Pancreatic 
cell lines were tested both with and without TF blocking.  All coagulation and invasion 
experiments were undertaken in triplicate.   
 
3.2.5 Results 
The highest TF expression as assessed by flow cytometry was noted with CFPAC1, and 
correlated with the shortest clotting time (CT; 28 S), the lowest (undetectable) expression was 
noted with MIA-PaCa-2 which correlated with the longest CT [120 S].  AsPC1 expression with 4% 
of TF positive cell showed a CT between these two extremes (74 S).  Blocking of TF receptors on 
these cells showed increased CT for all three cell lines; 95 S for CFPAC1, 119 S for AsPC1 and 
more than 241 S for MIAPaCa-2 (Table 3.2).  The highest cell invasion was achieved with 
CFPAC1 [240/ high power field (HPF)], followed by AsPC1 (86/HPF) and then MIA-PaCa-2 
(34/HPF).  Blocking of TF on these cells decreased cell invasion by approximately 50% in both 
CFPAC1 and AsPC1 but had only a minimal effect on the already low cell invasion potential of 
MIA-PaCa-2 (Table 3.2, Fig. 3.4, 3.5).  
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Table 3.2: Expression of tissue factor on pancreatic cell lines: correlation with TF activity and 
cell invasion.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The mean fluorescent intensity (MFI) of the negative controls has been subtracted from all 
values. CT and cell invasion experiments were repeated in triplicate. HPF; high power field. .   
 
Pancreatic 
Cell Line 
Mean CT (S)± SD Mean Cell Invasion/HPF± 
SD 
% of cells 
expressing TF  
[MFI]± SD Plasma + 
Cells 
Plasma, cells 
with TF  
blocking 
Cells + 
Serum 
With addition of 
anti TF antibody 
MIA-PaCa-2 120 ± 2 250 ± 1 42±3 34±3 0/[0] 
AsPC1 74 ± 2 119 ± 2 86± 2  48 ± 2 4/[8] 
CFPAC1 28± 2 95±4 240 ± 8 133 ± 2 90/[135] 
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Figure 3. 4: Mean pro-coagulant activity (mean ±SD) of PC cells with and without TF blocking. 
Data are an average of three independent experiments.   
 
 
Figure 3.5: Pancreatic cell invasion (mean ±SD) with and without TF blocking in matrigel  
chamber. Data are an average of three independent experiments.   
 
76 
 
3.3 Investigation of Induction of Cellular Invasion by Patient Sera 
 
3.3.1 Aim 
The principal aim of this investigation was to evaluate the effect of heparin and blocking of 
serum TF on cell invasion.   
 
3.3.2 Methodology 
MIA-PaCa-2 cells were used in this section of the study because they have low endogenous 
tissue factor (undetectable flow cytometry) and a low inherent invasiveness.  Culture, harvesting 
and adaptation to SFM are described in section 2.2.2.3. 
 
MIA-PaCa-2 cells were used to measure the ability of the patient sera to induce locomotion and 
cellular invasiveness using Boyden chambers with collagen IV as described in 2.2.8.1.  The 
baseline serum cancer cell invasion induction was assayed from four patients with advanced PC 
entered into the FRAGEM trial (Maraveyas et al., 2010a).  Samples of sera from patients with 
APC were placed in the bottom chamber (10% v/v) and supplemented with dalteparin (Fragmin) 
over a range of 0-100 anti-Xa international units/ml (final concentration).  Experiments were 
undertaken in duplicate. To confirm the function of TF in the induction of cell migration, aliquots 
of patients’ sera (n=4) were incubated with a range of concentrations (0-48 µg/ml final 
concentrations) of a neutralizing PoAb antihuman TF, prior to diluting with base medium.  The 
rate of cell migration was determined following 24 h incubation.  CTAOR (section 2.2.7.2.1) was 
used and the values of absorption were converted to number of cells from a standard curve.  
77 
 
3.3.3 Results 
A range of MIA-PaCa-2 (2000- 50000) cells were used to generate a standard curve (Fig. 3.6).  
The absorbance at 490 nm was recorded using an ELISA plate reader.  
 
 
Figure-3.6: Representative standard curve for MIA-PaCa-2 invasion that correlates the invaded 
cells with the average of absorbance value.   
 
The data presented in Fig. 3.7 suggests that there was no effect of extraneous dalteparin on the 
cell locomotion invasion of MIA-Paca-2 cells exposed to serum from APC patients (n=4).  A test 
for linear trend in the number of cells migrated with dalteparin level of exposure (U/ml) was 
made. This was not statistically significant (P= 0.194, Pearson correlation).  However, the cell 
invasion number when 0.01 U/L was significantly lower than control (8023 ± 898 vs. 8023 ± 
375, p= 0.01, Mann Whitney test). 
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Figure 3.7: Effect of increasing doses of extraneous dalteparin on cellular invasion of in Boyden 
chamber MIA-Paca-2 cells in response to patients’ sera.  The results represent the chemotaxis 
effect of sera from 4 PC sera.  The experiment was undertaken in duplicate   
 
Furthermore, the role of TF in inducing cell invasion was demonstrated by pre-incubation of 
patient’s sera with the anti human TF PoAb, which showed a clear reduction in MIA-Paca-2 
cellular invasion, paralleling the increase in neutralizing antibody (Fig. 3.8). 
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Figure 3.8: Incubation of the patient’s serum with anti-TF PoAb demonstrated a dose-
dependent inhibitory effect on cell invasiveness of MIA-Paca-2.  The results represent the mean 
± chemotaxis effect of sera from 4 PC sera.  The experiment was undertaken in duplicate  
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3.4 Effect of Sera from Pancreatic Cancer Patients, TF and VEGF on cell invasion 
Poor prognosis of PC cases is mainly due to tumour cell invasion beyond the pancreas (Sporn, 
1996). The difficulty of detection and diagnosis of early PC, and the complication of being highly 
invasive, leave more than 85% of patients inoperable at the time of diagnosis (Muchmore et al., 
1996).  Despite a general decrease in the rate of mortality and improved survival rate of patients 
following surgery, the overall 1- year survival rate after diagnosis of PC remains below 20% and 
the overall 5-year survival rate is around 3% (Web reference 4; 2010).  
3.4.1 Aim 
The aim of this study was to evaluate the chemotaxis activity of PC sera mediated by TF and 
VEGF.   
 
3.4.2 Growth Factor Receptors.   
Angiogenic receptors are the key targets of angiogenic factors presumed to be present in the 
serum of PC patients.  VEGFR 1, -2 and -3 expression on the pancreatic cell lines is shown in Fig. 
3.9.  
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Figure 3.9: Expression of VEGFR 1, -2 and -3 on the surface of MIA-PaCa-2, AsPC1 and CFPAC1 
cells.  Data are a representative example of three repeats. Solid blue colour is the negative 
control. Green line was the test antibody.   
 
In conclusion AsPC1 and MIA-PaCa-2 relatively expressed VEGFR 1,-2, -3 at higher levels than 
CFPAC1.  
 
3.4.3 Materials and Methods  
AsPC1 cells were used in this part of study to measure the ability of the TF and VEGF to induce 
locomotion and cellular invasiveness because it has low TF (4%) as described in section 3.2.3, 
has invasive properties and all the VEGF receptors are expressed at levels as shown in Fig. 3.9.  
Matrigel Invasion Chambers were used in this part of the study as described in section 2.2.7.1.   
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For evaluation of the chemotaxis effect of VEGF and TF, two baseline serums from patients with 
APC entered into the FRAGEM trial (ISRCTNU76464767, Maraveyas et al., 2010a) were used.  
Experiments were undertaken in duplicate.  AsPC1 cells were adapted to SFM as described in 
section 2.2.2.3.  Cells (2X105 in 250 µl of SFM ) were seeded on the top of the membrane, SFM 
RPMI 1640 (250 µl) supplemented with 10% v/v serum from APC, TF (a final concentration of 1 
unit/ml) and /or VEGF, in a final concentration of 2ng/ml was placed in the bottom.  The effect 
of 10% (v/v) PC serum with or without FBS (10%) was evaluated.  The rate of cell migration 
was determined following 24 h incubation, the CTAOR method was used to evaluate cell invasion 
assay as described in section 2.2.7.2.1 and the values of absorbance were converted to number 
of cells from a previously prepared standard curve.   
 
3.4.4 Result 
A range of AsPc1 (2000-25000) cells were used to generate a standard curve (Fig 3.10).  The 
absorbance at 490 nm was recorded using an ELISA plate reader. 
 
 
Figure 3.10: A CTAOR standard curve for the number of AsPC1.  The experiments were 
repeated twice and values represent the average.
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The highest chemotaxis effect (27002) was achieved when TF (1U/ml), VEGF (2 ng/ml) and PC 
sera acted synergistically.  Ten percent FBS and 10% of PC sera were used as a positive control 
while PC sera alone showed the lowest chemotaxis effect (903) (Table 3.3).   
 
Table 3.3:  The chemotaxis effect of PC sera, TF and VEGF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The values represent mean of chemotaxis effect of two PC sera and each experiment was  
undertaken in duplicate 
 
10% (v/v) PC sera plus Average number of AsPC1 cells  
10 % FBS (v/v) 44402 (41865, 46939) 
TF (1 U/ml) and VEGF ( 2 ng/ml) 27002 (29683, 24321) 
VEGF (2 ng/ml) 14822 (12649, 16995) 
TF (1 U/ml) 7863 (8345, 7381) 
Pancreatic serum (10%) only (v/v) 903 (838, 969) 
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3.5 Optimisation of Cell Invasion Method 
The aim of this part of the work was optimisation of a methodology to measure cell invasion for 
analysis of samples from the clinical trial.  For evaluation of the chemotaxis effects of serum’s 
proangiogenic factors, matrigel cannot be used because the commercial matrix is supplemented 
with several known angiogenic factors that will affect cell invasion (according to the 
manufacturer).  Therefore, Boyden chambers coated with highly purified collagen IV were used 
where the only angiogenic factors are those added to the lower chamber.   
 
AsPC1 was chosen as a model of PC cells for invasion experiment of the clinical part of the study 
due to its invasive features as it was originally derived from ascetic fluid.  Due to these invasive 
properties, AsPC1 is widely used in cell invasion experiments (Tan and Chu 1985).  Furthermore, 
the expression of TF on these cells was very low TF (4%), with moderate/high expression of 
several angiogenic receptors (VEGFR 1, 2, 3 and EGFR 1 expression are 22, 24, 20 % and 87%) 
which are the potential targets of many angiogenic markers in PC sera.  AsPC1 adapted to 
growth in SFM were used to assess (as described in section 2.2.3.1) the chemotaxis activity of 
11 PC sera using both CTAOR and slide methods.  There was insufficient sample available to 
repeat analysis in all samples.  The materials and methods were as described in sections 
2.2.7.2.1 and 2.2.7.2.2 respectively.  The values of absorbance with CTAOR were converted to 
number of cells from a standard curve (Fig. 3.11) over a range of AsPC1 (800-20000).  The 
experiments were undertaken in duplicate.  The results are summarised in Table 3.4.   
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Figure 3.11 A Standard curve of AsPC1 treated with CTAOR. The number represents the 
mean of three results. 
 
The motility of AsPC1 in response to the serum chemotaxis activity of 11 samples was re-
counted using slide methods as described in a methodology described in section 2.2.7.2.2.  The 
experiments were undertaken in duplicate.  The results are described in Table 3.4.   
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Table-3.4:  Comparison of CTAOR and slide method to determine invading cells.   
 
 
The experiment was repeated in duplicate for the cases with sufficient sample available on two 
separate occasions.  The numbers represent the mean of the two results.  No: number, HPF: 
high power field, CTAOR: Cell Titre Aqueous One Reagent.   
Sample First experiment Repeat experiment 
CTAOR Slide CTAOR Slide 
Mean No/HPF Total No Mean No/HPF Total No 
A 27204 121 28435 16594 99 23265 
B 11450 107 25145 6727 90 21150 
C 4367 92 21620 5483 87 20445 
D 2370 93 21855 11311 82 19270 
E 756 38 8930 6159 52 12220 
F 803 42 9870 5637 43 10105 
G 5302 97 22795 - - - 
H 1722 66 15510 - - - 
I 76522 124 29140 - - - 
J 719 105 24674 - - - 
K 20171 150 35250 - - - 
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The results of CTAOR represent total numbers of invading cells while the results of the staining 
method represent the mean number of invading cells of five microscopical fields of 40 objectives, 
therefore, to compare these directly, the total number of invading cells on the membrane was 
calculated thus:  
The diameter of the membrane was 7.36 mm.  The diameter of the microscopic field of the 40 
objective was 480 µm measured using a graticule ruler and stage micrometer.  Hence, the radius 
of the 40 objective field was 240 µm.  Because the microscopical field was circular, the area was 
calculated by A= πr2 giving a total area of the field as 180864 µm2 and the total area of the 
whole membrane was 42, 523136 µm2.  In summary, total membrane area was 235.1 times the 
microscopic field area.  Therefore the mean number of five HPF was multiplied by 235.1 to 
quantify the total number of invading cells on the membrane.  For standardisation of the 
methodology, the experiment of AsPC1 motility in response to 6 PC sera (A, B, C, D, E and F) 
was repeated using slide and CTAOR methods to allow the techniques to be compared for 
reproducibility.  Again the values of absorption with CTAOR were converted to number of cells 
(Table 3.4) from a freshly standard curve as described previously.  Comparing the two methods 
(CTAOR and slide methods) in the two experiments reveals the difference in the CTAOR method 
was more than the slide method (Fig.3.12-3.13).   
 
However the statistical comparison of two methods (QTAOR and slide method) reveal no 
significant difference in both methods as the results of both are within 95% limit of agreement.  
The statistical comparison of the results of 11 in the first experiment using QTAOR and slide 
methods revealed that the 95% limit of agreement was from -46511 to 29814.  The average and 
the difference of the results were within this limit except one result of sample I using QTAOR; 
76522 (Bland-Altman method comparison, Fig. 3.14).  The comparison of the results in repeated 
experiments in six samples revealed that the 95% limits of agreement average and the 
difference between the results were between -17882 to -300.  Therefore the average and 
difference of both results were within this limit (Bland-Altman method comparison, Fig.3.15). 
.
88 
 
 
Figure 3.12: Comparison of AsPC1 motility in response to PC sera using the CTAOR method. 
The experiments were conducted in duplicate.  
 
 
Figure 3.13: Comparison of AsPC1 motility in response to PC sera using the slide method.  The 
experiments were conducted in duplicate.  
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Figure 3.14: Average and the difference of QTAOR and slide method of the first experiment.  
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Average and the difference of QTAOR and slide method of repeated experiments. 
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3.6 Discussion 
The three PC lines studied varied in their surface expression of TF, as determined by flow 
cytometry.  PC cells grown in vitro have a pro-coagulant cell surface that can act as the basis of 
clot formation.  The cells with the highest TF expression (CFPAC1) also showed the fastest CT 
and highest cell invasion. 
 
The first interesting finding of this study is that TF expression on the surface of PC cell line is 
associated with cell invasion.  This result was in agreement with results of other studies.  Nitori 
et al., (2005) noted that in 113 PC cases, TF expression was associated with PC metastasis.  
Kakkar et al., (1999) noted that the mean number of MIA-PaCa 2 cell invasion using matrigel 
was 63 ± 13, the procoagulant activity using a two-stage clotting assay was 7.7 TF Units/ 104 
cells, total TF content was 377 ± 274 pg/ml (total tissue factor content/mg of protein).  The cell 
invasion, procoagulant activity and TF content of TF transfected MIA-PaCa-2 were significantly 
higher than those of anti sense TF transfected MIA-PaCa-2 cell (The mean number cell invasion; 
210 ± 57 vs. 42 ± 6, the mean procoagulant activity was 37.3 vs. 6.8 TF Units/ 104 cells, the 
total TF content was 8705 ± 301 pg/ml vs. 156 ±50 pg/ml).  Sawada et al. (1999) noted that 
there is a correlation between TF expression and invasion in non-small lung cancer NSCLC, Seto 
et al. ( 2000) postulated that there is a correlation between TF expression and hepatic 
metastasis of colorectal carcinoma whereas Koomagi and Volm (1998) reported that there is no 
correlation between TF expression and invasion lung cancer.  The latter disappointing results 
suggest that the relation between TF expression and cell invasion may be cell type specific.   
 
The current study shows a decrease of PC cell invasion by approximately 50% when cellular TF 
is blocked by anti-TF.  This result is again consistent with other studies.  Mueller et al. (1992), in 
a mouse model of experimental melanoma metastasis, found that anti-TF antibody decreased 
pulmonary metastasis.  Furthermore, it has been reported that phosphorylation of serines of 
cytoplasmic domain and the extracellular domain enhances the cell invasion and the substitution 
of the three serine of cytoplasmic domain decreases the cell invasion (Bromberg et al., 1999).  
Therefore, phosphorylation has an important role in the involvement of the cytoplasmic domain 
of TF in TF-VIIa signalling, which increases the chemotaxis ability of malignant cells (Bromberg 
et al., 1999).   
 
91 
 
Blocking of CFPAC1 and AsPC1 was shown to result in to prolonged CT and a decrease of the 
number of invading cells by approximately 50% and this might be anti-TF antibody was not 
enough to inhibit all the TF activity.  Both these cell lines (CFPAC1, AsPC1) were derived from 
metastatic cancers, whereas MIA-PaCa-2 was derived from primary pancreatic tumour and has 
very low expression of TF, undetectable by flow cytometry; however blocking of TF was seen to 
prevent coagulation, suggesting TF is present in relatively low levels on the cell surface.  The 
cellular clotting activity of this study is in agreement with other studies, including Hobbs et al., 
(2007) who noted that TF transfection into MIA-PaCa-2 cells resulted in a significant increase in 
procoagulant activity as determined by the one-stage PT method.   
 
The current study supported the hypothesis that the highly aggressive PC cell line derived from 
the liver metastasis has the highest TF expression, TF activity and the highest cell invasion 
number.  The result of this part of the work is in agreement with the results of other studies 
such as Silberberg et al., (1989).  These authors noted that RWP1 and RWP2 (PC cell lines 
derived from liver secondary) have the shortest CT (one stage PT was used) compared with NCI-
H69 and NCI-HH82 (human small cell lung cancer cells, Silberberg et al., 1989).  Furthermore, 
the result of our study is in accordance with the result of Kakkar et al. (1999).  These authors 
showed that over-expression of the TF gene was associated with an increase in TF expression 
and pro-coagulant activity and an increase in cell invasion.  Kakkar and his colleagues used MIA-
PaCa-2 pancreatic cell line for this transfection study.  Moreover, the result of our study is also in 
agreement with Moberg et al. (2002).  The authors noted that blocking of TF with monoclonal 
anti TF prolonged CT.  The pancreatic Islet cells were harvested in dilution medium, mixed with 
human plasma and the CT was measured using on oscillating rheometer.  The CT was 10 
minutes without blocking of TF vs. 38 minutes with blocking of TF.  It can be concluded that the 
PC cell invasion appears to be correlated with TF expression and activity.   
The coagulation abnormalities are driven by the tumour and similarly these trigger the 
thrombosis events of the underlying malignancy.  It has been shown that the in vitro incubation 
of patient’s sera with PoAb anti-tissue factor antibody inhibits soluble-TF activity and results in 
reduction of cellular invasion properties of these sera.  This is a reproducible, dose-dependent, in 
vitro effect, which supports the hypothesis that the reduction of circulating-TF antigen in the 
serum of these patients could be one of the mechanisms that could lead to reduction of cellular 
invasion.  It has been postulated that soluble tissue factor is able to interact with the cell surface 
(Pradier and Ettelaie, 2008, Ettelaie et al., 2007).  This interaction and subsequent activation of 
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different sets of associated coagulation enzymes results in a varied set of signalling pathways, 
which result in proliferation, apoptosis (Pradier and Ettelaie, 2008) and cell migration (Satta et 
al., 1994).  Here, we show that TF, as found in patients’ sera, has a measurable chemotactic 
effect on cancer-cell invasiveness that can be modulated by the use of dalteparin.  These results 
are in accordance with Ardissino et al. (1997) who noted a significant correlation (P<0.0001) in 
the concentration of TF antigen and TF activity in atherosclerotic plaque.  Furthermore, pro-
coagulant activity has been linked to the amount of tissue factor antigen (Marmur et al., 1996).   
 
There was no statistical trend effect in the concentration range studied in the dalteparin-spiking 
experiment.  However, statistical power was limited and a decrease was observed at 0.01 U/ml, 
in comparison to the control.  It has been shown in cancer cell lines that there may be a direct 
effect of dalteparin on TF expression through mechanisms as yet not clear.  The possibility can 
be excluded that the reduction of cellular invasion in vivo is the result of the effect of other 
molecules induced or reduced by the in vivo effect of dalteparin such as TFPI, which is known to 
have direct inhibitory effects on cancer promoting mechanisms (Hembrough et al., 2003).  
Furthermore, it has been suggested that cellular-invasion assays and soluble-TF antigen may find 
use as surrogate markers of the anti-malignant effect of dalteparin and other LMWHs and may 
inform the appropriate dosing of these agents in the use of LMWH for ‘oncological’ effects.  
Furthermore, in the current, the maximum AsPc1 cell invasion was achieved when AsPC1 PC sera 
were treated with TF and VEGF.  The dose of 1 U TF/ ml was used in this part of the work 
because it gives maximum angiogenesis (as will be described in section 3.4.4).   
 
Another interesting result of this study is that considerable chemotactic and angiogenic activities 
were realised in the serum of patients with PC.  This is further evidence that suggests the PC 
serum may contain considerable amounts of pro-angiogenic factors that could enhance cell 
invasion. Furthermore, this study shows that TF enhances cell invasion in a mechanism 
independent of the coagulation cascade and PAR.  The current study also shows that VEGF 
enhances cell invasion in a mechanism in-dependent of the cascade coagulation.  The maximum 
invasion was achieved when both TF and VEGF were added.  These results suggest that 
angiogenic markers including TF and VEGF play an important role in stimulating cell invasion of 
AsPC1 cells, pointing to the possibility that inhibition of the function of these molecules may be 
involved in the invasion of PC.  In summary, TF that is expressed on the cells and soluble TF in 
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the serum of PC play a major role in cell invasion.  Blocking of cellular and serum TF decreases 
cell invasion.  
 
For optimisation of the methodology to be used to analyse clinical samples, the slide method was 
chosen as a method for evaluating the chemotactic activity of PC sera in clinical study because 
this was easier and did not require formation of a standard curve.  Statistically the average and 
difference of both results (QTAOR and Slide method) reveals that the results of both methods 
were in 95% agreement except for one result, due to the high number of cell invasion in the 
QTAOR method in the first experiment.  Furthermore, the comparison of the two results (CTAOR 
and slide method; Table 3.4) reveals unexpected results with CTAOR, such as the result with 
sample I (76522).  CTAOR is time consuming as incubation with CTAOR takes approximately 4 h 
whilst staining requires 15 minutes.  Moreover, when the chemotaxis activity of 6 samples was 
tested in two experiments on two different days and the results of these two experiments were 
compared, there was a larger discrepancy in the number of invading cells with the CTAOR 
method than the slide method.   
 
Therefore it was decided to use AsPC1 pancreatic cell line, Boyden chamber coated with collagen 
IV and staining of the membranes for evaluation of the chemotaxis activity of the PC sera pre-
and post-operatively.   
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CHAPTER FOUR: ANGIOGENESIS ASSAY 
4.1 Introduction 
Angiogenesis is a vital step for tumour progression and is correlated with poor prognosis.  
Therefore, control of angiogenesis represents an alternative approach to the management of PC.  
Angiogenesis is mediated in part by the secretion of several growth factors, including VEGF.  
Therefore it may be possible to control angiogenesis by modulating these factors in PC and other 
solid tumours.  In this part of the work TF with serum from patients with APC from the FRAGEM 
trial (ISRCTNU76464767, Maraveyas et al., 2010a) was used to evaluate angiogenesis.  Anti-TF, 
anti-VEGF and suramin were used to inhibit the angiogenesis.  Suramin, a polysulfonated 
naphthylurea, is well known as treatment in trypanosomiasis and onchocerciasis.  It has been 
reported that suramin has growth factor blocking activity (Middaugh et al., 1992), inhibits cellular 
proliferation by inhibiting the binding of growth factors to their receptors (Coffey et al., 1987) 
and inhibits intra-nuclear enzymes and causes partial blocking of EGF signal transduction 
(Fujiuchi et al., 1997).  Therefore, it has been suggested that suramin could have anti cancer 
and angiogenic inhibition activity.   
 
4.2 Aim  
This part of the work was designed to:  
1. Optimise a standard methodology for assessing angiogenesis in vitro that can subsequently 
be used to study samples from a clinical trial.    
2. Evaluate the effect of pro-angiogenic and anti-angiogenic factors on capillary (tubule) 
formation. 
 
4.3 Growth Factor Expression 
VEGFR are the cellular target of VEGF which are presumed to be available on the serum of PC 
serum.  VEGFR 1, VEGFR 2, VEGFR3 and TF receptors were evaluated on the surface of ECV 304 
and HDMEC.  The methods of cell culture, growth and harvesting were described in sections 
2.2.2.1.1 and 2.2.2.2.1.  The method of detection of VEGFR 1-3 and TF was discussed in section 
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2.2.6.  It was noted in the current study that TF was expressed on 2% of ECV 304 and 10% of 
HDMEC (Fig. 4.1).  
                                     
Figure 4.1: TF expression on the surface of ECV 304 and HDMEC.  Data is a representative 
example of three repeats.  The blue histogram was the Ig G FITC conjugated control. The green 
line was cells stained with an anti TF FITC conjugated antibody.  
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Expression of VEGFR 1, -2 and -3 was in 17, 19 and 22% of ECV 304 respectively and 52, 41 and 
65% of HDMEC (Fig. 4.2).   
 
Figure 4.2: Expression of VEGFR 1, 2 and 3 on the surface of ECV 304 and HDMEC.  Data are  
a representative example of three repeats.  Blue colour was the negative control. Green colour 
was the VEGFR expression.   
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4.4 Materials and Methods  
Two types of cells were used; ECV 304 and HDMEC (Fig. 4.3).  Gels were formed in two different 
ways, as described in section 2.2.6.1.  The effect of the angiogenic activity of PC serum, pro- 
and anti-angiogenic factors on angiogenesis was evaluated using collagen type I gel assay.  
Three baseline sera from patients with APC (from FRAGEM trial) were used in this part of the 
study.  The experiments were undertaken in duplicate.  The methodology was described in detail 
in 2.2.6.  ECV 304 cells were treated with TF (1, 4, 10, 20 U/ ml at final concentration), PoAB 
anti-VEGF (1, 2 and 3.2 ng/ml at final concentration) and suramin (50, 100, 200 and 400 nM as 
final concentration).   
 
HDMEC were treated with TF (0.2, 0.5, 1, 4, 10, 20 U/ml at final concentration), anti-VEGF (1, 2, 
3.2 ng/ml at final concentration), suramin (50, 100, 200 and 400 nM at final concentration) and 
PoAb rabbit anti-human TF (48 µg/ml at final concentration).  Concentrations less than 1 U/ml 
TF were used to evaluate the effect of low doses of TF on HDMEC angiogenesis.  Ten pictures 
were taken of each well using an Imaging RETIGA 2000 R camera attached to a LeitZ Laborlux S 
fluorescence microscope.  The Image-Pro plus program version 5.1.2 was used to evaluate total 
length and number of tubule formation, allowing quantitative analysis of angiogenesis. 
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Figure 4.3: HDMEC have a typical cobblestone pattern (microscope magnification x 400).   
 
4.5 Results 
As described under materials and methods, the angiogenesis assay was performed using gel 
formed by two different methods.  Comparing the two types of gel reveals that the angiogenic 
tubules were well formed and easier to detect with method B.  For this reason and for other 
technical considerations that will be described in the discussion, method B was chosen as the 
standard protocol and the results of method A were ignored (Fig. 4.4-4.7).   
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Figure 4.4: Angiogenesis of ECV 304 treated with 1 U TF using method B (microscope 
magnification x 400).  
 
Figure 4.5: Angiogenesis of HDMEC treated with 1 U TF using method B (microscope 
magnification x 400).  
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Figure 4.6: Angiogenesis of ECV 304 treated with 1 U TF using method A (microscope 
magnification x 400).  
 
 
Figure 4.7: Angiogenesis of HDMEC treated with 1 U TF using method A (microscope 
magnification x 400).  
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As can be seen in Fig.4.8, maximum total length and number of capillary (tubule) formation were 
achieved when cells were treated with 1 U/ml final concentration of TF; the mean total capillary 
length and number of ECV 304 were 1930 ± 270 and 172 ± 16 (Fig. 4.4) respectively while 
those for HDMEC were 1500 ± 100 and 140 ± 36 respectively (Fig. 4.5).  There was a gradual 
decrease in the mean total length and number of the tubules when TF concentrations higher 
than 1 U/ml were used.   
 
The mean total lengths of capillaries of ECV 304 were 1700 ± 50, 1300 ± 132, 505 ± 83 when 
cells were treated with 4, 10 and 20 U/ml TF respectively, while those for HDMEC were 1233 ± 
153, 1020 ± 159, 367 ± 29 respectively.  The mean total number of capillaries of ECV 304 was 
110 ± 26, 75 ± 22 and 30 ± 10 when cells were treated with 4, 10 and 20 U/ml TF respectively 
while those for HDMEC were 113 ± 15, 70 ± 10 and 27 ± 12 respectively.  Furthermore, the 
mean total length and number of capillaries of HDMEC were 750 ± 50 and 73 ± 13 respectively 
when cells were treated with 0.2 U/ ml.  The mean total capillary length of HDMEC was 1007 ± 
178 and the mean total number was 100 ± 10 when cells were treated with 0.5 U/ml.  
Therefore, when HDMEC were treated with doses less than 1 U/ml (0.2 and 0.5 U/ml), no 
increase of angiogenic parameters was observed (Fig. 4.8).   
 
 
Figure 4.8: Effect of TF on Angiogenesis.   
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Furthermore, mean total length and number ± SD decreased when either cell type was treated 
with suramin.  The minimum ECV 304 total length and number (80 ± 26, 24 ± 5 respectively) 
was achieved when the cells were treated with 200 nM while those for HDMEC were 123 ± 31 
and 30 ± 9 respectively (Fig. 4.9).  Increase of the suramin dose to 400 nM did not appear to 
decrease the angiogenesis further (Fig. 4.9).   
 
 
Figure 4.9: Effect of suramin on angiogenesis.  The values represent the mean of the total 
length of three PC sera and each experiment was undertaken in triplicate.   
 
There were similar decreases in the total length and number of capillaries when cells were 
treated with polyclonal anti-VEGF antibodies.  Minimum mean parameters (total length and 
number) were achieved when cells were treated with 2 ng/ml anti VEGF.  The mean ± SD of ECV 
304 total length and number were 70 ± 17 and 23 ± 5 when cells were treated with 2 ng/ ml of 
anti-VEGF while those for HDMEC were 130 ± 10 and 30 ± 5 respectively.  Increasing the dose 
of neutralising anti VEGF up to 3.2 ng/ml did not show further decreases in capillary length and 
number.  Two ng/ml was used in angiogenesis because 2 ng/ml of VEGF increase cell invasion 
(section 3.4.4) 
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Inhibition of angiogenesis was achieved when HDMEC were treated with a combination of 
suramin, anti-VEGF and anti TF in doses of 200 nM, 2 ng/ml, and 48 µg/ml respectively.  
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4.6 Discussion 
As described under materials and methods, the angiogenesis assay was performed using gel 
formed by two different methods (section 2.2.6.1).  In method B, the capillaries were well 
formed and easier to detect than in method A.  Furthermore, method B is widely used and 
extensively described in the literature as reported in section 2.2.6.1.B, while the first is not.  
Thirdly it is less complicated than the first method.   
 
There are four main primary variables that are commonly used to determine the extent of 
capillary formation.  They are: total capillary length, total capillary number, average capillary 
length and average capillary number.  Total length and number of capillaries have been used 
widely to assess tubule formation (Hernandez et al., 2004, Isaji et al., 1997, Wu et al., 1997).  
Average tubule length is determined by dividing total capillary length by the number of tubules.  
As it is based on two other variables it cannot strictly be seen as a separate independent 
variable.  Therefore, measurements of total length and number in 10 pictures at 400 X 
magnification were used as a method for evaluation of the capillary assay and angiogenesis in 
this study.   
 
The tubules angiogenic assay allows the quantitative detection of endothelial cell capillary 
formation in response to serum with pro- and antiangiogenic factors.  At the beginning of the 
study, ECV 304 was selected to evaluate the effect of proangiogenic and antiangiogenic factors 
on angiogenesis.  It has been noted that ECV 304 does not express defining endothelial cell 
markers like Von Willebrand factor (vWF), CD31 and CD34, but it expresses VEGFR 1 and VEGFR 
2.  Furthermore, treatment of ECV 304 by TNF–α  , bacterial lipopolysaccharide (LP) and 
iterleukin-1B (IL-1B) resulted in expression of ICAM-1 but no E-Selectin and VCAM-1, while 
HDMEC and other primary endothelial cell lines expressed characteristic key markers such as 
vWF, CD31, CD34, VEGFR 1, VEGFR 2, ICAM-1, E-Selectin and VCAM-1 (Unger et al., 2002).  
 
In addition, it has been noted in the current study (section 4.3) that the positive expression of 
TF, VEGFR 1-3 was detected in 2, 17, 19, 22% respectively of ECV 304 while that for HDMEC 
was 10, 52, 41 and 65% respectively.   
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Using HDMEC, the maximum total length and number of capillary formations were achieved 
when cells were treated with low dose (1 U/ml) of TF.  Higher concentrations of TF resulted in a 
decrease of these angiogenic parameters, which may be due to the saturation of endothelial cells 
and or apoptotic changes with high doses.  The current study is in agreement with a study 
reported by Watanabe et al. (1999).  These authors noted that capillary formation was achieved 
when low doses of TF (10-30 µg/ml) were used and higher concentrations did not produce 
angiogenesis.  The maximum increase of capillary formation (250% increase compared to 
control) was achieved when bovine aorta endothelial cells were treated with 10 µg/ml of TF.  
This result was in accordance with that of  Pradier and Ettelaie (2008) who noted that the 
maximum capillary formation was achieved when HUVEC were treated with 1 U/ ml of TF due to 
the activation of caspase-3, expression of p53 and Bax, translocation of p53 into the nucleus and 
induction of DNA fragmentation.  Also, there was no tubule formation when HUVEC were treated 
with 100 U /ml of TF.  Moreover, our results were in accordance with  Ettelaie et al. (2008) who 
noted that 13 pg/ml of TF or 2 µM of VEGF resulted in enhancement of HDMEC capillary 
formation.   
 
It has been reported that TF expression has been significantly correlated with unfavourable 
prognostic factors such as enhancement of angiogenesis (Lwaleed and Cooper, 2000).  In the 
current study, there were no clotting factors used; therefore enhancement of angiogenesis by 
exogenous TF is clotting independent.  The clotting independent mechanism could be performed 
through any of four pathways, most of which are initiated by clotting factors.  These pathways 
include TF/FVIIa, TF/FVIIa/FXa, thrombin and directly by TF (as described in detail in section 
1.9.2).  In the current study, FVIIa/FXa was not used and because the first three pathways 
depend on TF and other clotting factors.  Therefore, the expected mechanism was the 
angiogenic changes resulted from the effect exogenous TF and soluble angeogenic markers in 
the serum.  Therefore, TF induces angiogenesis in a mechanism independent of coagulation 
which could be directly through the cytoplasmic domain of TF (Abe et al., 1999, Bromberg et al., 
1999, ) or through direct interaction with the cell surface protein (Pradier and Ettelaie, 2008).  
Still there is a possibility that the TF mechanism might be due to the effect of VEGF produced by 
the effect of TF as aberrant TF expression could enhance VEGF expression (Zhang et al., 2004, 
Abe et al., 1999).   
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It has been noted in the current study that anti-VEGF and suramin reduce the angiogenesis.  
Therefore, blocking of VEGF directly by anti-VEGF or by suramin decreased angiogenesis as 
expected.  Furthermore, a combination of anti VEGF, suramin and anti TF inhibits angiogenesis 
completely.  This result is in accordance with Bhargava et al. (2007) who noted that suramin 
inhibited PC cell proliferation, metastasis and angiogenic activity, represented by a dose 
dependent decrease of VEGF secretion (10, 100, 200 and 800 μg/ml in a mouse model.  
Furthermore, Bhargava and colleagues in a later study reported that tumour growth and 
metastasis of PC were reduced after the mice were treated with suramin when a dose of 60 
μg/kg was used.  The dose in the current study that decreases angiogenesis is (200 nM/ 20000 
cells) which is less than 60 ug/kg.  Therefore might low doses of suramin might be enough to 
decrease the angiogenesis with less side effects.   
 
The results of the current study have suggested some preliminary evidence for the concept of 
“multitargeted” therapy and the possibility of controlling pancreatic tumour angiogenesis, growth 
and metastasis through inhibition of the angiogenic factors such as TF and VEGF.  While 
gemcitabine has shown some promising results in PC treatment, chemotherapy in general has 
been ineffective (Storniolo et al., 1999).  Radiation therapy can be used as a treatment in the 
minority of patients with localised unresectable tumours but it cannot control distant metastases.  
The pre-clinical evidence of the efficacy of combination of anti-VEGF, anti TF and suramin 
inhibiting angiogenesis totally need be supported by clinical research and could represent the 
treatment of choice for this disease in the future.  The key mediator of angiogenesis is VEGF and 
its receptors and the targeting of VEGF may be an optimistic treatment in the future and to 
overcome resistance multiple combinations are used (Morelli et al., 2009).  Ning et al. (2010) 
reported the simultaneous combination of at least two angiogenic inhibitors with chemotherapy 
to overcome the resistance.  Suramin has been used previously in the treatment of prostatic 
cancer, but it has many serious side effects due to toxicity resulting in nephropathy (Garcia-
Schurmann et al., 1999).  Therefore, based on the results of the current study, it is suggested 
that suramin could be used at lower doses and if given in combination with chemotherapy, anti-
VEGF and anti-TF might have favourable results in treatment of PC cases.  However, anti-TF 
might has toxic effect.   
 
In the current study, both anti-VEGF and suramin had an anti-angiogenic effect.  Maximum anti-
angiogenic effects were achieved when the cells were treated with anti-VEGF (2ng/ml) and 
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suramin (200 mM/ml).  Furthermore, increasing the dose of anti-VEGF and suramin had no 
further effect; this might be due to saturation of the cells. 
As a conclusion, TF induced angiogenesis in a mechanism independent of the coagulation 
cascade.  Angiogenesis was almost entirely inhibited when suramin, anti-TF and anti-VEGF were 
induced together.  HDMEC was chosen as a primary endothelial cell model to evaluate the 
angiogenesis in the clinical part of the study.  Method B of gel formation was chosen as the 
method for gel formation in the angiogenesis experiment of the clinical part of the study.  Total 
length and number of capillaries were chosen as a method for evaluation of the angiogenesis 
only.  The evaluation of clinical samples is important but insurance that the assays and in vitro 
studies are given due credence 
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CLINICAL PART 
CHAPTER FIVE: CLINICOPATHOLOGICAL 
DETAILS of PATIENTS 
The current study is a prospective cohort clinical trial to evaluate the effect of resection of 
localised PC on tissue-factor promoted pathways of thrombosis, cell invasion and angiogenesis.  
The trial was approved by the research ethics committee (MREC, number: 08/H1305/59) and by 
the NHS Trust research and development (R&D) / NHS Trust organisation (number RO721).  
Forty-one patients underwent attempted pancreatic resection including pancreatic 
adenocarcinoma (Fig. 5.1), pre-cancerous malignant pancreatic conditions (Fig. 5.2) and 
cholangiocarcinoma.  In addition, 22 cholecystitis patients undergoing laparoscopic 
cholecystectomy served as controls (Fig. 5.3).  A consort diagram of the study is shown in Fig. 
5.3.  Whipple surgical operation was performed to remove the tumour.  For unresectable tumour 
bypass surgical removal was performed to releave the symptoms (see section 1.6). 
 
 
Figure 5.1:  Histopathological section of pancreatic adenocarcinoma stained with H&E (x 
400).   
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Figure 5.2: Representative example of histopathological section of pre-cancerous mucinous 
pancreatic cyst stained with H&E (x 100).  Black arrows are the columnar epithelium of the cyst.  
Yellow arrows are the pancreatic tissues.   
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Consort diagram of study patients.   
Total number of 
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(63) 
Pre-malignant 
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 (9) 
Pancreatic 
adenocarcinoma 
(27) 
 
Whipple  
(14). 
 
Cholangiocarcinoma  
(5) 
 
Bypass 
 (13). 
 
Whipple  
 (2) 
 
Bypass  
(3). 
 
Cholecystitis 
(22) 
 
110 
 
Eligible patients for the study were identified, registered with the clinical trial data manager and 
then approached by the chief researcher or research nurse who explained the purpose of the 
trial.  The relevant patient information sheets (Appendix A) and consent forms (Appendix B) 
were discussed in detail.  Time was given to patients to read them carefully, and to discuss them 
with friends, relatives and their GP, before written informed consent was obtained.  Demographic 
data were recorded, relating to the conventional pre-operative patient assessment such as 
haematological tests including haemoglobin, white blood cells, neutrophil and platelet count.  
Biochemical tests include C-reactive protein; bilirubin and liver enzymes were added to the data 
collection sheet (Appendix C).  
 
The protocol was to collect blood pre-operatively, post-operatively (6-8 weeks after operation, 
when the drain tubes were removed, if there was no sign of infection, the patient being in good 
health or as soon as the patient exhibited of post-operative recovery signes), twice during 
chemotherapy (week 8 and week 24 during chemotherapy treatment) and then eight weeks 
after chemotherapy.  For the cholecystectomy control group, only pre- and post-operative 
samples were collected.   
 
All clinical samples were submitted to serological analyses, which included: evaluation of 
chemotaxis activity; angiogenic activity, TF-bearing MP number; CD14-bearing MP number, PT 
and VEGF ELISA.  A subset cases were submitted to annexin bearing MP, CD 31 bearing MP, CD 
42b bearing MP, MP activity (ELISA), auto annexin antibody (ELISA), angiogenesis array using 
angiogenesis array kit and leptin ELISA.  The cholecystectomy group was used as a control for 
cell invasion and angiogenesis, and where possible the cholecystectomy cases were analysed by 
ELISA experiments (Fig. 5.4).   
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Figure 5.4: Serological experiments.  PPP: platelet poor plasma, NO: number, PT: 
prothrombin time.  TF -MP NO, CD 14 MP NO, PT, cell invasion and angiogenesis were performed 
on all cases.  TF, TFPI and VEGF ELISA were performed in all available cases.  Angiogenesis 
array, annexin MP NO and Leptin ELISA were performed in a subset of cases.  MP ELISA and 
auto annexin antibody ELISA were performed in some clinical trial and cholecystectomy cases.   
 
Post-operative samples were only collected in approximately one half the cases (Table 5.1).  
Week 8, week 24 during chemotherapy and week 8 after chemotherapy samples were collected 
in a few cases (6 cases; week 8 chemotherapy, 5 cases; week 24 chemotherapy and 1 case; 
week 8 after chemotherapy).  The lack of samples was mainly due to high post-operative 
mortality, withdrawal of the patients and difficult phlebotomy or in some cases results were 
excluded from the study due to partial or complete haemolysis of blood samples.   
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Table 5.1: Number of cases with pre-and post-operative blood samples.   
 
In addition to that, there were 4 cases from group D [all unresected cases of malignant cases 
(groups II and VI)] with pre-and postoperative blood samples.  In this thesis, the data was only 
related to the pre-operative and post-operative period.  The part of the study relating to effects 
of chemotherapy is on-going.  The patient groups and post-operative blood samples collected for 
this study are summarised in Table 5.1.  Laboratory analyses were blinded to clinical provenance 
of specimens.   
 Group I:  PC cases successfully resected.  
 Group II: PC cases with a bypass  
 Group III: Pre-malignant pancreatic cases successfully resected.   
 Group IV:  Chronic cholecystitis cases treated by laparoscopic cholecystectomy. 
 Group V: Cholangiocarcinoma cases successfully resected.  
 Group VI: Cholangiocarcinoma cases with bypass.   
For the statistical analyses the cancer cases were also summatively grouped as follows:  
 Group A: All PC cases (groups I and II).   
 Group B: All malignant cases (groups I, II, V and VI).   
 Group C: All resected cases of malignant cases (groups I and V).   
 Group D: All unresected cases of malignant cases (groups II and VI).   
 Group E: All cholangiocarcinoma cases (groups V and VI).   
 
Pancreatic Cancers 
(Group I) 
Cholangiocarcinoma  
(Group V) 
Precancerous lesions 
(Group III) 
Cholecystectomy  
(Group IV) 
9 2 5 11 
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5.2 Blood Samples  
The blood was collected in two types of tubes.  For plasma, blood was collected in 5 ml sodium 
citrate tubes [citrate concentration of 0.109 mol/L (3.2%)], in the ratio 1 to 9.  These plasma 
tubes were blue topped vacutainers.  The tubes were centrifuged (at 360 xg for 10 minutes) to 
prepare platelet-rich plasma (PRP).  The PRP was further centrifuged (15 minutes at 13000 xg) 
to obtain PPP as described previously (Jimenez et al., 2003).  TF bearing MP, CD 14 bearing MP 
(for monocytes) , CD 31 (for endothelial cells), CD 42b (for platelets) count and PT were 
performed on fresh PPP (within the first four hours of venepuncture).  The remaining plasma 
was kept as 200 µl aliquots in 0.5 ml polypropylene tubes at -80oC.  Frozen PPP samples (not 
thawed previously) were used in ELISA experiments (TF, TFPI, MP activity) and annexin MP 
count (Fig. 5.4).    For the serum, blood was collected in 5 ml serum-separating tubes (also 
known as yellow topped vacutainers).  These tubes contain a gel that separates the clot from 
serum.  The tubes were centrifuged at 360 xg for 10 minutes.  The serum was aliquot (200µl) in 
0.5 ml polypropylene tubes at -80 0C.  Serum samples were used to evaluate the expression of 
angiogenic markers in the serum of PC, cell invasion and angiogenesis.  Frozen samples were 
used to evaluate angiogenesis array, cell invasion, angiogenesis assay (capillary formation), 
VEGF and leptin concentration using ELISA (Fig. 5.4).  All samples used in the current trial were 
not thawed previously.   
 
5.3 Age and Sex 
The mean age of group B was 61.2 ± 11.1 years.  No patient was operated on below the age of 
39 years or above 81 years.  The Male: Female ratio was 1.2:1.  The mean age of group III 
(premalignant cases; 9 cases) was 58.8 ± 13.1 years.  Male to female ratio was 1.2:1.  The 
mean age of group IV (Cholecystectomy group; 22 cases) was 63.7 ± 7.4; male: female ratio 
was 0.5:1.  
 
5.4 Clinical and Social History 
Two cases were hypertensive out of 27 (group B); there was no history of infection or ischemic 
heart disease.  Two cases from group II, one case from group III and 2 cases from group E were 
on prophylactic dalteparin (5000 U).   
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Three cases out of 27 of group A were diabetic; one case of group III was diabetic.  Two cases 
of group IV were diabetic.   
 
Four out of 31 of group B were ex-smokers, 5 patients smoked 1-10 cigarettes/day; two patients 
smoked 11-20 cigarettes/day.  One patient out of nine of group III smoked 10-20 cigarette/day.  
Three patients of group IV were ex-smokers, three patients smoked 1-10 cigarettes/day; two 
patients smoked 11-20 cigarettes/day.   
 
Four cases in group B drank alcohol 1-7 glasses/week and four cases were drank eight or more 
glasses/week.  Three cases of group III drank 1-7 glasses/week and 3 cases drank 8 glasses or 
more/week.  Three cases out of 22 of group IV drank 1-7 glasses/week and 3 patients drank 8 
or more glasses/week.   
 
5.5 Haematological Finding 
The mean haemoglobin concentration of group B was 12 ± 2.3 g/L.  Mean platelet number of 
group B was (258.3 ± 66.8) x 109/L, WBC count was (6.2 ± 1.4) x109/L, neutrophi count was 
(3.9 ± 1.2) x109/L.   
 
5.6 Statistical Analysis  
The statistical analysis was performed under supervision of Dr Victoria Alga (Senior Lecturer in 
Medical Statistic in Hull Yorkshire Medical School).  The median was used as the main 
comparator in this study when the data were asymmetrical (skewed), while the mean was used 
when the data were normally distributed. GraphPad prism 5 statistic programme was used for 
statistical analysis.   
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CHAPTER SIX: ANGIOGENESIS ARRAY  
6.1 Introduction 
The regulation of tumour angiogenesis in cancers, including PC depends on a delicate balance 
between pro-angiogenic (angiogenic activators) and anti-angiogenic factors (angiogenic 
inhibitors) which are secreted by the tumour and surrounding cells (Chang et al., 2008, Hicklin 
and Ellis, 2005, Poon et al., 2001).  The point at which the balance shifts towards pro-angiogenic 
factors is called the angiogenic switch (Baeriswyl and Christofori, 2009, Abdollahi et al., 2007).  
The suggestion therefore, is that the on and off of the angiogenic switch plays a crucial role in 
determining whether a tumour grows or regresses (Chang et al., 2008, Hicklin and Ellis, 2005, 
Poon et al., 2001).  Hence, angiogenesis could be induced by an increase in pro-angiogenic 
factors, a decrease of anti-angiogenic factors or a combination of both (Sasano and Suzuki, 
2005) and in reverse angiogenesis could be inhibited.   
 
In past years many proteins have been categorised as angiogenic activators.  Foremost among 
them are VEGF, PDGF, bFGF, erythropoietin, PDGF, IL-10, TGF-β, CD 34, NO and uPA.  
Angiogenic markers have been widely used to predict the prognosis, relapse and recurrence of 
cancers (Achimas-Cadariu et al., 2009, Andersen et al., 2009, Alamdari et al., 2007, Konukoglu 
et al., 2007).  Furthermore, two important anti-angiogenic factors are angiostatin and 
endostatin; both are produced by proteolytic cleavage of plasminogen or collagen XVIII, 
respectively (Oreilly et al., 1997, 1994).  Moreover, TSP-1, TSP-2 and the chemokines such as 
CXCL4, CXCL9, CXCL10 and CXCL11 can also inhibit angiogenesis (Strieter et al., 2006).  A 
summary of pro and anti-proangiogenic markers was given in section 1.13.  
 
It has been widely reported that PC is a highly angiogenic tumour (McElroy et al., 2009, Ikeda et 
al., 1999, Itakura et al., 1997).  At the time of diagnosis, most PC patients already have locally 
advanced or metastatic disease (Yeo et al., 1997).  However, the surgical removal of PC followed 
by chemotherapy is the treatment of choice.  Unfortunately this can only be performed in 15-
20% of PC cases (Takamori et al., 2006, Zuckerman and Ryan, 2008).  Because of this, and 
because the overall five year survival rate of PC remains disappointing (Sohn et al., 2000), there 
has been an interest in recent years in understanding the markers that control angiogenesis in 
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PC and looking to manipulate the balance between pro-and anti-angiogenic markers inducing a 
shift towards the anti-angiogenic status.  
 
Therefore, manipulation of the angiogenic balance may represent a therapeutic target in the 
future.  Because multiple factors may contribute to angiogenesis in PC, it is critical to determine 
the serum expression of multiple factors simultaneously.  In many studies, the expression levels 
of multiple angiogenic factors were quantified by ELISA or at the mRNA level by reverse 
transcription-PCR.  The ability of these techniques to measure multiple samples of angiogenic 
factors simultaneously is limited because they required always large sample volumes, and exhibit 
low throughput.  Therefore, using array technology has several advantages over other 
techniques, such as detection of expression levels in small serum volume (100 µl); it is cheaper 
than other techniques and all the markers are tested in a standardised approach.  
 
Angiogenesis arrays (an example of a multiplex assay) have been recently used by several 
researchers. Byers et al. (2010) used this technique in measurement of the effect of hypoxia 
regulated factors in the treatment of squamous cell carcinoma of the head and neck tumours.  
Funk et al. (2010) used a multiplex assay as well to measure the angiogenic markers in the 
ocular fluid.  Whereas Yurkovetsky et al. (2007) used it to evaluate the angiogenic markers in 
melanoma patients.  The authors found that the angiogenic markers were higher in the serum of 
patients with melanoma vs. healthy control.  Furthermore, they found that VEGF, EGF and 
hepatocyte growth factor decreased in melanoma patients after treatment with interferon-A2b.  
Keyes et al. (2003) used multiplex technology to measure angiogenic markers in serum of mice 
bearing human tumour.   
 
The main aim of this study is to identify angiogenesis-related factors, other than TF, that could 
potentially influence the result of the angiogenesis.  In the current study, array kits from 
different companies were evaluated and the angiogenesis array of the R&D system company was 
chosen because the number angiogenic markers (55) are higher than others.  Each membrane 
was coated with duplicate spots of antibodies to activin A; ADAMTS-1; angiopoietin; 
amphiregulin; artemin; angiogenin; angiostatin; tissue factor; CXCL 16; DPPIV, EGF; EG-VEGF; 
endoglin-1; endothelin-1; endostatin; FGF; basic FGF, acidic FGF; basic fibroblast growth factor; 
FGF4; FGF7; the GDNF family of ligands (GFL) consists of four neurotrophic factors:GDNF, NRTN, 
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ARTN) and PSPN; GM-CSF; HB-EGF); HGF ;IGFBP; IL-1B; IL-8;  LAP; leptin; MMP8;MMP9 ;MCP1; 
NRG1-B1 is active EGF; PTX3; PIGF; PDGF (AA, BB and AB); PF4;Prolactin; Serpin ; TIMP 1) and 
TIMP4; thrombospondin-1; TFG-β); Vasohibin and VEGF.  To the best of the author’s knowledge, 
this study is the first that has used an angiogenesis array in PC to study changes of 55 
angiogenicmarkers pre-and post-operatively.   
 
6.2 Materials and Methods 
The relative expression of 55 angiogenic markers was evaluated using R&D angiogenic array kit.  
The angiogenic markers with six positive controls and two negative controls were spotted in 
duplicate on nitrocellulose membrane.  The light emitted after incubation of the membrane with 
test samples and ECL agents was proportional to the protein expression of the specific markers 
(see section 2.2.10).  The tested pre- and post-operative samples totalled seven; six from group 
I (1 case; stage I, 1; stage IIIa and 4; stage IIIb) and a single pre-cancerous pancreatic case 
(group III).  The chemotherapy part of the protocol is on-going and not reported here and in all 
clinical chapters.  Two cases of week 8 chemotherapy were studied to evaluate the relationship 
between angiogenic markers.  Methodology was described in detail in chapter 2, section 2.2.10.  
VEGF ELISA was performed in all available samples and the methodology was described in detail 
in section 2.2.12.1.  Leptin ELISA was performed to validate the angiogenesis results.  The 
methodology of Leptin ELISA was described in detail in section 2.2.12.4.   
 
6.3 Results 
6.3.1 Comparison between X-ray and Direct ECL Detection Systems  
After incubation of the membranes with sample and ECL reagents, a gel doc system 
(transmission mode scanner) was used to detect the light emitted from the spots; the scanner 
captured one picture every five minutes.  Pictures were taken at 5, 10, 15 and 20 minutes.  As 
the duration of exposure increased the optical densities of all the dots on the membranes 
increased for both the test and background.  Therefore, the first picture (5 minutes) was chosen 
for analysis because the dots were clearest against the background (Fig. 6.1A).  After the 
analysis on the gel doc system, the membranes were incubated in fresh ECL reagents.  The 
membranes were again exposed to x-ray films for different durations of 1, 3, 5, 7 and 10 
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minutes sequentially.  Three minutes exposure to x-ray was chosen because the dots were 
clearest against the background (Fig. 6.1B; 2).  
         
A       B 
Figure 6.1: Representative example of membrane and X-ray film results of Angiogenesis 
Array.  A- Represents the pre-operative and post-operative protein expression of angiogenic 
markers measured directly from the membrane after five minutes exposure.   B- Represents the 
pre-operative and post-operative protein expression of angiogenic markers using X-ray film after 
three minutes.  
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Figure 6.2: Representative example of X-ray film showing pre- and post-operative 
angiogenic markers on a PC serum.  Positive controls are marked by     .  Negative controls are 
marked by     .  VEGF is marked by    PF4 is marked by   .  
 
To assess which method is preferable for analysis, the relative expressions of angiogenic markers 
were both measured directly from the membrane and from X-ray film.  The latter was 
recommended by the supplier.  The analysis was conducted twice on different days using the 
same samples and different membranes to allow the techniques to be compared for 
reproducibility.  After subtracting the negative control and normalising the results against the 
mean of 6 positive controls spotted on the membrane, as shown in Fig. 6.3, the difference in the 
summation of normalised values of optical densities for all 55 values, emitted directly from the 
membrane, in the first and second experiments was greater than that of the x-ray (Fig. 6.3). 
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Figure 6.3:  Comparison between the reproducibility of X-ray and membrane methods. v The 
summation of the normalised values of optical densities of all angiogenic markers including the 
Positive controls have been considered as an indicator.  The first experiment is represented in 
blue colour, the second in red.  
 
Furthermore, the mean normalised values of the duplicate relative expressions of each 
angiogenic markers were compared individually; the differences between corresponding markers 
were greater with the membrane method than the X-ray method (Fig. 6.4; 6.5).  This difference 
was seen in both pre- and post-angiogenic factors; however, it must be noted that wide 
discrepancies were observed in some factors in the x-ray too.   
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Figure 6.4:  Comparison between pre-operative optical densities of the first and second 
experiment using x-ray and membrane methods.  The upper part represents x-ray optical 
density.  The lower part represents membrane optical density.  The first experiment is shown in 
blue, the second experiment in red. 
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Figure 6.5:  Comparison between post-operative optical densities of the first and second 
experiment using the x-ray and membrane.  The upper part represents x-ray optical density.  
The lower part represents membrane optical density of pre-operative samples.  The first 
experiment is shown in blue, the second experiment in red. 
 
Based on these evaluations, the X-ray method was adopted to assess the angiogenic markers in 
the study.  The difference in the comparability between the two methods may be explained at 
least in part due to a technical problem with the direct analysis of optical density from the 
membranes.  This is because after making the grid on the membrane, the dots became hazy and 
unclear.  Therefore, it was difficult to recognise and encircle some of the dots in a reproducible 
manner.  This problem was not found when the x-ray film was used and the dots were clear and 
easy to encircle accurately.   
 
6.3.2 Optimisation and Normalisation of Data 
The average optical density of the duplicate negative controls was subtracted from the average 
optical density of each duplicate positive control on every membrane.  The test factor expression 
value was normalised as a percentage against the average of six positive controls spotted on 
each membrane.  In total, 16 membranes (48 pairs of positive controls) were investigated.  As 
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shown in Fig. 6.6, in 92 % of cases, the optical density of each duplicate positive control was 
equal to the overall mean of all positive controls ± 10%.  
 
 
 
 
 
 
 
 
 
 
Figure 6.6:  The distribution of the average positive control values; estimated from the mean 
of the six positive controls; were spotted in three pairs on each individual membrane.   
 
 
Therefore, a normalised value ≤ 10% was considered as not detectable and changes of ≤ 10% 
between samples were not considered significant due to this level of variation.  For example in 
one membrane the optical densities of the six positive controls were (167, 197), (194, 185), 
(196, 185).  The average of the duplicate negative controls was three.  The values after 
subtraction of the average control were (164, 194), (191, 182), (193, 182): the average of each 
duplicate was 179, 186.5 and 187.5 respectively.  The mean of these values was 184.  Thus, 
each of these normalised values was within the range of positive control ± 10.   
 
In the current study the expressions of 30 angiogenic markers were undetectable in the serums 
of any of the PC patients because their normalised values of expression were ≤ 10%.  For 
example, the normalised value of artemin on one membrane was 3%, the same value as the 
average of the six positive controls.  Therefore the expression of this marker was considered 
undetectable.  In another example, the normalised value of angiogenin on one membrane was 
94% of the average six positive controls; this marker was considered detectable.  
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The thirty markers that were undetectable in PC sera were: Activin A, ADAMTS-1, Angiopoietin-
2; Amphiregulin, Artemin, Coagulation Factor III , EG-VEGF, FGF acidic, FGF basic, FGF 4, 5FGF 
7 ,GDNF, GM-CSF, HB-EGF , HGF, ILB , IL8, LAP(TGF-B1), MCP-1, MIP-1a, NRG1-B1,PD-EGF; 
Preserphin, PIGF , Serpin B5, Serpin F1, TSP-2, uPA, Vasohibin and VEGF C.  Twenty five 
markers were detectable (≥ 11% of positive controls) in the serum of the serum of PC patients.  
These are listed and grouped into three categories (Table 6.1).  TF was not detectable in this 
experments could be due to several causes such as the samples are frozen sample not fresh 
plasma, the expression of TF below the threshold of the array kit, the idiotype of the antibody 
used in microarray could be different from used in other techniques or might be combination of 
two or more causes.  The undetectable expression of ILB and IL6 could be pro-inflamatory 
process.   
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Table 6.1:  Summary of expression of angiogenic markers in PC sera 
Undetectable < 11% Low 11-25% Moderate > 25 < 75% High > 75% 
 Activin A Angiostatin/plasminogin Angiopoietin-1 Angiogenin 
ADAMTS-1 Endoglin CXCL 16 IGFBP-1 
Angiopoietin-2 Endothelin DPPIV IGFBP-2 
Amphiregulin Platelet factor 4 EGF IGFBP-3 
Artemin Thrombospondin-1 Endostatin/collagen XVIIII PDGF-AA 
Coagulation Factor III  Leptin PDGF-AB/PDGF-BB 
EG-VEGF  MMP-8 Serpin E1 
FGF acidic  MMP-9 TIMP-1 
FGF basic  Pentraxin  
FGF 4  Prolactin  
FGF 7  TIMP-4  
GDNF  VEGF  
GM-CSF    
HB-EGF    
HGF    
ILB    
IL8    
LAP(TGF-B1)    
MCP-1    
MIP-1    
NRG1-B1    
PD-EGF    
Preserphin    
PIGF    
Serpin B5    
Serpin F1    
TSP-2    
uPA    
Vasohibin    
VEGF C    
 
Note: Values expressed as percentages of positive control average.   
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To semi-quantify the level of expression, the normalised value of the pre-operative expression 
was considered.  If the mean value of % expression of factor of PC cases was below 25%, the 
expression was considered low.  If the mean value was > 25% < 75%, the expression was 
considered moderate.  If the expression was > 75%, it was categorised as high.   
 
For example the pre-operative normalised values of angiogenin in six PC cases were 121%, 
120%, 133%, 109%, 90%, 89% giving a mean of 110%.  Therefore, the expression was high.  
 
The pre-operative normalised values of TSP-1 in 6 PC cases were 16%, 1%, 4%, 0%, 22%, 37% 
giving a mean of 13; thus TSP-1 was considered low expression.   
 
Accordingly nine markers showed high expression, eleven factors showed moderate expresion 
and five markers showed low expression (Table 6.1). 
 
6.3.3 Correlations between Expression of Different Angiogenic Factors  
Individual membranes were used to evaluate the angiogenic markers of seven cases (six PC 
cases pre- and post-operative samples with two week eight, a single non PC case with pre- and 
post-operative samples).  The normalised expression of angiogenic markers was evaluated by 
investigating correlation in their expression.  No correlation was found between any two 
angiogenic markers in PC except between VEGF and EGF expression when analysed in a pair-
wise manner.  When all sixteen results were taken into consideration, there was a significant 
correlation between VEGF and EGF (0.002, corelation test, Fig. 6.7).  
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Figure 6.7:  The correlation between VEGF and EGF expression in PC cases  
 
6.3.4 Effect of Pancreatectomy on the Expression of Angiogenic Markers. 
The mean and median expression of the normalised values for each angiogenic markers pre- and 
post-operatively are shown in Table 6.2.  There was a significant decrease of angiopoietin-1, 
angiostatin/plasminogen, PDGF-AA, PDGF-AB/PDGF-BB and VEGF (Wilcoxon matched pairs 
signed rank test).  All of these markers are pro-angiogenic except angiostatin/plasminogen, 
which acts as an angiogenic inhibitor.  Furthermore, there was no significant changes in the 
expression of other angiogenic inhibitor factors such as endostatin, endothelin-1, pentraxin, 
platelet factor 4, serpin E1, TIMP-1, thrombospondin-1.  Moreover, there was no significant 
increase of any angiogenic marker post-operatively. 
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Table 6.2: Pre- and post-operative expression of angiogenic markers of PC sera.   
 
Note: Wilcoxon signed rank test was used for statistical analysis.  IQR is interquartile range.  Five 
highlighted angiogenic markers show significant post-operative changes.  The unit of expression 
is optical density
Marker  Pre-operative mean Post-operative mean  P  
Mean ± SD Median IQR Mean ± SD Median IQR 
Angiogenin 115 ± 16 120 (100-127) 101± 34 113 (76-120) 0.56 
Angiopoietin-1 43±25 38 (20-68) 28±22 21 (11-50) 0.03 
Angiostatin/ 
Plasminogen 
13±11 12 (3-21) 6±6 3.5 (1-12) 0.03 
CXCL 16 45 ±25 59 (23-61) 42±19 47 (30-53) 0.4 
DPPIV 63±25 74 (37-80)  57±32 67 (31-78) 0.2 
EGF 31± 25 34 (5-51)  21 ±17 20 (7-31) 0.43 
Endoglin 15±18 6 (2-31) 15±18 7 (1-36) 0.1 
Endostatin/collagen 
XVIII 
39±28 43 (8- 65) 31 ±24 28 (11-52) 0.11 
Endothelin-1 16 ±21 7 (1-36)  7 (1-28) 126 ± 15 0.5 
IGFBP-1 79 ±19 89 (61-93) 64 ±34  80 (37-86) 0.2 
IGFBP-2 86 ±7 86 (79-93) 74± 39 81 (53-104) 0.6 
IGFB-3 86±13 87 (73-98) 80±21 80 (60-101) 0.2 
Leptin 25±31 11 (8-58) 42± 43 42 (0-72) 0.3 
MMP-8 62±18 67 (47-77) 57± 26 64 (48-72) 0.4 
MMP-9 104±15 105 (93-116) 105±31 116 (93-121) 0.8 
Pentraxin 29±25 22 (10- 48) 25±20 23 (8-39) 0.8 
PDGF-AA 95±8 94 (88-104) 83±18 86 (73-98) 0.03 
PDGF-AB/PDGF-BB 78±9 83 (67-84) 61±20 68 (48-74) 0.03 
Platelet factor 4 21±20 16 (2- 41) 25±23 20 (3-50) 0.14 
Prolactin 30±27 35 (1-54) 12±10  11 (4- 21) 0.15 
Serpin E1 92±13 94 (77-103) 91±27 100 (79-105) 0.5 
TIMP-1 111±10 109 (105-116)  102±18 101 (81-116) 0.12 
Thrombospondin-1 13±15 10 (1-26) 16±4 12 (3-27) 0.2 
VEGF 30± 16 26 (17-46) 19 ±15 14 (6.5-38) 0.03 
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The results were re-analysed by comparing the mean of six PC cases pre-and post-operatively 
and using 10 points difference as a cut-off.  Therefore, if there was an 11 point change between 
pre- and post-operative, the expression would be considered as a post-operative increase or 
decrease accordingly.  However, if the difference between the mean pre-operative and post-
operative was less than 11%, the results would be considered as no change.   
 
For example: The mean normalised value of PC cases of angiogenin was 115% pre-operatively 
and 101% post-operatively, so the decrease of post-operative expression was 14 points.  
Therefore the expression of this marker was considered to have decreased post-operatively.   
 
Conversely in the same sample, the mean CXCL 16 expression was 45 pre-operatively and 41 
post-operatively, so the decrease of post-operative expression was 4 points.  Therefore the 
expression of this marker was considered as no change.   
 
Not all values decreased post-operatively; for example the mean expression of the normalised 
values of leptin pre-operatively was 25% while post-operatively it was 42%.  In this marker 
there was an increase of 17 points at post-operative over pre-operative.  Therefore, the 
expression of this marker was considered as increasing post-surgery.   
 
There was no change in the expression of angiostatin/plasminogen, CXCL 16, DPPIV, EGF, 
endoglin, endostatin/collagen, endothelin-1, IGFB-3, MMP-8, MMP-9, Pentraxin, Platelet factor 4, 
Serpin E1, TIMP-1, Thrombospondin-1.  
 
Furthermore the expression of angiogenin, angiopoietin-1, IGFBP-1, IGFBP-2, PDGF-AA, PDGF-
AB/ PDGF-BB, prolactin and VEGF decreased post-operatively in PC cases.  Leptin expression 
increased post-operatively (Table 6.3).   
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Table-6.3: Summary of Post-operative changes of angiogenic markers of PC cases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Looking at the changes of PC cases, it was clear that all those which showed a decrease of at 
least 10% post-operatively were pro-angiogenic (angiogenin, angiopoietin-1, IGFB-1, IGFB-2, 
PDGF-AA, PDGF-AB/ PDGF-BB, prolactin and VEGF).   
Decrease  No change Increase 
Angiogenin Angiostatin/plasminogine Leptin 
Angiopoietin-1 CXCL 16  
IGFB-1 DPPIV  
IGFB-2 EGF  
PDGF-AA Endoglin  
PDGF-AB/ PDGF-BB Endostatin/collagen  
Prolactin  Endothelin-1  
VEGF IGFB-3  
 MMP-8  
 MMP-9  
 Pentraxin  
 Platelet factor 4  
 Serpin E1  
 TIMP-1  
 Thrombospondin-1  
131 
 
6.3.5 VEGF ELISA 
This work was designed to measure VEGF concentration of PC cases.  This experiment was 
conducted in 29 cases of group B, 9 cases of group III and 14 cases of group IV as these were 
the only cases for which serum was available.  The second aim was to optimise the angiogenesis 
array results.   
 
6.3.5.1 Baseline Results  
The sample VEGF was measured from a standard curves that performed on the same day of the 
experiment (Fig. 6.8).   
 
 
Figure-6.8: Representative standard curve for VEGF measurement that correlates with the 
average of absorbance value.   
 
The VEGF concentration of group B (all malignant cases) was significantly higher than that of 
control group IV.  Median and interquartile range (IQR) of group B was 840 (464-1477) pg/ml 
vs. 355 (212-433) pg/ml in the controls, p= 0.005.  The VEGF concentration of group B was also 
higher than that of group III but the difference was not significant (Table 6.4).   
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Table 6.4: VEGF concentration of pancreatic sera compared with the control groups.   
Note: Mann Whitney test was used for statistical analysis.  29* (available samples). 
 
6.3.5.2 Pre and post operative data   
To investigate the effects of the surgery, VEGF serum level was analysed pre- and post-
operatively.  The post-operative VEGF concentration of group C was significantly lower than the 
pre-operative [median and IQR was 409 (218-723) pg/ml vs. 840 (611-1846) pg/ml, p=0.013, 
Table 6.5], while the post operative VEGF of group III and IV did not differ significantly from the 
pre-operative level {[Median and IQR was 695 (228-1656) pg/ml vs. 1048 (371-1053), p= 1], 
[278 (204-486) vs. 373(325-486) pg/ml , p=0.359] respectively, Table 6.5}.  
Table 6.5: Pre- and post-operative serum VEGF of PC cases and control groups.   
 
 
 
 
 
 
Wilcoxon signed rank test was used for statistical analysis. IQR is interquartile range.  4* (The 
analysis was conducted in 4 out of 5 cases, 1 case was not involved because the entire serum 
sample had been used previous experiments). 
  
Group  No  VEGF Concentration pg/ml 
Median and IQR P Value 
B (all cancer cases) 29* 840 (464-1477) B vs. III 
P= 0.371 III (pre-cancerous)  9 600 (206-1048) 
IV (cholocystectomies) 14 355 (212-433) B vs. IV 
p=0.005 
Group No VEGF Concentration pg/ml P value 
Pre-vs. post-operative Pre-operative   Post-operative  
Median & IQR Median & IQR 
C 11 840 (611-1846) 409 (218-723) 0.013 
III 4* 1048 (371-1053) 695 (228-1656) 1 
VI 9 373 (325-486) 278 (204-486) 0.359 
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6.3.6 Leptin ELISA  
 
This part of the work was designed to evaluate the results of the angiogenesis array kit.  A leptin 
ELISA kit from the same company as the angiogenesis array (R & D) was performed in available 
pre- and post-operative PC samples (7), including the six PC samples of angiogenesis array.  The 
methodology was described in section 2.2.12.3.  The pre-operative leptin level of PC cases (using 
ELISA) was lower than the post-operative (5511 ± 4055 pg/ml vs. 8890 ± 7686 pg/ml, p= 0.29, 
Wilcoxon matched-pairs signed rank test).  Furthermore the pre-operative normalised optical 
density of the PC cases (using angiogenesis array) was lower than the post-operative (25 ± 31 
vs. 42± 43).  The post-: pre-operative mean ratio of leptin was 1.6 using ELISA while that for 
angiogenesis array was 1.7.  Therefore, the results of ELISA were comparable to angiogenesis 
array.  
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6.4 Discussion 
Angiogenesis is a prerequisite for growth and metastasis of solid tumours including PC (Folk 
man, 2002 and 1997).  There is increasing evidence that the disturbance of the balance of pro-
and anti-angiogenic factors contributes to the pathogenesis of numerous disorders (Abdollahi et 
al., 2005, Carmeliet, 2005, Hanahan and Folkman, 1997).  A detailed understanding of the 
mechanism of angiogenesis would probably improve the therapeutic options.  Furthermore, 
measurement of angiogenic markers in a PC patient’s serum may provide useful prognostic 
features.  Although the main factor studied in this thesis is TF which “straddles” the thrombosis 
and angiogenesis pathway, it would be expected that it would not be the only factor driving 
these complex processes; therefore to gain a greater insight into the potential impact of other 
angiogenic factors a limited pilot micro-array study was undertaken to try and uncover other 
angiogenesis related markers that may be affected by the removal of the cancer. 
 
Seven cases were investigated in this pilot including six PC cases and a single pre-malignant 
lesion.  A few previous studies used protein array in PC.  One of these, Chang et al. (2008), 
compared biomarkers in PC cases stage using a multiplex assay.  The authors found that several 
tumour markers, such as CA19-9, may have prognostic significance.  Furthermore, Fredriksson et 
al. (2008) evaluated 20 angiogenic markers using an angiogenesis array in a series of 18 PC 
cases with 19 healthy controls plus 19 ovarian cancer with 20 healthy control.  Fredriksson noted 
that CA-125 expression was increased in pancreatic and ovarian cancer serum vs. control groups.   
 
The current study is to the best of the author’s knowledge the first study to look at an 
angiogenesis array of 55 markers in PC pre- and post-operatively. It was found that the 
expression of 30 angiogenic markers (Table 6.1) was undetectable in the serum of the PC cases.  
This may be due to these angiogenic markers being expressed by PC tumours at very low level 
and therefore secreted into the circulation at levels below the threshold of detection of the 
angiogenesis array kit.  Furthermore, the undetectable level might be related to biochemical and 
physiological features of these markers such as their solubility or to the stage of the tumour 
(none of the cases included had distant metastases at the time of attempted resection).   
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Ivanovic et al. (2006) measured the plasma concentration of TGF-β in 53 breast cancer cases vs. 
37 healthy controls.  The authors reported that the mean plasma concentration of TGF- β of 10 
cases of stage I and stage II; (0.94 ng/ml) was significantly lower than that of 43 breast cancer 
patients with stage III and IV was (2.3 ng/ml).  Duranyildiz et al. (2009) reported that the 
TGFβ1 concentration at early stages of PC is not higher than that of healthy controls (0.19 ng/ml 
vs. 0.19 ng/ ml).  The level of TGF-β was undetectable in the six PC cases submitted in the 
current study.  In addition to what was mentioned previously, the discrepancy might be related 
to serum being used in the current study while plasma was used in Ivanovic and Duranyildiz’s 
studies.  Furthermore, Ivanovic and Duranyildiz used ELISA.   
 
aFGF, bFGF and FGF 7 were undetectable in the current study, in contrast to other studies 
(Pistol-Tanase et al., 2008).  These authors reported that the concentration of bFGF was 
significantly higher than that found in healthy controls (28.19 pg/ml vs. 11.7 pg/ml) using ELISA 
in 32 PC cases (21 cases; stages I and II, 11 cases; stages III and IV).  Furthermore, it was 
reported that the serum level of bFGF in 14 out of 21 stage I and II PC cases was < 25 pg/ml, 
whilst in 10 cases out of 11 stage III and IV PC cases the serum level was 25 pg/ml or greater.  
There is no immediate explanation for this difference.  Given that the microarray is much more 
sensitive we would have expected to have seen raised levels of bFGF.  However, it is possible 
that the idiotypes of the antibodies used in microarray could be different from those used in 
ELISA.  This difference was found to be significant (Pistol-Tanase et al., 2008).  Furthermore, the 
current study did not show high expression of HGF, although other studies show high levels of 
EGF and HGF in other types of cancer such as colorectal cancer (Yoon et al., 2006).  
 
Two markers were measured by ELISA (leptin and VEGF) for validation of the angiogenesis 
results.  Both leptin and VEGF ELISA results were comparable to angiogenesis array results.  In 
both techniques, there was increase of leptin and decrease of VEGF post-operatively.  The VEGF 
concentration using ELISA was significantly higher than control group IV (median and IQR of 
group B was 840 (464-1477 pg/ml) vs. 355 (212-433 pg/ml), p= 0.005).  This result was in 
accordance with other studies such as Pistol-Tanase et al. (2008).  In the latter study, VEGF of 
32 PC patients was measured by ELISA and bead-based multiplex assay.  They found a 
significant increase of the mean concentration of VEGF vs. 20 healthy controls (349.28 pg/ml vs. 
115.06 pg/ml).  This is consistent with results of other studies (Karayiannakis et al., 2003).  In a 
series of 58 PC cases, the authors observed significant increases of serum VEGF vs. 51 healthy 
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controls [median and IQR; 505 (284–839) pg/ml) vs. 193 (104–297) pg/ml].  Furthermore, the 
authors noted a significant increase of serum VEGF in 40 PC cases with lymph node metastasis 
vs. 18 PC cases without lymph nodes metastasis (609 vs. 301 pg/ml).  Furthermore, it has been 
reported that in a series of 92 PC cases vs. 60 healthy controls, there was a significant increase 
of serum VEGF and PIGF.  The authors postulated that there was a reverse relationship between 
serum VEGFR 1 receptor and PC stage and a high VEGF/VEGFR 1 ratio using ELISA was 
significantly associated with poor prognosis of PC (Chang et al., 2008).  This kind of high VEGF 
expression has been reported for other cancers too.  Heer et al. (2001) reported that the VEGF 
serum level of 200 breast cancer cases was significantly higher than that of 80 controls (median 
with IQR; 306 pg/ml (157-452) vs. 168 pg/ml (102-245) using ELISA). 
 
In the current study, multiple analyses were undertaken looking for correlations of expression of 
these markers.  A correlation was found only between VEGF and EGF expression (Fig. 6.8).  
When 16 serum samples were considered, there was a correlation between expression of VEGF 
and EGF (R2=0.64, using linear equation p< 0.002).  The result of the current study was in 
agreement with the results of other studies such as Summy et al. (2005) and Tabernero, (2007).  
Therefore, the suggestion was that the synergistic targeting of VEGF and EGF might have a role 
in the treatment of PC.  The author notes, however, that in the current study, EGF did not 
change statistically in the post-operative vs. pre-operative setting.  It is possible that the 
correlation found could be a statistical event rather than a biological one and the result of the 
multiple tests undertaken. 
 
This study found there was a significant decrease of angiopoitin-1, angiostatin/plasminogen, 
PDGF-AA, PDGF-AB/PDGF-BB and VEGF post-operatively (Wilcoxon signed rank test).  This result 
was supported by significant decrease of VEGF concentrations post-operatively when analysed by 
ELISA.  The post-operative VEGF concentration of group C was significantly lower than the pre-
operative [The median and IQR was 409 (218-23) pg/ml vs. 840(611-1846) pg/ml, p=0.013], 
while the post operative VEGF of group III and IV did not differ significantly from the pre-
operative  {[Median and IQR was 695 (228-1656) pg/ml vs. 1048(371-1053), p= 1], [278 (204-
486) vs. 373 (325-486) pg/ml, p=0.359] respectively, Table 6.5, Fig 6.11}.   
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All of these markers are pro-angiogenic except angiostatin/plasminogen, which acts as an 
angiogenic inhibitor.  Furthermore, there was no change in the expression of angiogenic inhibitor 
factors such as angiostatin, endostatin, endothelin-1, pentraxin, platelet factor 4, serpin E1, 
TIMP-1, thrombospondin-1.   
 
However, analysing data using the ≤ 10 cut off point; the current study shows that 15 factors 
showed no changes, eight of which were angiogenic inhibitors.  At the same time, there was an 
increase in the mean serum expression of leptin post-operatively.  Leptin regulates energy intake 
and expenditure (Brennan & Mantzoros 2006) but does not have a direct effect on angiogenesis 
and cell invasion.  Moreover, the expression of angiogenin, angiopoitin-1, IGFBP-1, IGFBP-2, 
PDGF-AA, PDGF-AB/PDGF-BB, prolactin and VEGF was decreased post-operatively.  Furthermore 
the summative change of all these pro-angiogenic markers showed a collective reduction post-
operatively.  Therefore, the re-analysis of data using the cut off point 10 reveals an increase of 
leptin and a decrease of other interesting factors such as IGFBP-1, IGFBP-2 which did not show 
significant changes using statistical test, which might be due to the limited tested samples.  
 
Karayiannakis et al. (2003) reported that serum VEGF of the 12 PC cases with distant metastasis 
was significantly higher than that of 46 PC cases without distant metastasis (1142 pg/ml vs. 390 
pg/ml).  In a series of 58 PC cases that underwent surgical removal, there was a significant 
decrease of serum VEGF levels post-operatively compared with pre-operatively 580 pg/ml vs. 
512 pg/ml (Karayiannakis et al., 2003).  Justinger et al. (2008) noted that VEGF and HGF 
increased post-operatively in PC sera after pancreatic and hepatic resection (1-3 days) thought 
to be associated with wound healing.  
 
A decrease of VEGF post-operatively was noted with other malignancies, serum VEGF 
concentration was decreased after surgical removal of breast cancer (Konukoglu et al., 2007, 
Zhao et al., 2004) , colorectal cancer (Nakayama et al., 2002) and osteosarcoma (Kaya et al., 
2004).   
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Surprisingly, the current study shows a decrease of angiostatin/plasminogen post-operatively.  
Based on these results the tumour is not only the source of pro-angiogenic markers but also the 
source of anti-angiogenic markers.  Therefore removal of the tumour might decrease both pro-
angiogenic and anti-angiogenic factors.  This finding is in accordance with the result of other 
studies such as Peeters et al. (2005) who noted a decrease of angiogenic inhibitors including 
angiostatin and endostatin after surgical removal of colorectal cancer (Peeters et al., 2005).  The 
crucial point is the angiogenic balance which depends on the ratio of the pro- to anti-angiogenic 
factors and control of the angiogenic switch.  Abdollahi et al. (2007) proposed that there are 
different simultaneous genes that could control the angiogenic switch in pancreatic disease, 
which include “angiogenesis off” as in the normal pancreas, “angiogenesis on” as in PC and 
somewhere between “on and off” as in chronic pancreatitis.  The current study suggests that 
pancreatectomy significantly decreases angiopoitin-1, PDGF-AA, PDGF-AB/PDGF-BB and VEGF.  
All of these markers are pro-angiogenic.  Furthermore, as hypothesised there was no significant 
increase of any pro-angiogenic markers.  Moreover, there was no change in the expression of 
key angiogenic inhibitors such as endostatin, endothelin-1, pentraxin, platelet factor 4, serpin E1, 
TIMP-1, thrombospondin-1.  Sequentially, pancreatectomy decreases the ratio of pro-angiogenic 
factors: angiogenic inhibitors and shifts the angiogenic balance to the angiogenic inhibitor state.  
Lastly, this study suggested that the tumour could be the source of pro-angiogenic and 
angiogenic inhibitors as there was a decrease of angiostatin/plasminogen, which is an angiogenic 
marker.   
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CHAPTER SEVEN: CHEMOTAXIS AND 
ANGIOGENIC ACTIVITY OF PANCREATIC 
CANCER PATIENTS’ SERA 
7.1 Introduction  
7.1.1  Pancreatic Cancer and Invasion 
There are a number of factors that influence cancer cell motility.  The necessary preconditions 
and the impact of the coagulation pathway on this process are extensively discussed in section 
1.18.  There are ,however, other molecular pathways that can contribute to this process in the 
cancer setting and should be mentioned such as growth factors (EGF, TGF β1, Barrandon and 
Green, 1987) and cytokines (TNF-α, IL-6, IL-8, Tamm et al., 1994, Orosz et al., 1993, Rosen et 
al., 1991).  In an early study of motility factors secreted from the tumour a molecule termed 
‘scatter factor’ was shown to enhance the movement of cells (Stoker et al., 1987).  A subsequent 
study showed that this factor is identical to hepatocyte growth factor, which induces cell growth, 
motility and invasion (Naldini et al., 1991).  Furthermore, it was reported that 
geranylgeranyltransferase-I inhibits pancreatic cell invasion in vitro (Kusama et al., 2003) by 
blocking the biosynthesis of farnesylpyrophosphate and geranylgeranylpyrophosphate.  Baran et 
al. (2009) reported that tumour infiltrating monocytes and macrophage increase pancreatic cell 
invasion due to secretion of TNF alpha.  Moreover, radiation increases PC invasion by blocking of 
a matrix metalloproteinase inhibitor (Qian et al., 2002).   
 
7.1.2.  Factors Enhancing Angiogenesis Specifically for APC 
The first factor found to be important in angiogenesis was basic fibroblast growth factor (bFGF), 
which was discovered in the 1980s.  Fibroblast growth factors (FGF) are heparin-binding proteins 
involved in angiogenesis, wound healing and embryonic development and cell proliferation 
(Okada-Ban et al., 2000).  FGF-acidic (aFGF), also known as FGF-1 and HBGF-1, is a 17 KDa 
protein produced by different cell types which has an essential role in cell proliferation, 
development and angiogenesis (Yamagishi and Okamaoto, 2010).  In normal tissue, bFGF is 
present in basement membranes and in the sub-endothelial extra-cellular matrix of blood vessels 
(Botta et al., 2000, Okada-Ban et al., 2000).   
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VEGF is another essential pro-angiogenic factor in the stimulation of angiogenesis.  It stimulates 
vasodilatation of the existing vessels and increases permeability of the vessel.  It plays an 
important role as a general activator of endothelial cell proliferation and capillary formation 
(Ferrara et al., 2003).  VEGF is described in detail in section 1.12.   
 
The angiopoietin group has a role in the survival of normal and malignant endothelial cells 
(Peters, 1998).  Angiopoietin -1 (Ang-1) plays an important role in endothelial survival and 
inhibits apoptosis by the activation of the PI3K/Akt survival pathway through activation of 
tyrosine kinase receptor Tie-2 (Papapetropoulos et al., 2000).  However, there are some 
contradictory reports about Ang-1; some have shown that it prevents hepatic growth, vascular 
permeability and angiogenesis (Stoeltzing et al., 2003).   
 
Transforming growth factor beta (TFG-β) acts as a pro-angiogenic factor in low doses because it 
up-regulates angiogenic factors and proteinases, while in high doses it acts as an angiogenic 
inhibitory factor because it prevents endothelial cell growth, stimulates differentiation of smooth 
muscle cells and enhances formation of the basement membrane (Carmeliet, 2003).   
 
Several interactions among VEGF, Ang and other angiogenic factors have been described by 
Harvey and Oliver (2004) who identified retinaldehyde dehydrogenase 2, Norrin, Frizzled-4 and 
Noge-B genes that contribute to these processes.  Furthermore, it has been postulated that 
hedgehog pathway is one of the “core” signalling pathways that undergo somatic alterations in 
PC.  Therefore targeting of this pathway might be helpful in treatment of cancer (Hidalgo & 
Maitra 2009).  Moreover, in mouse experiments, Feldmann (2008) noted that cyclopamine, which 
blocks hedgehog signalling, prolongs survival in PC.  The hedgehog signalling pathway, which 
has been known to be involved in cancer, is an important regulator of the embryonic 
development that becomes reactivated in cancer. 
 
Angiogenesis and metastasis are vital aspects of cancer biology and impact on PC treatment.  
Therefore identifying mechanisms of PC invasion may facilitate the development of more 
effective treatments that could improve patient outcome.  To the best of the author’s knowledge 
this is the first study to evaluate PC serum chemotaxis activity (chemo-taxis; also called 
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haptotaxis) which is represented in vitro by quantitative differences in AsPC1 motility and 
angiogenic activity as represented by the induction of tubular formation.   
 
7.2 Aims 
The purpose of this part of the work was to determine the following: 
1. Whether the chemotaxis and angiogenic activity of PC sera is higher than that of control 
groups. 
2. Whether the serum chemo-attractive and angiogenic activity of PC cases’ sera are decreased 
post-operatively.  
3. Correlation of cell invasion and angiogenesis with each other and with microparticles levels.   
 
7.3 Methodology  
7.3.1 Methodology of Cell Invasion  
AsPC1 cells were cultured and harvested to grow in SFM as described in section 2.2.3.1.  The 
Boyden chamber was coated with collagen IV and 10% (v/v) of PC sera was added to the lower 
compartment as described in section 2.2.7.1.  The methylene blue stain method was used to 
evaluate the invaded cells.  The AsPC1 migration is represented by the mean number of 
migrating AsPC1 counted in five high–powered fields per membrane at 40x objective 
magnification. 
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7.3.2 Methodology of Angiogenesis  
HDMEC were adapted in SFM (as described in section 2.2.2.2.1) and seeded on the top of 
collagen type I gel (2.2.6.2).  The gel was formed using method B described in section 2.2.6.1.B 
as this was shown to be the most reliable.  HDMEC were treated with PC and control sera (100 
µl) pre- and post-operatively.  Capillary (tubule) development was observed over a 3-day period 
and recorded using an Imaging RETIGA 2000 R camera attached to a LeitZ Laborlux S 
fluorescence microscope as described in section 2.2.6.3.  The total length and number in 10 
pictures at 40x objective magnification was used as a method for evaluation of the tubule assay 
and angiogenesis in this study, as detailed previously.   
 
7.4 Results 
7.4.1 Cell Invasion Results 
7.4.1.1  Baseline Evaluation 
Median values of ASPC1 invasion for the cancer groups (A, B, E) were significantly higher than 
those of control groups III and IV (P= 0.0001, Kruskal-Wallis test).  There was no statistical 
difference in the median values of the AsPC1 cell invasion assay between cancer subgroups 
(Mann Whitney test).  The subgroup comparative analyses to control cases were as follows: 
the level of AsPC1 cell invasion of group B was significantly higher than that of group III and 
group IV (Table 7.1; Fig. 7.1).  AsPC1 cell invasion of PC cases (groups A); median and IQR; 
124 (102-148, mean 126 ± 27) was significantly higher than the pre-operative level of group 
III (p= 0.05, Mann Whitney test) and was also significantly higher than that of group IV (p= 
0.0001, Mann Whitney test, Table 7.1; Fig. 7.1). 
 
The median value for all PC cases (group A) did not differ significantly from that found for 
group E (median and IQR; 143 (60-131), p= 0.2, Man Whitney test, Figure 7.1).  The median 
of all resected cases group C did not differ from that of the unresected cases (group D, 
statistics not shown) indicating the homogeneous nature of the ‘cancer diagnoses’ at baseline.   
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Table 7.1:  The baseline chemo-attractive effect of cancer serum and control group 
represented by the mean of AsPC1/HPF.   
 
 
 
 
 
 
Note: All samples were conducted in duplicate.   
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1:  The baseline chemo-attractive effect of PC serum and control group that was 
represented by the mean of AsPC1 /HPF.  All samples were conducted in duplicate.  The red bar 
represents the median.  Full statistical correlations in the text and salient correlations in table 
7.1.  This figure shows all cancer cases (Group B) and all pancreatic cases (Group A)-and all 
cholagiocarcinoma cases Group E for illustrative purposes. 
Group  No  Cell Invasion 
(Cell /HPF) 
Median and IQR Mean ± SD  P Value 
B (all cancer cases) 32 131 (104-153) 129 ± 26 B v III 
P= 0.04 III (pre-cancerous)  9 79 (55-158) 95±50 
IV (cholecystectomies) 20 54 (48-59) 54±10 B v IV 
p=0.0001 
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7.4.1.2  Pre- and Post-Resection Data  
A comparison of pre-operative and post-operative levels of group C (all the 11 resected cases) 
revealed that the post-operative level was significantly lower than that of the pre-operative 
(Wilcoxon signed rank test, Table 7.2, Fig. 7.2-7.4).  Comparison of pre-operative and post-
operative levels in the nine PC cases of group I, for which both samples were available, revealed 
that the post-operative median and IQR; 88 (76-100) was significantly lower compared with the 
pre-operative median; 123 (104-144, p= 0.007; Wilcoxon signed rank test, Fig 7.2-4).   
 
There were no statistically significant differences between the pre-operative and post-operative 
chemotaxis activity of AsPC1 motility of groups III and IV (P = 0.12, 0.6 respectively, Wilcoxon 
signed rank test, Table 7.2).  There was no statistically significant difference between the pre-
operative and post-operative chemo-attractive activity of AsPC1 motility of group D (4 cases, p= 
0.6).  
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Table 7.2:  Comparison of the chemo-attractive activities of PC and control sera represented 
by the mean of AsPC1 cell invasion pre- and post-operatively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2:  A comparison of AsPC1 cell invasion using pre- and post-operative sera.  The red 
bar represents the median.   
Group No Cell Invasion P 
Pre-operative   Post-operative  
Median & IQR Mean ± SD Median & IQR Mean ± SD 
C 11 125 (107-158) 131 ± 23 88 (85-112) 95±27 0.002 
III 5 79 (53-158) 100 ± 55 79 (49-110) 79 ± 35 0.12 
VI 11 55 (41-61) 54 ± 13 56 (48-58) 54 ± 7 0.6 
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Figure 7.3:  Representative example of pre- and post-operative cell invasion. A- Invaded 
AsPC1 with pre-operative pan.  B- Invaded AsPC1 with post-operative pancreatic serum was 
used as a chemo-attractant (x100)  
 
Figure 7.4:  Representative example of the effect of serum chemotactic activity on AsPC1 cell 
migration.  A- Pre-operative.  B- Post-operative (x100).   
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7.4.2 Angiogenesis Results 
7.4.2.1 Baseline Evaluation  
The median values of total length and capillaries number of groups (A, B and E) were 
significantly higher than those of control groups III and IV (P= 0.0001, Kruskal-Wallis test).  
There was no statistical difference in the median values of total length and capillaries number 
between cancer subgroups (Mann Whitney test).  The subgroup comparative analyses to 
control cases were as follows: The HDMEC total length of capillaries of group B was 
significantly higher than those of control groups III and IV (Mann Whitney test Table 7.3, Fig. 
7.5).   
 
Furthermore, the total number of group B cases was significantly higher than those of group III 
and IV (Mann Whitney, Table 7.3, and Fig. 7.5-7.6).  The median and IQR of total length and 
number for all the PC cases (groups A) did not differ significantly from that found for group E [ 
Total length; 6226(5117-8409) vs. 5679 (4518-8406); p= 0.7, total number; 40(33-44) vs. 
36(32-41); p= 0.3].  
 
143 (131-60), p= 0.2, Mann Whitney test).  The median value subgroup of all resected cases 
group C did not differ from that of the unresected cases (group D, statistics not shown) 
indicating the homogeneous nature of the ‘cancer diagnoses’ at baseline. 
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Table 7.3:  The total length and number of capillary formation assay of HDMEC treated with 
   serum.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5:  The median of total length of capillary formation assay of HDMEC treated with 
the serum.  The red bar represents the median.   
 
Group No Total length of Capillary/ 
10 HPF 
Total number of Capillary/  
10 HPF 
Median and IQR P value  Median and IQR P value  
B 32 6010 (5014-8373) B vs. III=0.0015 40 (33-44) B vs. III= 0.003 
 III  9 989 (883-5446) 19 (13-36) 
IV  20 691 (574-1177) B vs. IV=0.0001 15 (9.5-17) B vs. IV=0.0001 
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Figure 7.6:  The median of total number of tubule formation assay of HDMEC treated with 
the serum.  The red bar represents the median. 
 
7.4.2.2 Pre- and Post-Resection Data  
A comparison of pre-operative and post-operative levels of group C (all the 11 resected cases) 
revealed that the post-operative median total length and number were significantly lower than 
that of the pre-operative (Wilcoxon matched-pairs signed rank test, Table 7.4, Fig 7.7-7.9). 
 
The pre-operative and post-operative levels in the nine PC cases of group I for which both 
samples were available revealed that the post-operative median total length and IQR was 
significantly lower compared with the pre-operative [2174 (1708-3628) vs. 8726 (4518-8406), 
p= 0.0039, Wilcoxon signed rank test].  Furthermore the total median post-operative number of 
capillaries of group I was significantly lower than that found pre-operatively [24 (16-31) vs. 44 
(38-48), p= 0.012, Wilcoxon signed rank test].  There were no significant differences in the total 
length and number of capillaries pre-and post operatively in both groups III and IV (Wilcoxon 
signed rank test, Table 7.4A - 7.4B).  There was no statistical difference between the pre-
operative and post-operative total length and number of capillaries of group D (4 cases, p= 0.25 
and 0.5 respectively). 
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Table 7.4A:  Total length of tubules pre- and post-operatively.  
 
 
 
 
 
 
 
 
Table 7.4B:  Total numbers of tubules pre- and post-operatively.  
 
Group No Total length P values 
Pre-vs. post-
operative pre-operative   
median & IQR 
post-operative   
median & IQR 
C 11 7593 (5570-7593) 
 
2488 (1807-4261) 0.001 
III 5 897 (761-3560)  980 (766-2567) 1 
IV 11 810 (586-1219) 665 (590-1234) 0.2 
Group Number Total number  P values 
Pre-vs.Post- 
operative 
pre-operative   
median & IQR 
post-operative   
median & IQR 
C 11 43 (36-46) 27 (16-46) 0.02 
III 5 15 (12-26)  14 (12-25) 0.78 
IV 11 17 (12-18) 15 (13-17),  0.09 
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Figure 7.7:  Pre- and post-operative total lengths of capillaries  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8:  Pre-and post-operative total number of capillaries. 
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Figure 7.9A:  Representative example of capillary formation when HDMEC were treated A- 
with pre-operative serum from patient with PC.  B- with post-operative serum from patient with 
PC (x100).   
 
 
Figure 7.9B:  Representative example of capillary formation when HDMEC were treated A- 
with pre-operative serum from patient with PC.  B- with post-operative serum from patient with 
PC (x400).   
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Figure 7.9C:  Representative example of capillary formations when HDMEC were treated A- 
with pre-operative serum from patient with PC.  B- with post-operative serum from patient with 
PC (x400).   
 
 
Figure 7.9D:  Representative example of capillary formations when HDMEC were treated A- 
with pre-operative serum from patient with of PC.  B- with post-operative serum from patient 
with of PC (x400).   
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Figure 7.9E:  Representative example of capillary formation when HDMEC were treated A- 
with pre-operative serum from patient with PC.  B- with post-operative serum from patient with 
PC (x400).  
 
7.4.3 Correlation of Cell Invasion with Angiogenesis   
There was a significant correlation between base line and post-operative of group B and III cell 
invasion with total length of capillaries (non parametric Spearman correlation, 0.0001, Fig. 7.10).   
  
Figure 7.10:  The correlation between number of cell invasion and total number of capillaries 
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7.5 Discussion: 
Cancer cell invasion and angiogenesis involve cell migration, proliferation and differentiation.  In 
the in vitro experiments of this thesis, it was demonstrated that TF and VEGF increase AsPC1 
invasion (section 3.4.4).  Furthermore it has been shown that the pro-coagulant activity of PC 
cells is correlated with cell invasion (section 3.2.5).  The blocking of TF on PC cell lines using 
polyclonal anti-TF antibody also decreases cell invasion (section 3.2.5).  Furthermore, it was 
shown that the maximum tubule formation was achieved when HDMEC were treated with PC 
sera and 1 U/ml TF.  Furthermore, a combination of suramin, anti VEGF and anti TF inhibits 
angiogenesis (section 4.5).  These findings are in accordance with Pradier and Ettelaie (2008).  
It was first suggested that these assays may have clinical application in monitoring the effects of 
LMW on the cancer promoting properties of the serum of PC patients with metastatic disease 
(Maraveyas et al., 2010a).  In that work, however, only an invasion assay was used, similar to 
the one used in this chapter but with a different pancreatic cancer cell line (MIA-PaCa 2).  In this 
chapter it is demonstrated that these optimised in vitro assays for invasion may also have clinical 
significance in the setting where the cancer is removed.  The additional contribution of this work 
is that for the first time it is demonstrated that a further assay developed to study HDMEC 
locomotion and tubule formation (in vitro angiogenesis assay) may also contribute further 
information.  This assay is based on the same principles of studying the capacity of cancer 
patients’ sera to induce locomotion but in this case of a primary non- malignant endothelial cell 
line (HDMEC).  The role of TF on cell invasion was discussed in sections 1.18 and 3.6.  The role 
of TF on angiogenesis was discussed in sections 1.9.1, 1.9.2 and 4.6.   
 
Obviously there can be many other factors in the serum of a cancer patient promote cell invasion 
and angiogenesis.  It was suggested from the angiogenesis array chapter (chapter 6) that the 
angiogenic balance was shifted to the anti-angiogenic state post-operatively.  Therefore this part 
of the work was designed to investigate whether the change in the angiogenic balance post-
operatively has a real impact on decreasing the pancreatic cell invasion and angiogenesis.  It was 
hypothesised that pro-angiogenic and angiogenic inhibitors shift the angiogenesis toward the 
inhibition of angiogenesis and inhibit chemotaxis activity due to the qualitative and quantitative 
decrease of angiogenic markers.  Furthermore, it was hypothesised that the molecules secreted 
from the tumour have more than one activity at the same time, as they enhance the migration 
and differentiation of the cells.  
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Cancer metastasis involves tumour cells invading the surrounding tissue.  Invasive cells must 
traverse barriers such as basement membrane, composed largely of collagen.  Matrix 
metalloproteinases have a major role in degrading the collagen matrix (Ellenrieder et al., 2000, 
Mignatti and Rifkin, 1993, Clark, 1979).  There is accumulating evidence that growth factors also 
play major roles as chemo-attractant factors.  Farrow et al. (2003) suggested that sodium 
butyrate inhibits AsPC1 cell invasion and reduces integrin expression.  EGF was used as a 
chemo-attractant in these experiments.  Wey et al. (2005) postulated that VEGFR 1 expression 
on PC cell lines increased cell invasion and VEGF was used as a chemo-attractant agent.  Albo et 
al. (1997) postulated that TGF-β1 and TSP-1 increase AsPC1 cell invasion through up-regulation 
of the plasminogen/plasmin system.  Moreover, glial cell–derived neurotrophic factor (GDNF) is a 
well known factor that is a major chemo-attractant in epithelial tumours including PC (Pozas and 
Ibanez, 2005, Tang et al., 1998, Pichel et al., 1996).   
 
It has been noted in the current study that the maximum serum chemotaxis activity (AsPC1 cells 
motility) and HDMEC angiogenesis (total length and total number) were induced by the baseline 
serum of the patients with cancer (group B) in the presence of the cancer and was clearly 
greater than that of the control groups.  These findings support the hypothesis that these 
processes are cancer specific.  This suggestion is strengthened by the finding of a significant 
decrease in the induction of AsPC1 cell motility and HDMEC capillary formation by the post-
operative sera compared to the pre-operative sera, of the resected cancer patients (Group C).  
There was no such effect of resection either in the group III patients (precancerous pancreatic 
cases, control group) or in the group IV patients (chronic cholecystitis, control group). 
 
The main hypothesis of this thesis is that these processes are promoted by TF through the 
coagulation pathway and direct signalling; however it is very likely that other pathways may also 
be involved. The work in chapter 6 points to a significant decrease of four angiogenic markers 
(angiopoietin-1, angiostatin/plasminogen, PDGF-AA, PDGF-AB/PDGF-BB and VEGF).  Therefore 
the decrease of post-operative cell invasion and angiogenic activity could possibly due to the 
decrease of several chemotaxis agents and angiogenic markers.  In patient serum, it is very 
likely that the same can be said for the process of invasion for which the ASPC1 assay is a 
marker.  Airaksinen and Saarma (2002), for example, have suggested that the nerve tissue in PC 
secretes a variety of chemokinetics that facilitate nerve invasion in vivo. 
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As a conclusion, sera from PC patients have higher chemotaxis and angiogenic activity than the 
control group, which strongly suggests factors made by the tumour itself are responsible.  
Removal of the tumour decreases chemotaxis and angiogenesis mediated by serum taken from 
the same patients.  Migratory behaviour of PC cells and capillary formation may be correlated 
with quantitative and qualitative differences in parameters that govern the integration of 
molecular components. 
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CHAPTER EIGHT: MICROPARTICLES NUMBER 
AND ACTIVITY 
8.1 Introduction 
MP are membrane vesicles of 0.1-1 μm in diameter shed from the plasma membrane of healthy, 
apoptotic and stimulated cells (Mostefai et al., 2008b).  It is well known that TF bearing MP, in 
addition to their role in coagulation, play a major role in tumour growth, metastasis, 
angiogenesis and thrombosis (Yu and Rak, 2004, Muller et al., 2003).  It was also demonstrated 
recently that increased levels of MP can be found in patients with various types of cancers and 
that the highest levels are observed in PC patients (Zwicker et al., 2009, Tesselaar et al., 2007).   
 
Several studies correlate TF-bearing MP numbers in PC with the pro-coagulant activity as will be 
discussed in detail in section 8.6.  To the best of the author’s knowledge, no study correlates TF-
bearing MP with in vitro cell invasion and angiogenesis.  Furthermore, to the best of the author’s 
knowledge, the current study is the first study to evaluate TF bearing MP, pro-coagulant activity, 
cell invasion and angiogenic activity pre- and post-operatively.  Therefore the author 
hypothesised that there is a link among all these indices.  Based on this hypothesis, the author 
suggested that all these indices together are driven by the PC tumour.   
 
Therefore, in the current study, the correlation of TF bearing MP number with the pro-coagulant 
activity, cell invasion and angiogenesis was investigated to give a comprehensive insight about 
the thrombotic and aggressiveness course of PC.  There are few studies evaluated the 
association between surgical removal of PC and MP number and/or activity, among these 
Zwicker et al., 2009 and Tesselaar et al., 2007.  Furthermore, there are some limitations 
including low numbers in these studies.  It was shown in chapter 6 that there was a decrease of 
some angiogenic markers post-operatively.  Furthermore, it was shown in chapter 7 that there 
was a decrease of angiogenic and chemotaxis activity of pancreatic cancer sera.   
 
In this chapter a series of experiments were performed to evaluate the number of different types 
of MP and coagulation state.  TF bearing MP, MoMP, EMP and one stage PT assay were 
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performed using fresh PPP.  Furthermore, frozen PPP were used to measure annexin bearing MP 
number using flow cytometry, TF, TFPI and MP activity using ELISA.   
 
8.2 MP Count 
8.2.1 Optimisation  
A flow cytometric study was designed to study total number of MP bearing TF, CD 14, CD 31 CD 
(for EMP) and 42b (for PMP) / µl in fresh PPP as described in section 2.2.8.2.  Annexin bearing 
MP number was counted in a separate experiment using frozen PPP (section 2.2.8.3).  The 
methodology of MP count was explained fully in section 2.2.8.2.  Megamix beads are a mixture 
of fluorescent beads comprising populations of 0.5; 0.9 and 3 µm in diameter.  These beads 
were used to determine the size of tested MP, which ranged from 0.1-1 µm (Robert et al., 2009, 
Vince et al., 2009, Fig. 8.1, R1 box).  The counting beads allow the setting of the flow 
cytometery to study MPs within a fixed sized region providing reproducible MP counts. 
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Figure 8.1:  A dot plot of Forward scatter (X axis) and Side scatter (Y axis) for a megamix 
beads sample 0.5 µm and 0.9 µm diameters.  MP will be expected within the quadrant box 
defined as R1. 
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MPs were identified according to their scatter properties and further according to the specific 
antibody labelling (TF (FITC), CD 14 (PE), CD 31 (FITC), CD 42b (PE); in a separate experiment 
annexin bearing MP were counted (Fig. 8.2). 
 
                           
Figure 8.2:  A dot plot with CALTAG counting beads was determined.  There are two beads 
in the right upper quadrant, bead A (685) and bead B (667).  The negative control is in the lower 
left quadrant.  The expression of FITC marker is in the right lower quadrant.  The PE expression 
is in the upper left quadrant.  Dual FITC/PE stained MP will be in the upper right quadrant.   
 
The samples were analysed firstly according to the expression of surface antigen.  Negative 
controls FITC and PE were used to evaluate the specific expression of TF FITC and CD 14 PE, CD 
31 FITC and CD 42b (Fig. 8.3).   
162 
 
 
Figure 8.3:  Representative example of Mouse IgG negative FITC and PE.   
 
Then the expression of markers was determined according to the expression of negative control 
(Fig. 8.4, 8.5). 
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Figure 8.4:  Representative example of pre-operative (A) and post-operative (B) plasma TF 
expression. 
 
164 
 
                
Figure 8.5:  Representative example of pre-operative (A) and post-operative (B) plasma CD 
14 expression. 
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The counting bead (A and B) has known number/µl (provided by the supplier) and known 
number counted from flowcytometry.  The plasma MP has known number counted from the 
flowcytometry.  Therefore absolute number of plasma MP/μl was determined by using the 
following equation.  
 
For example:  
1 TF expressing-MP number was 5928.   
2 Number of bead A was 685 and number of bead B was 667.  Total bead A and bead B is 1352. 
3 The number of beads / µl is 1050.  Therefore 
        
                               =4604 
 
8.2.2 Aims  
Group IV was not involved in this study and group III control study was used only because the 
cases of group III are pancreatic lesion and submitted to surgical resection as test cases.  
The purposes of this study were to:  
1. Investigate whether serum from PC patients contained higher absolute numbers of TF, 
CD 14 and annexin bearing MP than the serum of the non-tumour control (group III).  
 2. Investigate the absolute number of TF, CD 14 and annexin bearing MP decreased post-
  operatively following removal of the tumour.   
3. Correlate TF MP number in vivo with the in vitro pro-coagulant, cell invasion and 
angiogenic activities.   
 
 
 
A C 
E 
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8.2.3 Results  
8.2.3.1  TF Bearing MP 
8.2.3.1.1 Baseline Evaluation 
The TF bearing MP number of cancer groups (A, B and E) was significantly higher than that of 
group III (p= 0.0034, Kruskal-Wallis test).  There was no statistical difference in the median 
values of total number of TF-bearing MP between cancer subgroups (Man Whitney test).  The 
subgroup comparative analyses with control cases (Mann Whitney test) were as follows: 
The total TF bearing MP number of all malignant cases (group B) was significantly higher than 
those of control groups III (Table 8.1, Fig. 8.6).  The median number and IQR of group A; 4568 
(2557-5623) was significantly higher than that of the control group (group III, p= 0.0002) but it 
did not differ significantly from that of group E; 4387 (2182-32535); (P= 0.8355, Fig. 8.6).  The 
baseline total number of MP of groups I and II differed significantly from control group III 
(0.004, 0.002 respectively) but it did not differ significantly from that found with group E (0.74, 1 
respectively).  
Table 8.1: Baseline median number of TF bearing MP/ µl.   
Group NO Median & IQR P value vs.  III 
B 32 4476 (2592- 5574) 0.0002 
III 9 852 (273-2160) 
 
 
 
 
 
 
 
Figure 8.6:  Absolute number of TF bearing MP/µl in each group of patients.  The red bar 
represents the median. 
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8.2.3.1.2 Pre- and Post-Resection Data  
The median and IQR post-operative TF bearing MP number of group C; was significantly lower 
than the pre-operative [1296 (363-4475) vs. 4874 (2257-21363), p= 0.042, Wilcoxon matched-
pairs signed rank test, Fig. 8.7].   
 
The median post-operative total TF bearing MP median of group I was significantly lower than 
the pre-operative total TF bearing MP [1296 (467-4983) vs. 4874 (3007-14479) respectively, p= 
0.03, Wilcoxon matched-pairs signed rank test).  The post-operative total TF bearing MP number 
of group III did not differ significantly from the pre-operative [319 (196-1289) vs. 269 (148-
870), p= 0.39, Wilcoxon matched-pairs signed rank test].  Furthermore, the post-operative 
median TF bearing MP of group D did not differ significantly from the pre-operative (p=0.62; 
Wilcoxon matched-pairs signed rank test).   
 
 
 
 
 
 
 
 
 
 
 
Figure 8.7:  Pre-and post-operative TF bearing MP.  The red bar represents the median.   
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8.2.3.2 CD 14 MP – Baseline  
8.2.3.2.1. Baseline CD 14 Bearing MP 
The CD-14 bearing MP of groups A, B and E were significantly higher than those of group III (p= 
0.05, Kruskal-Wallis test).  The study shows that the median and IQR pre-operative level of CD 
14 bearing MP/ µl of group B was significantly higher than that found in group III [2179 (1349-
3799) vs. 264 (170-1991), Mann Whitney test, Table 8.2, Fig. 8.8].  There was no statistical 
difference in the median values of total number of CD-14-bearing MP between cancer subgroups 
(Mann Whitney test).  The subgroup comparative analyses to control cases (Mann Whitney test) 
were as follows:  
The median number and IQR of CD-14 bearing MP of group A differed significantly from control 
group III [median and IQR; 2167 (1017-9363), p= 0.02] but did not differ significantly from 
those of group E [median and IQR; 3646 (2403-8255), p= 0.07].  Furthermore, there was no 
significant difference between the median CD 14 bearing MP of group I and that of group II 
(0.34, Mann Whitney test). 
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Table 8.2:  Total number of CD 14 bearing MP/µl of cases involved in the study.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.8:  Absolute number of CD 14 bearing MP.  The red bar represents the median.   
 
8.2.3.2.2 Pre- and Post- Resection Data 
The post-operative CD 14 bearing MP number of group C was significantly lower of the pre-
operative.  Median and IQR was 349 (37-1530) vs. 3444 (1505-3850), p= 0.02, Wilcoxon 
matched-pairs signed rank test, Fig. 8.9.  The median post-operative total CD 14 bearing MP 
median of group I was significantly lower than the pre-operative total TF bearing MP (post-
operative median; 349 (50-2702) vs. 2394 (1089-4049) , p= 0.03, Wilcoxon matched-pairs 
signed rank test.  The post-operative total TF bearing MP number of group III did not differ 
significantly from the pre-operative [median and IQR; 183 (128-2646) vs. 234 (89-560), p= 
0.39, Wilcoxon matched-pairs signed rank test].  The post-operative CD 14 bearing MP median 
Group NO Median & IQR P value  
B 32 2179 (1349-3799) B vs. III= 0.02 
III 9 264 (170-1991) 
A B E III
0
1000
2000
3000
4000
5000
6000
8000
10000
Group
C
D
 1
4
 B
e
a
ri
n
g
 M
P
/µ
l
170 
 
of group D did not differ significantly from the pre-operative (Wilcoxon matched-pairs signed 
rank test, p= 0.12). 
 
 
 
 
 
 
 
 
 
 
Figure 8.9:  Pre-and post-operative CD 14 bearing MP of all malignant cases including 
pancreatic adenocarcinoma.  The red bar represents the median.   
 
Other MP group subsets (CD 31, CD42b and annexin) were studied and did not show differences 
between groups at baseline, nor did surgery have any influence on their levels. 
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8.3 Pro-coagulant Activity  
One stage PT and TF MP activity ELISA were used to evaluate the pro-coagulant activity of PC 
samples.   
8.3.1 Methods and Principles 
8.3.1.1 One Stage Prothrombin Time 
One stage PT evaluates the extrinsic pathway of coagulation.  Clinically, PT is used to monitor 
the coagulation state of patients with vitamin K deficiency and during treatment with vitamin K 
antagonists such as warfarin (Bogdanov et al., 2003).  PT depends on six factors [I, II, III (TF), 
V, VII, X], one of which is TF.  Therefore, one stage PT can be considered as a general indicator 
of coagulant status.  Using the principles of one stage PT on fresh PPP (within first four hours of 
venapuncture) could give a good insight into coagulation activity of TF bearing MP shed from the 
tumour.  Blood was taken by venesection and was collected in sodium citrate tubes to inactivate 
Ca2+ by chelation.  Sample collection and preparation was described in section 5.2.  Methodology 
of PT was described in section 2.2.9.   
 
After breaking the annonymisation code, it was noted that five patients were treated with 
prophylaxis dalteparin (5000 U); two patients were from group B; two were from group E and 
one from group C.   
 
8.3.1.2 Microparticles Activity  
The pro-coagulant activity of MPs was evaluated using the ZYMUPHEN MP-Activity kit.  Frozen 
PPP was used to evaluate the MP activity as explained in section 2.2.11. The principle of this kit 
was to evaluate the pro-coagulant activity with the limiting factor being phosphatidyl serine (PS) 
of MP.  Therefore the results represent the concentration of PS on MP.  The plasma, controls and 
calibrator were diluted with sample diluents, supplemented with Factor Xa inhibitors and 
prothrombin inhibitor added to the microplate wells previously coated with streptavidin and 
biotinylated annexin V and incubated for one hour.  Following washing, the Factor Xa-Va mixture 
containing calcium and finally purified pro-thrombin were added.   
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MP binds to annexin V and exposed causes PL to be on the MP surface, thus allowing FXa-FVa, 
in the presence of calcium, to activate prothrombin into thrombin.  There is a direct relationship 
between the PS concentration and the amount of thrombin generation, which is measured via its 
activity on the thrombin substrate (Fig. 8.10).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.10:  Diagrammatic representation of the mechanism of zymuphen MP activity. The 
limiting factor was the PL which represents the MP activity.  R1: Bovine FXa-FVa mixture also 
containing calcium. R2: Human pro-thrombin. 
Blood sample Ca2+ ions 
were inactivated by 
sodium citrate in the 
vacutainer and by Ca2+ 
inhibitor that was 
provided with the sample 
diluents.  Standard 
calcium concentration 
was provided with (R1) 
The sample’s 
prothrombin was 
inactivated by sample 
diluents and human 
prothrombin was 
provided with reaction 
buffer R2 
 
Sample Xa was inactivated by 
sample diluents and bovine 
Xa was provided in sample 
buffer (R1) 
Bovine Va was provided in 
(R1) 
This is the variable and limiting factor for 
the thrombin formation and depends on 
the concentration of phosphatidyl serine 
expressed by the MP in the aliquot of 
serum  
Prothrombin Thrombin 
Phosphatidyl serine 
Ca2+, Xa, Va 
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8.3.2 Aims  
This part of the study aimed to find out:  
 1. Whether the baseline pro-coagulant activity in PC patients is higher than that of the 
  control (group III).  
 2. Whether the pro-coagulant activity of the cancer patient decreased post-operatively.   
 
8.3.3 Results  
8.3.3.1 Prothrombin Time  
8.3.3.1.1 Baseline Evaluation  
The PT of groups A, B and E was significantly shorter than that of group III (P. 0.019, Kruskal-
Wallis test).  The current study shows the baseline PT (S) of group B was significantly shorter 
than that of group III (Mann Whitney test, Table 8.3, Fig. 8.11).   
 
There was no statistical difference in the median values of PT between cancer subgroups (Man 
Whitney test).  The subgroup comparative analyses to control cases (Mann Whitney test) were 
as follows:  
PT of PC cases [group A, median and IQR; 35 (33-37, mean; 34.7± 2.9)] was significantly 
shorter than that of group III (p= 0.02, Mann Whitney test) but it did not differ significantly from 
that of group E (median and IQR; 35 (32-37), mean; 34.6 ± 3.2, p= 0.85).   
 
174 
 
Table 8.3:  Baseline prothrombin time.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.11:  Median PT of PC cases and control group.  Red bar represents the median. 
Group  No  Median IQR (seconds) Mean ± SD  
(seconds) 
P value  
 
B 32 35 (33-36.7) 34.6 ±2.9 B vs. III = 0.02 
III 9 40 (35-41) 38.11± 3.25 
A B E III
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8.3.3.1.2 Pre- and Post- Resection Data   
 
The post-operative PT (S) of group C (11) was significantly longer than the pre-operative 
[median and IQR; 37 S (37- 40), mean; 37.9 ±2.9 vs. 34 (31-35), mean; 33.5 ±2.1, p= 0.008, 
Wilcoxon matched-pairs signed rank test (Fig. 8.12)].  Comparison of pre-operative and post-
operative levels of group I cases revealed that the post-operative PT (S) was significantly longer 
than pre-operative PT [median and IQR; 37 S, (36-40) vs. 33 (31-35), p= 0.02, Wilcoxon 
matched-pairs signed rank test].   
 
The pre-operative median PT (S) of group III did not differ significantly from the post-operative 
[median and IQR; 40 (37-41.5) vs. 41 (38-41.5), p= 0.34, Wilcoxon matched-pairs signed rank 
test]. The pre-operative PT median of group D did not differ significantly from post-operative 
(Wilcoxon matched-pairs signed rank test, p= 0.12). 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.12:  Pre-and post-post-operative prothrombin time.  Red bar represents median. 
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8.3.3.2 MP Activity  
The PS concentration of tested MP was calculated from the standard curve generated as part of 
the experiment (Fig. 8.13).   
  
Figure 8.13:  Representative standard curve of the phosphatidyl serine concentration using 
Zymphen assay.  
 
MP activity ELISA was not performed in all cases as it emerged during this work that this test 
was unreliable and this was also borne out in our experience from the few ‘pilot’ cases we 
studied, which demonstrated pre-operative PS concentration (nM) of group B (conducted in 12, 
median and IQR  was 9.4 (6.6-16) nM, mean; 10.4 ± 4.9 nM) did not differ significantly from 
that of group III [four cases, median and IQR was 6.4 (5.4-7.3) nM, mean; 6.4 ± 1 nM, p= 0.13; 
Mann Whitney test].  In seven cases (six group A, and one group E), post-operative PS did not 
differ significantly from pre-operative [median and IQR (7.1 nm (4.6-8.2) nM vs. (5.7 (5.8-18.4) 
nM, p= 0.2; Mann Whitney test].  Recently, several authors have disappointing results (see 
8.6.1). 
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8.4 TF and TFPI ELISA 
Frozen PPP samples were used to evaluate the level of TFPI and TF.  The methodology was 
described in sections 2.2.12.2 and 2.2.12.3 respectively.   
 
8.4.1 Results 
The TFPI and TF (pg/ml) levels were measured from respective standard curves generated as 
part of each experiment (Fig. 8.14 – 8.15 respectively). 
 
 
 
Figure 8.14: Standard curve of TFPI 
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Figure 8.15: Standard curve of TF 
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A few PPP samples had run out; therefore TF and TFPI were conducted in available PPP plasma 
samples, which included 23 samples from group B, 6 samples from group III and 21 samples 
from group IV.   
 
8.4.1.1 Baseline Evaluation 
In 23 cases of group B, the concentration of TFPI (pg/ml) was significantly higher than that 
found in control group III (Mann-Whitney test, Table 8.4, Fig. 8.20) and significantly higher than 
TFPI concentration of control group IV as well (Mann-Whitney test, Table 8.4, Fig. 8.16).   
180 
 
Table 8.4 Pre-operative TFPI concentration of PC cases and control groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.16: Pre-operative TFPI concentration of PC cases and control group. 
 
Group  NO Media and IQR (pg/ml) P value  
Group B 23 357 (253-417) B vs. III = 0.02 
Group III 6 250 (154-298) 
Group IV 21 204 (177-242)  B vs. IV = 0.0001 
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The TF (pg/ml) concentration of group B did not show a significantly higher level than control 
groups III and IV.  [The median and IQR, 20.4 pg/ml (17.8-25.7), mean, 22 pg/ml ± 4.5 vs. 
21.8 pg/ml (14.3-25), (20.4 pg/ml ± 5.1) of group III, and [(27.5 pg/ml (24.9-30.2), 28.2 pg/ml 
± 4.6 of group IV].   
 
8.4.1.2 Pre-and Post-Resection Data  
The pre- and post-operative evaluation was conducted in 10 cases from group B and 4 cases 
from control group III.   
 
The pre-operative TFPI of group C did not differ significantly from the post-operative.  [The 
median and IQR; 300 (214-374), mean; 333 ± 179 vs. 360 (259-447); 356 ± 112, p= 0.31, 
Wilcoxon signed rank test].  The pre-operative TFPI of group III did not differ significantly from 
the post-operative as well [The median and IQR; 262 (119-302), mean; 228 ± 102 vs. 291 (155-
323); 356 ± 97, p= 0.48, Wilcoxon signed rank test].   
 
There was no significant difference between the pre-operative and post-operative TF 
concentration of group B [the median pre-operative TF; 21.4 pg/ml (15.9-25.7), mean; 21.2 
pg/ml ± 5.4 vs. 23.3 pg/ml (19.7-32.1), 26.6 pg/ml ± 9.2, p= 0.4, Wilcoxon signed rank test].  
Furthermore, there was no significant difference between pre- and post-operative TF 
concentration of group III (The median pre-operative TF; 18.9 pg/ml (14.1-24.6), mean; 19.2 
pg/ml± 5.7 vs. 14.3 (5.4-25.9), 15.2 pg/ml ± 7, p= 0.4, Wilcoxon signed rank test).   
 
There was a significant correlation between the concentration of TF and TFPI pg/ml of all 
samples (p= 0.0005, Spearman correlation).   
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8.5 Correlations of TF Bearing Microparticles with other Indices  
There was a significant correlation between baseline and post-operative of group B and III)] TF 
bearing MP levels and PT (non parametric Spearman correlation, 0.0001).  Furthermore, there 
was a significant correlation between TF bearing MP and cell invasion [(All samples (baseline and 
post-operative)], non parametric Spearman correlation, 0.004, spearman.  Moreover, there was 
a significant correlation between [all samples (base line and post-operative samples)] TF bearing 
MP and total length of capillaries (non parametric Spearman correlation, 0.0001, Spearman).  
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8.6 Discussion 
The number of MP differs from one study to another depending on the methodology used and 
the type of MP.  Some authors reported that the number of TF-bearing MP ranged from 240/µl 
to 1550/µl in PC and breast cancer (Tesselaar et al., 2007) and endothelial MP from 148-448 /µl 
in small vessel vasculitis (Erdbruegger et al., 2008), while other studies showed the range varied 
from 70,000/µl - 2,300,000/µl in healthy cases, PC, breast cancer, lung, colorectal and ovarian 
cancers (Zwicker et al., 2009).  In the current study the median number of TF bearing MP was 
4568/µl in PC cases, 852/µl in pre-malignant pancreatic cases, 4387/ µl in cholangiocarcinoma 
cases.  The median CD 14 MP number was 2167 in PC cases, 264/ µl in pre-malignant pancreatic 
cases and 3646/µl in cholangiocarcinoma cases.  Therefore, it is necessary to standardise the 
methodology of detection of MP and this is in accordance with the recommendation of the 5th 
International Society on Thrombosis and Haemostasis (ISTH) 2011 that was held in Kyoto in 
Japan 23-28-July 2011.   
 
8.6.1 The Significance of MP in Thrombosis 
The current study shows that the TF-bearing MP and the pro-coagulant activity of PC patients 
were significantly higher than those of the control.  In this regard the results of the current study 
were consistent with the results of other studies (Tesselaar et al., 2009, Zwicker et al., 2009, 
Tesselaar et al., 2007).  It has been reported that an increased level of MP could be found in 
patients with a number of cancers but the highest levels of TF activity were those in PC patients. 
In a series of 37 cancer-free controls, 23 advanced PC and 17 advanced breast cancer, the upper 
limit of TF activity in the normal range was 273 fM Xa min-1(Tesselaar et al., 2007).  Thirty-four 
percent of PC patients and 29% of advanced breast cancer cases involved in the latter study had 
TF activity above the upper limit of the normal range.  Interestingly, it has been reported that 
there was no correlation between the absolute number of MP and the reported TF activity.  
Furthermore, Tesselaar and co-workers used the same upper limit for normal range of TF 
activity, and also reported that the TF activity associated with TF + MP was significantly higher in 
cancer patients than non-cancer patients.  For 51 cancer patients with thrombosis the mean TF 
activity was 1125 fM Xa min−1 (19–12,333 fM Xa min-1).   
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This group consisted of patients with the following types of tumour: 14 colorectal, 10 pancreatic, 
six testicular, four renal, three ovarian, two oesophageal, two prostatic, two bones, two 
laryngeal, two breasts, two respiratory tracts, one bile duct and one adrenal cancer.  Of these, 
the highest noted MP associated average TF activity was 2,080 fM Xa min−1 (510–12,333) in PC.  
TF activity was also relatively high (55–1,578 fM Xa min−1) in colorectal cancer.  The range of 
other tumours studied showed a TF activity between 80–603 fM Xa min−1 (Tesselaar et al., 
2009).  The mean TF + MP activity in 49 cancer patients without thrombosis was 162 fM Xa 
min−1 (23–535 fM Xa min−1).  Moreover, in a series of nine patients with lung cancer, three with 
breast cancer, one with PC, one with renal, one with sarcoma and 23 healthy controls, Tilley et 
al. (2008) reported that PC had the highest TF activity (48.3 pM) of all malignancies tested 
within the study.  Zwicker et al. (2007) observed that there was no statistical difference in TF + 
MP numbers in healthy controls and non-small cell lung cancer, while TF + MP were significantly 
higher in PC (32 of 47 PC cases).  It was reported that the highest incidence of patients with TF 
+ MP above a lower detectable limit was observed in PC (25 of 39) followed by colorectal 
carcinoma (7 of 12), compared with non-cancer controls (6 of 31) and that the number of TF + 
MP in PC and colorectal cancer was significantly higher than in non-cancer controls (Zwicker et 
al., 2009).  However, the difference in the number of TF + MP compared with non-cancer 
controls was insignificant in lung cancer (5 of 28), breast cancer (4 of 9) and ovarian cancer (5 
of 8) suggesting that TF + MP have an important role in the pro-coagulant phenotype and may 
be a contributing factor related to the high incidence of TE associated with PC patients.  
Furthermore, Zwicker et al. (2009) reported that two thirds of PC patients have a high number of 
TF-bearing MPs in plasma.  The number and the activity of TF of advanced colorectal, pancreatic 
and breast cancer were higher than those of healthy normal controls but this was not true for 
small cell cancer of the lung were (Hron et al., 2007, Khorana et al., 2007, Tesselaar et al., 
2007, Zwicker et al., 2007).  Khorana et al. (2007) noted that the level of TF antigen increased in 
PC and it is associated with a high incidence of thrombosis.  Similarly, Horn (2007) noted the 
same finding but this study used D-Dimer as an indicator of clotting.  In a series of 20 advanced 
colorectal cancers and in 20 age-sex matched healthy controls, the median (inter-quartile range) 
number of TF bearing MP using flow cytometry (25.9 (15.4-42.0) x 103/ml) was significantly 
higher than the control group (medium and inter-quartile range (IQR); 13.1 (11.9 - 19.7) x 
103/ml plasma, p = 0.007.  This high TF bearing MP was significantly associated with high 
concentration of D-Dimer.  D-dimer is a fibrin degradation product that is present in blood after a 
blood clot gets degraded by the process of fibrinolysis (Hron et al., 2007).   
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The work presented here shows there was significant increase in the number of TF bearing MP in 
PC cases compared with the control group III.  This change was associated with high pro-
coagulant activity (shorter PT) of PC cases compared with control.  However, the MP activity 
(using ELISA) did not show a significant difference from that of the control.  This was not 
unexpected; the recently presented data at 5th ISTH 2011 is casting doubt on the discriminating 
ability of these markers (MP activity kit).  Lin et al. (2011), reported that MP activity using 
Zymuphen MP test kit did not correlated with the incidence of DVT (conf reference 2).  Kleinjan 
et al. (2011) (conf reference 3) reported that the hypercoagulable condition in cancer patients 
was not associated directly with the PL MP dependent activity.  Furthermore, flowcytometry has 
been recently acknowledge as a more sensitive and precise method than ELISA (conf reference 
1, conf reference 2, Vignali 2000).  The authors noted that five cancer patients (12%) that 
developed venous thromboembolism had comparable levels of phospholipid dependent MP pro-
coagulant activity.  Therefore, the assay was not used in the current study after the analysis of a 
small number of cases.  Furthermore, in the current study the number of annexin bearing MP/µl 
of PC cases did not differ from that of the control group.  However, MP activity and annexin MP 
results might be affected by freezing as frozen PPP was used for these assays.  At the same time 
there was no auto annexin antibody against the annexin.  That indicates that the pro-coagulant 
activity of PC depends mainly on the TF.  Therefore, pro-coagulant activity of PC depends mainly 
on the TF bearing MP as the freezing affect the number of MP.  This finding was supported by, 
TF (measured by ELISA) of PC cases in the current study was not higher than that of control 
groups III and IV and this indicates that not only the TF activity but also the TF antigen is 
affected by long time freezing.   
 
Therefore it is suggested that the ELISA might not be a sensitive method for measurement of TF 
or that due to long time freezing of PPP, the TF bearing MP was completely degraded.  This 
supports the suggestion that the measurement of TF bearing MP in fresh PPP using flow 
cytometry is more sensitive than ELISA. Furthermore, the current study showed that the post-
operative TF (measured by ELISA) did not differ significantly from the pre-operative level.   
 
In the current study one stage prothrombin time was used to evaluate the pro-coagulant activity 
in the PPP of PC cases.  Although it is not specific for TF activity, it provides an idea about the 
pro-coagulant activity.  However it was noted after breaking the code that 5 out of 41 patients in 
the clinical trial were treated with prophylaxis 5000 U of dalteparin.  Two were from group II, 
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two from group E and one patient from group III.  It is postulated that that dalteparin has no 
effect on PT (Stief, 2006) .  Furthermore Vargo et al. (2009) postulated that 100 U/ Kg twice 
daily has no effect on PT and activated partial Thromboplastin (APTT) because the main function 
of dalteparin is to allow the body’s natural clot lysis mechanisms to work normally to break down 
clots that have already formed.  Dalteparin binds to and accelerates the activity of anti-thrombin 
III.  This is why PT and APTT are not helpful in monitoring coagulation state when dalteparin is 
used, particularly when dalteparin is used prophylactically (web reference 5, web reference 6).  
Moreover it has been noted in feline experiments that 1000 U dalteparin daily or divided into two 
doses did not affect PT, APTT and platelet factor 4 (web reference 7).  Therefore deltaparin has 
no effect on one stage PT.   
 
Two out of 5 cases (which were treated with dalteparin) were from group E, PT was 35, 30.  The 
median of PT of group was 40 and the mean 38.1 S.  PT of both cases was shorter than the 
mean of group E.  This indicated that the prophylactic dalteparin did not prolong PT more than 
the mean of the PT of group E.  Therefore, dalteparin did not decrease the pro-coagulant activity 
more than the mean of the group.  Two cases were from group II.  PT was (39 and 35).  The 
median PT of group B was 36 and the mean 36.2 S.  This indicated that the prophylactic 
dalteparin did not prolong the PT of one case and might have had an effect on the other case.  
Therefore, the current study was in agreement with previous findings that suggest prophylactic 
doses of dalteparin have no effect on PT.   
 
Another interesting result of the current study was that there was a significant decrease of TF 
bearing MP number and pro-coagulant activity (represented by PT) after surgical removal of the 
PC but annexin bearing MP did not decrease post-operatively.  In regard to the decrease of MP 
post-operatively, the result of the current study is comparable to the result of others ( Zwicker et 
al., 2009, Tesselaar et al., 2007,), although only three patients were included in the Zwicker 
study and it is also comparable to the results of other cancer studies such as Haubold et al. 
(2009), who found a significant decrease of TF MP two weeks after surgical removal of prostatic 
cancer using automated thrombography that was used to monitor thrombin formation.  It can be 
suggested that the result of this study supports the hypothesis that tumour cells are the main 
source of TF-bearing MPs.  Moreover, Francis et al. (2010) found a decrease of TF MP activity 
after surgical removal of glioblastoma multiforme.  Therefore the significant decrease of TF MP 
and pro-coagulant MP activity may have an important role in the decrease of the PC 
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aggressiveness and metastasis.  Therefore the origin and the type of the tumour might have an 
effect on coagulant activity.  The pro-coagulant activity of PC might be related mainly to the TF 
bearing MP.  In this regard our results support the prevalent theory that TF bearing MP accounts 
for a major fraction of circulating TF activity and supports the suggestion that TF-bearing MPs 
are the main source of TF activity produced by cancer cells (Yu and Rak, 2004).  
 
The findings of the current study indicate that the majority of patients with PC will have high 
levels of MPs and pro-coagulant activity.  These findings have prompted the commencement of a 
trial (Micro-TEC).  The MicroTEC study is investigating enoxaparin in patients with pancreatic, 
lung, and colorectal cancer with elevated plasma TF microparticles.  Patients with high levels of 
circulating MP activity are randomised to treat with anticoagulation vs. no anticoagulation (Web 
reference 8).   
 
8.6.2 Circulating TF- and the Metastatic Process 
As shown previously, the majority of the existing work has emphasised the potential correlation 
of increased levels of total TF bearing MPs with thrombosis as shown in Zwicker et al. (2007) and 
Teselaar et al. (2007) and other studies.  The current study is in agreement with other studies 
(described in section 8.6.1) that showed significant increase of TF bearing MP and procoagulant 
activity compared with the control.  However, to the best of the author’s knowledge the current 
study was the first study to correlate the TF bearing MP with the aggressiveness of the tumour 
as there was significant correlation between TF bearing MP and tumour cell invasion (p=0.004) 
and on HDMEC angiogenesis assay (p=0.003).  Therefore, the importance of TF bearing MP is 
not limited to the coagulation state through the extrinsic pathway but might play a major role in 
enhancement of cell invasion and angiogenesis that has been demonstrated in section 8.2.3.1.  
Furthermore, the decrease of TF bearing MP and the pro-coagulant activity post-operatively 
might be a causative factor in the decrease of cell invasion metastasis, angiogenesis post-
operatively.  The main author was blinded and therefore he couldn’t correlate the finding with 
the clinical outcome.   
 
CD 14 bearing MP behave like the TF bearing MP.  The CD 14 bearing MP of PC cases was 
significantly higher than that of the pre-cancerous control group.  The absolute number of CD 14 
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bearing MP was decreased post-operatively.  This is evidence that could support the hypothesis 
that removal of the tumour decreases many factors, including TF and CD 14.   
As the current study suggested that TF has an important role in thrombosis, cell invasion and 
angiogenesis, targeting of TF might therefore have a role in the controlling of the aggressiveness 
of PC.  This result and suggestion supports the use of anti TF therapy in combination with 
chemotherapy in the treatment of PC.   
 
It has been postulated that recombinant nematode (hookworm Ancylostoma caninum) 
anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex 
with novel antithrombotic activity (Zhao et al. 2009).  In addition to its anticoagulant activity it 
inhibited angiogenesis, primary and metastatic tumour growth in mice (Hembrough et al. 2003).  
Furthermore a randomised phase II clinical trial of gemcitabine with and without PCI-27483 (1.2 
mg/kg two times daily, which act as TF and FVIIa inhibitors) in patients with advanced PC is 
ongoing (Ramanathan et al. 2011).   
 
Based on this data, MP appear to have an important role in aggressiveness and thrombotic 
conditions of PC.  Therefore control of MP might have an important role in the prognosis of PC.  
This could be achieved through removal of MP from the blood by dialysis, enhancement of anti-
tumour immune response and or through inhibition release of MP.  In this regard, in a clinical 
trial, the asciticfluid MP have been captured by specific antibodies and then removed completely 
by dialysis using HemopurifierTM [(Ichim et al., 2008).  Furthermore, it has been reported that 
dendritic cells promote initiation and amplification of anti-tumour immune response (Chaput et 
al., 2004a, Wolfers et al., 2001).  This process has been manipulated to create an anti-tumour 
vaccine.  Chaput et al. (2004b) proposed two distinct methods for treating melanoma and 
ovarian cancer.  Two clinical trials aim to amplify the anti-tumour cytotoxic T cell response. 
“Vaccination” consists of injecting the patient with dendritic cell-derived MP loaded with tumour 
peptides.  An alternative method of “vaccination” starts with the isolation of ascites-derived MP 
from a patient with ovarian carcinoma.  The MP were supplemented with adjuvant and re-
injected into the patient.  The MP are injected into the subcutaneous tissues at different sites, 
which provokes a strong and targeted anti-tumour T cell response (Liu et al., 2006).  The third 
method which might control MP is inhibition of MP formation and release.  Taxol and vinca 
alkaloids, as conventional chemotherapeutic medicaments not only inhibit cell division, but 
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additionally decrease MP release.  Using proton pump inhibitors, exosome formation can be 
blocked in lack of gradually decreasing acidic milieu (Iero et al., 2008).  At the same time 
ceramide inhibition leads to exosome release block (Trajkovic et al., 2008).  Additional proteins, 
such as clathrin, sorting nexins and more have also been described to be over expressed in 
different tumours (Wright, 2008, Cheng et al., 2005, Jordens et al., 2005).  Control of these 
might have an important role in the inhibition of release of MP.   
 
Conclusion 
It has been observed that there was a significant correlation between MP number and PT and 
this could explain the short PT in PC patients and decrease of PT after surgical removal was 
mainly due to TF that related to MP.  The other interesting correlation is the significant 
correlation between the MP and angiogenic and cell invasion activity and this could indicate that 
the tumour could be responsible for different malignant mechanisms such as high procoagulant 
activity, cell invasion and angiogenesis and all synergistically might be responsible for the 
aggressiveness of PC.  Therefore the suggestion is that controlling these factors might affect the 
aggressiveness of PC cases.   
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CHAPTER NINE: HISTOPATHOLOGY  
9.1 Introduction  
This section involved the evaluation of the expression of TF, VEGF, VEGFR 1, VEGFR 2, EGF, 
EGFR 1 and CD 34 by immunohistochemistry on PC tissue and non cancerous lesions from the 
patients involved in the clinical study. Correlation was also studied between the level of 
expression of these markers with each other and with the serological/plasma findings from the 
invasion, angiogenesis, pro-coagulant activity and MP assay results previously described in 
chapters 7 and 8. 
 
9.2 Methodology 
9.2.1 H & E Staining  
All cases shown in Fig. 9.1 (24 cases) were stained with H & E.  For the rest of cases 
histopathological evaluation, including grading was taken from the existing histopathological 
reports.  Therefore, analysis of histopathologial grading was conducted in all malignant cases 
of group B (32 cases) shown in Fig. 5.3.   
9.2.2 Immunohistochemistry Staining  
The methodology and the optimization necessary for each of the markers have been 
described in section 2.214.  Immunohistochemistry staining was conducted for 24 cases, of 
which 10 were from group I, 8 from II, 3 from group E and 3 from group III.  Therefore a 
total of 21 malignant cases were available for the immunohistochemistry study (Fig. 9.1).  
The sections were stained in single batches at for each specific marker.   
All cases were reviewed and scored separately by two specialist pathologists (Dr Hussein 
Echrish and Dr Justin Cooke) in an anonymised manner.  The two pathologists then examined 
and discussed the sections together and agreed a score that was allocated to each sample as 
the definitive value.  Both investigators were ‘blinded’ to the results of the serology and 
plasma assays.  The purpose of immunohistochemistry is to visualise and localise the 
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expression of a particular protein in the tissue.  The histopathological sections of PC cases 
were classified as positive or negative for each factor.  Interpretation of positive versus 
negative expression is relatively subjective and due to this each immunohistochemically 
stained protein was allocated a scoring system based on relevant and validated methodologies 
published in the literature (Smith et al., 2010, Pryczynicz et al., 2009, Pryczynicz et al., 2008, 
Vermeulen et al., Khorana et al., 2007, Kajita et al., 2001, Weidner et al., 1991).   
 
 
 
 
 
 
 
Figure 9.1: Consort diagram sample studied by immunohistochemical analysis. 
The Islets of Langerhans give strong signals for many markers such as VEGF (Christofori et 
al., 1995, Kuroda et al., 1995) TF and EGFR (Feng et al., 2002).  Therefore in this study the 
Langerhans cells were used as an internal positive control.  Similarly, large blood vessels were 
used as an internal quality control for CD 34 staining.  In this project, only the cancer areas 
were scored and normal areas, if present, were disregarded.  Also, staining around the 
periphery of the section was often more intense; this is widely recognised as edge-artefact 
and these areas were also disregarded.  In the assessment of the positivity of the staining, 
the intensity of the stain as well as the coverage of the stain were both taken into 
consideration.    
There are differing degrees of positivity that were categorised and optimised for each marker 
to conform to the relevant published data.  In all cases the scoring system adopted was based 
on the existing literature. 
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9.3 Results.   
9.3.1 H & E Stain (whole cohort) 
All sections were stained with H&E.  For the 24 cases used in the correlative 
immunohistochemistry study H&E sections were reviewed and re-examined by two pathologists 
(Dr Hussein Echrish and Dr Justin Cook) and the grading according to cell differentiation agreed. 
For the cases that were not available for studying in this thesis grading based on the existing 
pathological reports was used. The histological categories were correlated on the grounds of 
differentiation grade with the serological data generated from these patients (Chapters 7 and 8).  
For statistical analysis, well and moderately differentiated cases were grouped together.   
 
The current study revealed that out of 32 cases in group B (all malignant cases), 20 (64.5%) 
were poorly differentiated.  This included 8 cases out of 16 of resectable malignant cases (group 
C and 12 cases out of 16 uresectable malignant cases (group D).  There was no statistical 
difference in grading between groups C and D (Chi square; p= 0.17).   
 
TF bearing MP in patients with poorly differentiated pancreatic cancer were significantly higher 
than those with well and moderately differentiated cancers [Median and IQR was 4604 (3580-
7596) vs. 2696 (2342-3922), p= 0.011, Mann Whitney test].  There was no other significant 
correlation between any of the other measured variables (PT, chemotaxis activity and angiogenic 
activity) with the histological grade of the cancers.   
 
No correlations between the stage of the resected cancers and the peripheral markers were 
undertaken due to the relatively small number of resected patients, which would make the 
statistical analysis unreliable (advice from Dr. Victoria Allgar, biostatistician).  
 
9.3.2 Immunohistochemical Correlation Study (Fig.9.1) 
Twenty four patients had complete immunohistochemical evaluation of the relevant tumour 
marker expression and distribution on the pancreatic cancer, the results of which were correlated 
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with circulating factors of biological activity of angiogenesis and invasion as described in the 
previous chapters (7 and 8).   
 
9.3.2.1 TF Expression  
The first marker to be evaluated was TF using a polyclonal rabbit anti human antibody.  For TF 
scoring, intensity was divided into 4 degrees: 0 when there was no staining, 1 when the staining 
was weak, 2 when the staining was moderate and 3 when the staining was of strong intensity.  
TF staining was considered “positive” when the staining intensity was moderate or strong and 
according to the proportion of expression in this group staining was sub-divided into 3 grades, 
grade I when the expression was 1-33%, grade II when the expression 34-66% and grade III 
when the expression was 67-100% (Khorana et al., 2007).  The total number of group B cases 
(PC and cholangiocarcinoma) was 21, of which 13 (62%) were positive for TF expression.  Five 
of these cases (38%) were grade I, 5 cases (38%) were grade II and 3 cases (23%) were grade 
III.  All 3 cases in control group III were TF negative.  The results of TF staining are summarised 
in Table 9.1, and typical examples of staining shown in Fig. 9.2.   
 
Table -9.1: TF expression. 
 
 
 
 
Note: Group B represents all malignant cases. Group III represents control group.
Group  Positive  Grade of Staining Negative  Total  
Grade I Grade II Grade III 
B 13 5 5 3 8 21 
III 0 0 0 0 3 3 
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Figure 9.2A: Representative example of PC case typifying ‘negative TF expression (x400).  This 
is a poorly differentiated tumour.  No staining is observed.  
 
Figure 9.2B: Representative low-power section (x40) typifies internal control process.  Islets of 
Langerhans showing positive TF expression (black circles) were used as a positive control.   
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Figure 9.2C: Representative example of high magnification (x100).  As can be seen 
immunohistochemistry staining of pancreatic tissue.  Islet of Langerhans (circle) with positive 
cytoplasmic TF expression (arrows).  
 
 
Figure 9.2D: Representative section typifying ‘positive cytoplasmic’ TF expression in a PC 
specimen (x400).  Black arrows represent examples of positive expression.  Yellow arrows 
represent examples of negative expression.  This was a moderately-poorly differentiated 
pancreatic adenocarcinoma. 
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9.3.2.2 VEGF Expression 
VEGF was the second marker evaluated on the PC tissue in this study using a polyclonal rabbit 
anti-human antibody.  For VEGF, the intensity was divided into four groups (0-4) similar to the 
TF.  Positive staining (medium and strong staining and the proportion of expression more than 
5%) was graded according to the proportion of staining into three grades: grade I when the 
proportion of the staining was 6-36%; grade II when the proportion of the stain was 37-68% 
and grade III when the proportion of the staining was 69-100% (Khorana et al. 2007).  The 
current study showed that 20 cases (95%) out of 21 of group B expressed VEGF.  All cases of 
group III were VEGF negative.  Table 9.2 and typical examples shown in Figure 9.3 demonstrate 
the staining findings for VEGF.   
 
Table 9.2: VEGF expression.   
 
 
 
 
Note: Group B represents malignant cases.  Group III represents pre-cancerous pancreatic 
lesions.   
Group  Positive  Grade  Negative  Total  
Grade I Grade II Grade III 
B 20 4 10 6 1 21 
III 0 0 0 0 3 3 
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Figure 9.3A: Representative example of negative VEGF Expression (x100).  No staining is 
observed.   
 
 
Figure 9.3B: Representative section of cytoplasmic VEGF positive expression (black arrows) in a 
poorly differentiated PC (x100).   
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Figure 9.3C: Representative example of well differentiated PC with positive VEGF expression 
(x400).  Black arrows represent examples for positive expression.  Yellow arrows represent 
examples of negative expression. 
 
9.3.2.3. VEGFR 1 Expression 
VEGFR1 was evaluated in the current study using a polyclonal goat anti-human antibody.  
Five per cent expression and less was considered negative.  The intensity of expression was 
again divided into four groups: none, weak, medium and high.  Weak and no staining were 
considered as negative in agreement with Smith et al. (2010) and Kajita et al. (2001).  The 
grades of scoring were then subdivided according to the proportion of the expression of 
VEGFR in a method similar to that used with VEGF (Khorana et al., 2007).  Medium and 
strong intensity were considered as positive.  The current study showed that sixteen cases 
(76%) out of 21 cases of group B expressed VEGFR 1, of which 10 cases (48%) were grade I 
and six cases (29%) were grade II.  Five cases (24%) were considered as negative.  Two 
cases out of three of control group III were positive.  Table 9.3 and typical examples shown 
in Fig. 9.4A-9.4B demonstrate the staining obtained with VEGFR1. 
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Table-9.3: VEGFR 1 expression by PC cases.   
 
Group  Positive  Grade Negative  Total  
Grade I Grade II Grade III 
B 16 10 6 0 5 21 
III 2 0 2 0 1 3 
 
  
Figure 9.4A: Representative section typifying negative cytoplasmic and nuclear VEGFR1 
expression of normal pancreatic tissue (x100). 
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Figure 9.4B: Representative section typifying ‘positive cytoplasmic’ VEGFR1 expression in a 
poorly differentiated PC specimen (x100).  Black arrows represent examples of positive 
expression.  Yellow arrows represent examples of negative expression.  
 
9.3.2.4 VEGFR 2 Expression  
The VEGFR2 expression of PC cases was evaluated using a goat polyclonal anti-human antibody.  
The scoring was the same as in VEGFR1 (section 9.3.3).  The current study showed that out of 
21 cases of group B, 13 (62%) expressed VEGFR 2; of which eight cases (62%) were grade I 
and five cases (38%) were grade II.  Out of the 10 cases in group I, five (50%) showed positive 
expression.  Six cases out of the eight (75%) in group II had positive expression of VEGFR 2.  All 
cases of the control group were negative.  Table 9.4 and typical examples shown in Fig. 9.5 
demonstrate the staining findings for VEGFR2.   
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Table 9.4: VEGFR 2 expressions of cases submitted to immunohistochemistry 
Group  Positive  Grade Negative  Total  
Grade I Grade II  Grade III 
B 13 8 5 0 8 21 
III 0 0 0 0 3 3 
 
 
Figure 9.5: Representative section typifying ‘positive cytoplasmic’ VEGFR2 expression in a 
poorly differentiated PC specimen (x100).  Black circles represent examples of positive 
cytoplasmic expression.  Red arrows represent examples of negative expression.   
 
9.3.2.5 EGFR 1 Expression  
EGFR1 expression of PC cases were evaluated using a polyclonal rabbit anti-human EGFR1 
antibody.  The scoring of EGFR 1 and EGF (9.3.2.6) was divided simply into positive and 
negative.  The result was considered negative if there was no staining or the intensity was weak 
and/or the proportion was less than 30%.  Expression was considered as positive if the intensity 
of the staining was moderate to strong and the proportion of expressing cells was ≥ 30% 
(Pryczynicz et al., 2009, Pryczynicz et al., 2008).  In the current study, out of 21 cases of group 
B, 12 (57%) were EGFR 1 positive.  Table 9.5 and typical examples shown in Fig. 9.6 
demonstrate the staining findings for EGFR1.   
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Table 9.5: EGFR 1 expression of cases that submitted to immunohistochemistry study.  
 
Group  Positive  Negative  Total  
B 12 9 21 
III 1 2 3 
 
 
Figure 9.6A: Representative section typifying negative cytoplasmic and nuclear EGFR1 
expression of in a poorly differentiated PC specimen (x100).   
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Figure 9.6B: Representative section typifying ‘positive cytoplasmic’ EGFR1 expression in a 
poorly differentiated PC specimen (x400).  Black circles represent examples of positive 
cytoplasmic expression.  Yellow arrows represent examples of negative expression.   
 
 
9.3.2.6 EGF Expression  
EGF on PC tissue was evaluated using polyclonal rabbit antihuman antibody.  Scoring was the 
same as that used for EGFR (section 9.3.2.6).  Seven cases out of 21 malignant cases of group B 
were EGF positive (33%).  All cases of control group III (3) were negative.  Typical examples 
(Fig. 9.7) demonstrate the staining findings for EGFR. 
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Figure 9.7: Representative section typifying ‘positive cytoplasmic’ EGF expression of a poorly 
differentiated PC specimen (x400).  Black circles represent examples of positive cytoplasmic 
expression.  Green arrows represent examples of negative expression.  
 
9.3.2.7 Microvascular Density 
MVD of PC cases was evaluated using a CD 34 polyclonal rabbit antihuman antibody.  The 
highest 3 neovascularised areas (discrete micro-vascular staining for CD 34) were identified 
under low power (100X).  The number of micro-vessels was counted in 400x magnification 
(Khorana et al., 2007, Vermeulen et al., 2002, Weidner et al., 1991).  The mean number of 
capillaries in three high power fields (PC cores) was considered as microvascular intensity.  
The current study showed that the mean number of new capillaries/ HPF (400x) of group B 
cases was 47±11 while that for control group III (four cases) was 17±6.  Typical examples 
(Fig. 9.8) demonstrate the staining results for CD 34. 
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Figure 9.8: Representative section typifying ‘positive cytoplasmic’ CD 34 expression of a 
poorly differentiated PC specimen (x400).  Red arrows represent examples of positive 
cytoplasmic expression.  
 
 
9.3.3 Correlation  
This part of the thesis undertook the chemotaxis activity, angiogenic activity (chapter 7), TF 
bearing MP number and pro-coagulant activity according to the positive or negative expression 
(chapter 8) of these tissue markers on the histopathological sections.  As the values were not 
normally distributed the non-parametric Mann Whitney test was used for statistical analysis.   
9.3.3.1 TF  
Firstly the number of TF bearing MP, pro-coagulant activity, chemotaxis activity and angiogenic 
activity were correlated with the positive or negative TF expression on the histological sections.  
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9.3.3.1.1. Correlation of TF Expression with TF Bearing MP:  
The number of TF bearing MP in immunohistochemically TF positive cases did not significantly 
differ from that of TF negative cases [median with IQR, 4585 (3479-8787) vs. (2251-5008, p 
0.065)].  Although it was statistically non significant, the p value was 0.06, which is tending 
towards the significance threshold (Fig. 9.9).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.9: The relation between TF expression and TF bearing MP/ µl.  The red bar 
represents the median.   
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9.3.3.1.2. Correlation of TF Expression with PT 
The pro-coagulant activity was evaluated according to positive or negative TF expression on the 
histological sections.  The current study showed that the median pro-coagulant activity of 
immunohistochemistry TF positive cases was significantly higher (low PT) than that of negative 
TF cases [median PT and IQR; 33 (33-37.5) S] vs. [36.5 (34.7-40) S, p= 0.029, Fig. 9.10)]. 
 
 
 
 
 
 
 
 
 
Figure 9.10: The relation between TF expression and PT.  The red bar represents the median 
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9.3.3.1.3. Correlation of TF Expression with Cell Invasion  
The chemotaxis activity of sera was evaluated according to the positive or negative TF 
expression on the histopathological sections.  The level of invaded AsPC1 cells from 
immunohistochemistry TF positive cases [median and IQR; 136 (115-147) did not differ 
significantly from the TF negative cases [136 (74-163), p= 0.9].   
 
9.3.3.1.4. Correlation of TF Expression with Angiogenesis 
The angiogenic activity (total length and number of gel capillaries and MVD) of sera was 
evaluated according to the positive or negative TF expression on the histological sections.  The 
current study showed that the total length and number of gel capillaries of 
immunohistochemistry TF positive cases were significantly higher than those found in negative 
cases [median and IQR, 8001 (4437-9407) and 40 (32-44) vs. 4489 (915-5678) and 32(15-36), 
(p= 0.01, 0.02) respectively] (Fig. 9.11-9.12).   
 
 
 
 
 
 
 
 
Figure 9.11: The relation between TF expression and total length of capillaries.  The red bar 
represents the median. 
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Figure 9.12: The relation between TF expression and total number of capillaries. The red bar 
represents the median 
 
The microvascular density of TF positive cases was higher than that of negative cases but the 
result was not significant [median and IQR (45 (17-47) vs. 37 (27-52), p= 0.07)].  
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Finally the correlation between the TF expression and VEGFR2 (angiogenic receptor) was 
evaluated.  Fourteen cases showed positive TF expression, of which 11 (79%) showed positive 
VEGFR 2 and 10 cases showed negative TF expression, of which three (30%) showed positive 
VEGFR 2 expression.  The difference was statistically significant (p= 0.01, Chi square, Fig. 9.13).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.13: The relation between TF and VEGFR 2 expression.  1- Positive TF expression.  2- 
Negative expression of TF.   
 
 
As a conclusion, correlation data appear to show that TF factor expression of the tissue is 
significantly correlated with the procoagulant activity of the plasma, angiogenic activity of the 
serum and the tissue.   
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9.3.3.2. VEGF  
In the same manner as for TF, these parameters were correlated with the positive or negative 
expression of VEGF on the histopathological sections.  However as mentioned in section 9.3.22, 
95% of PC cases showed positive VEGF expression; therefore further analysis of TF bearing MP, 
pro-coagulant activity, chemotaxis and angiogenic activity according to the grade of VEGF 
expression was added.  VEGF expression was simply divided into high VEGF expression (Grades 
II and III) and low VEGF expression (Grade I and negative expression).   
 
9.3.3.2.1. The Correlation of VEGF Expression on PC Tissue with TF Bearing MP and PT.  
The current study showed that the number of TF bearing MP and procoagulant activity of 
immunohistochemistry VEGF positive cases did not significantly differ from that of VEGF negative 
cases {[median number and IQR of TF MP/ µl was 4476 (2336-7300) vs. 1171 (181-6226), p= 
0.09], [median PT and IQR was [35 (31.5-38)] vs. [37 (32.5-40), p= 0.5)] respectively}.  
Furthermore, the TF bearing MP and PT of high VEGF expression cases did not significantly differ 
from those of negative VEGF expression cases.   
 
9.3.3.2.2. The Correlation of VEGF Expression on PC Tissue with Cell Invasion 
There were no significant changes in cell invasion, either between VEGF positive and negative 
cases or between high and low VEGF expression.  The median cell invasion number and IQR of 
positive VEGF was 136 (109-157) vs. 113 (62-155) of negative VEGF expression cases, p= 0.4).  
Furthermore, the median cell invasion number and IQR of high VEGF expression was 134 (107-
106) vs. 138 (90-57) of those with low VEGF expression, p= 0.8.   
 
9.3.3.2.3. The Correlation of VEGF Expression on PC Tissue with Angiogenesis 
There were no significant changes in angiogenic activity between VEGF positive and negative 
cases.  However, when cases divided into high and low grade of VEGF expression, the current 
study showed that there was a significant relation between the number of gel capillaries formed 
and MVD (tissue capillaries detected by CD 34) with the grade of VEGF expression.  The total 
number of capillaries (gel capillaries) of high VEGF expression cases was significantly higher than 
that of those with low expression [median and IQR, 40 (34-44) vs. 30 (14-35), p= 0.02, Fig 
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9.14].  Furthermore, MVD of VEGF positive expression cases were significantly higher than that 
of low expression cases [median number and IQR of new blood vessels detected by CD 34 was 
53 (46-59) vs. (16-37), p= 0.0009, Fig 9.15)].   
 
 
  
 
 
 
 
 
 
 
 
Figure 9.14: The relation between VEGF expression and total number of gel capillaries.  The 
bar represents the median.  
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Figure 9.15 The relation between VEGF expression and number of new blood vessels on 
tissue.  The bar represents the mean.   
 
The pro-coagulant activity of positive VEGFR2 cases was significantly higher than those of 
negative cases [median; 33.5 (31-36.2) vs. 36.5 (34-40.2), p= 0.05].   
 
There was no significant relation between TF bearing MP, chemotaxis activity and angiogenic 
with the positive and negative cases or high and low expression of VEGFR 1, VEGFR 2, EGFR and 
EGF on the histopathological section.  There were no significant differences in the procoagulant 
activities of positive and negative cases or between high and low TF, EGF and EGFR 
immunohistochemical markers. 
 
Table 9.6: Summary of immunohistochemical correlation with other indices.   
 
 
 
 
 
 
 
 
TF expression on the 
tumour   
Significant , p 
value 
VEGF expression on the 
tumour 
Significant, p value  
TF-bearing MP No , p= 0.065 TF-bearing MP No, p=0.09 
Procoagulant acttivity Yes, p=0.029 Procoagulant activity No, p=0.5 
Cell invasion NO, p=0.9 Cell invasion No, p=0.4 
Total number of capillaries Yes, p=0.01 Total number of capillaries Yes, p=0.02 
Total length of capillaries Yes, p=0.02 Total length of capillaries No, 0.06 
VEGFR2 on the tissue Yes, p=0.01 VEGFR2 on the tissue No, p=0.1 
MVD (CD 34) No, p=0.07 MVD (CD 34) Yes, p=0.0009 
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9.4. Discussion  
This study was designed to evaluate the correlation between TF bearing MP, procoagulant 
activity, chemotaxis activity and angiogenic activity with relevant immunohistochemical markers 
such as TF, VEGF (and receptors VEGFR1, VEGFR2) and EGF.  It was originally planned to 
include all cases as per the consort diagram (Fig 5.3).  However, it was only possible to study 24 
cases (Fig. 9.1) because of time constraints in obtaining the tissue from Pathology archives.   
 
Several studies correlate the TF expression on PC tissue with procoagulant activity; other studies 
correlate the TF expression with the MVD on the tissue.  To the best of the author’s knowledge 
this study is the first that correlates TF expression on the tissue with the serum and tissue 
angiogenic activity, plasma TF bearing MP and procoagulant activity.   
 
It is postulated that there is no TF expression on the exocrine part of the normal pancreas 
(Kakkar et al., 1995).  In the current study, Islets of Langerhans expressed TF and other 
markers in accordance with literature references (Feng et al., 2002, Kuroda et al. 1995, 
Christophori et al. 1999).  Therefore these Islets were used as an internal positive quality 
control.   
 
It has been reported previously that the high TF expression on PC (tissue) is associated with 
accelerated growth of the primary PC (Kakkar et al., 1999).  Several studies have shown positive 
expression of TF on PC tissue; some have shown a high percentage of PC cases expressing TF, 
such as the study of Khorana et al.(2007), who of 130 PC cases studied noted positive TF 
expression in 89%.  The cases in the latter study were preserved in 10% formalin and after 
processing were embedded in paraffin similar to the cases in our study.  Furthermore the scoring 
system was similar to that used in our study.  Moreover, Nitori et al. (2005) on paraffin 
embedded PC tissues, found that in a series of 113 PC cases, 12% showed negative TF 
expression, 42% showed weak TF expression and 42% showed strong expression of TF.  In the 
latter study the TF expression was considered as negative when the expression was 0%, weak 
when the TF expression was 1-24% and strong when the expression was ≥ 25.  Among these 
studies, the current study is the smallest but it yielded a high level of TF expression (62%).   
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Several studies (Khorana et al. 2007, Nitori et al. 2005, Kakkar et al. 1999) have been used to 
support the role of TF (on the tissue) in the hypercoagulable condition of PC cases and certainly 
in the current study the procoagulant activity of immunohistochemistry TF positive cases was 
significantly higher than that of TF negative cases [the median and IQR PT was 33 (33-37.5) vs. 
median was 36.5 (34.7-40), p= 0.029] corroborating the effect of cancer related TF on the 
procoagulant status of the host.  This result is supported by the finding of TF factor bearing MP 
of TF positive cases being higher than that of TF negative cases (p value was 0.06 which is 
tending towards significance).   
 
The aim of this work, however, has been much more than just to demonstrate the procoagulant 
impact of tissue derived from the cancer.  Following previous observation from co-investigators 
from our group (Maraveyas et al. 2010a) the serum of patients with PC, apart from having high 
levels of circulating TF, also demonstrated high levels of invasion activity.  A correlation was 
found between high TF and high invasion activity, it was hypothesised that TF could be a major 
factor driving this process, inhibition of which may have a therapeutic effect on pancreatic 
cancer.  Several studies postulated the relation between the TF expression on the tissue and the 
intratumour MVD as quantified by different endothelial markers in different studies e.g. CD34, 
CD31, von Willebrand factor or the correlation of TF expression with tumour angiogenic markers 
such as VEGF or VEGF 2.  Khorana et al. (2007) for example noted that 80% of 122 cases that 
showed TF also expressed VEGF.  Furthermore the authors in the latter study observed that the 
MVD of cases with high TF was higher than in those with low TF expression.  Nakasaki et al., 
(2002) reported that there was a correlation between TF expression and VEGF expression with 
MVD.  Furthermore, TF expression was correlated with the immunohistochemical distribution of 
von Willebrand factor (Guan et al., 2002).  However none of these and other studies correlated 
tumour TF with the serum angiogenic activity.   
 
In the current study, several lines of evidence are presented to show that TF expression on the 
tissue is significantly correlated with high angiogenic activity of sera and the tissue.  These 
include the significant correlation between tumour TF expression on tissue and the angiogenic 
activity of the serum [total length and number of capillaries] when HDMEC was treated with the 
serum.  Furthermore, out of 14 positive TF expressing PC cases, 13 of these (93%) showed 
positive expression of VEGF, and 79 % showed positive staining for VEGFR 2.  The VEGFR 2 
expression on positive TF cases was significantly higher than that of TF negative cases (p=0.01).  
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Furthermore, MVD of immunohistochemistry positive TF expressing cases was higher than that 
of negative TF expressing cases.  However the relationship only tended towards significance 
(0.07), possibly due to a relatively small cohort.  
 
Based on the result of the current study we provide support to the theory that tumour TF 
expression may be enhancing angiogenesis and the coagulable state either by its extracellular 
domains through clotting dependent mechanism (section 1.9.1) or through other indirect 
(clotting independent) mechanisms -such as induction of VEGF but that TF , the source of which 
based on the  current study (Chapter 7 and 8) is most likely from the tumour, should be viewed 
as a major link between the hypercoagulable state and angiogenesis.  
 
One of the hypotheses of the present study was that TF contributed to the serum induced 
invasiveness as measured by the ASPC1 assay optimised earlier in this work.  Although in the 
previous part of this work it was shown that circulating TF MP changes before and after surgery 
was closely correlated to the changes in the invasion assay, in the smaller sample of cases 
submitted to immunohistochemistry analysis, no difference in serum invasion properties was 
found between positive TF expression cases (in tissue) compared to negative TF expression.  If it 
had been possible to analyse the full cohort, some correlation may have been found.  A further 
explanation may be the necessity to use serum for the invasion assay. In this work it has been 
shown that most TF antigen dependant activity relates to TF bearing MP, which remains in this 
state only in fresh plasma and therefore some of the effect on invasion could be from small 
amounts of soluble TF.  The lack of correlation between histological TF and invasion raises the 
hypothesis that it is possible that the effects seen on the serum assay may be driven by other 
soluble factors not studied in this thesis.   
 
Another marker is tumour VEGF, which has shown different results from one study to another in 
the literature, possibly depending on the variety methodology and the scoring systems used.  In 
a series of 140 PC cases investigated using immunohistochemistry, 94% of cases showed 
positive VEGF expression and this expression was associated with MVD (Seo et al., 2000).  It has 
been reported in another study that in a series of 70 PC cases, 81% were VEGF positive.  
Niedergethmann et al. (2002) observed that VEGF expression is associated with MVD in PC.  
Ikeda et al., (1999) reported that in a series of 40 PC, 27 (68%) were immunohistochemistry 
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positive.  Furthermore, in a series of 124 cases of PC tissue studied by immunohistochemistry, 
the expression of VEGF was observed in 70 cases (56%) (Khorana et al., 2005).  Moreover, 
Khorana et al (2007) noted that in PC with high tissue TF, VEGF expression was higher than in 
cases with low TF expression (80% vs. 27%).   
 
Among these studies, although the number of cases submitted in the current study is the 
smallest, high expression of VEGF (95%) was noted as well.  Furthermore, in a total of 21 
immunohistochemical VEGF positive cases, 13 expressed TF (62%), 13 cases expressed VEGFR 2 
(62%), 16 (76%) expressed VEGFR 1 and 12 cases (57%) expressed EGFR.  The VEGF 
expression associated with microvascular density as the mean intra-tumour microvascular 
density of cases of high VEGF expression cases (grade II and III) VEGF was significantly higher 
than that of low VEGF expression cases (grade I and negative expression).  Furthermore, the 
total number of HDMEC capillaries (gel capillaries) from high VEGF expressing cases was 
significantly higher than in those with low expression.  This result was in accordance with the 
results of other studies such as that of Niedergethmann et al. (2002) and Seo et al. (2000).  
Furthermore, it has been reported in section 6.3.5 of the current study that there are several 
angiogenic molecules driving the PC; one of these is VEGF.  This result has been supported by 
the VEGF ELISA result as VEGF concentration of PC sera was significantly higher than that of 
control.  Furthermore, post-operative VEGF concentration was significantly lower than pre-
operative.  Therefore we also conclude that VEGF plays an essential role in angiogenesis in PC.  
This result is also supported by the in vitro results in chapter 3 as the maximum AsPC1 invasion 
was achieved when PC sera were supplemented with extra TF and VEGF.  Moreover, the 
maximal angiogenesis inhibition was achieved when HDMEC were treated with anti-VEGF, anti TF 
and suramin.  Therefore, there is strong evidence that VEGF on PC tissue and soluble serum 
VEGF play an essential role in the aggressiveness and pathogenesis of PC and the combined 
targeting of these molecules might provide the basis for a synergistic antiangiogenic strategy for 
the treatment of PC.   
 
Out of 21 malignant cases of group B that submitted to immunohistochemistry study, 12 (57%) 
were EGFR positive and 7 (33%) were EGF positive.  For EGFR1, the result of this study is in 
agreement with the results of other studies such as Lozano et al. (2011) and Pryczynicz et 
al.(2008).   
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Lozano et al. (2011) noted that in a series of 50 PC cases, 52% of them were positive for EGFR1 
1 2.  Pryczynicz et al. (2008) noted that in a series of 40 PC cases, 50% of them were positive to 
EGFR1.  In a series of 87 PC tissues, Yamanaka et al. (1993) noted that the expression of EGFR 
was 43% and the expression of EGF was 46 %.  Furthermore Pryczynicz et al.(2008) noted that 
in a series of 40 PC cases, 50% of them were positive to EGF.  EGF expression in this study was 
not in accordance with the results of other studies might be due to small number of cases 
involved in this study.   
 
Furthermore, it has been noted in the current study that immunohistochemistry VEGFR 2 positive 
cases were significantly correlated with pro-coagulant activity (PT).  This correlation might be a 
real correlation and therefore further study is indicated to prove that or it could be indirect 
correlation, because it has been noted that there was a significant correlation between the 
immunohistochemistry expression of TF and VEGFR2.   
 
In summary, this study has shown that high TF and VEGF expression in PC tumours are 
associated with high new capillary formation and MVD.  These results lead to the conclusion that 
these molecules and their pathways are both equally important in driving angiogenesis in 
pancreatic cancer and interrelated, raising the possibility of a dual targeting strategy of the 
angiogenesis pathway. 
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CHAPTER TEN: GENERAL DISCUSSION 
PC has the poorest prognosis of all adenocarcinoma in humans (Jemal et al., 2003) and it is one 
of the malignancies with the highest prevalence and incidence of TE in the western world  
(Khorana et al., 2007, Chew, et al., 2006 ).  There is accumulating evidence of a correlation 
between TF activity expressed by MP and (TE) in cancers (Tilley et al., 2008).  The suggestion 
that the tumour may be the main source of TF bearing MP comes from the demonstration that 
the number and activity of these parameters reduce substantially after successful surgery to 
remove a tumour (Zwicker et al., 2009, Tesselaar et al., 2007) and the fact that there is a 
correlation between the level of TF bearing MP activity and incidence of thrombosis in cancer 
(Khorana et al., 2007).  Recently, Lomberk (2010) also showed that rapid tumour growth was 
positively correlated with increased angiogenesis of the tissue.  Therefore, it has been suggested 
that the very poor prognosis of PC might be related to the enhanced procoagulant status of 
these patients strongly promoting the metastatic process (angiogenesis and cell invasion 
activity).  However, the biological link(s) between PC cancer, haemostasis, cell invasion and 
angiogenesis remain unclear.  These three indices may be driven by PC cells directly or may be 
related to the cancer’s effect on the microenvironment of the host tissues or the 
macroenvironment of the host itself or a combination of one or more of these.  Our hypothesis 
was that factors affecting the coagulation pathway (e.g. TF) directly attributed to the cancer also 
promote the mechanisms underpinning cancer invasion and metastasis and that the removal of 
the tumour should result in reversal of these abnormalities.   
 
The initial experiments were designed to optimise the methodology that would be used in the 
clinical study.  It was demonstrated that TF and VEGF increase AsPC1 invasion (section 3.4.4).  
Furthermore it was shown that the pro-coagulant activity of PC cells was correlated with cell 
invasion (section 3.2.5).  The blocking of TF on PC cell lines or in the serum, using a polyclonal 
anti-TF antibody, also decreased cell invasion (section 3.2.5).  In another series of experiments, 
it was shown that weight adjusted dalteparin is strongly associated with the reduction in the 
capacity of patient’s sera to stimulate cancer cell invasion in vitro, a key phenotypic feature of 
cancer progression and metastasis.  Therefor, it has been suggested that LMWH could ha a role 
prevention of tumour progression.  Based on these two findings the suggestion was that the 
coagulation and cell invasion activities in PC are driven by the tumour and similarly the trigger of 
the thrombosis relates to the biological properties of the underlying malignancy.  Furthermore, in 
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a complementary series of experiments it was shown that TF also enhanced angiogenesis (total 
length and number of capillaries on gel).  The in vitro evidence of the efficacy of the combination 
of anti-VEGF, anti TF and suramin to inhibit angiogenesis completely (section 4.5), needs to be 
supported by clinical research as this could represent a novel form of treatment following 
additional experimentation.    
 
In the clinical part of the study, 55 angiogenic markers were evaluated in the serum of a small 
series of PC cases pre- and post-operatively using an angiogenesis array kit.  This revealed that 
angiopoietin-1, PDGF-AA, PDGF-AB/PDGF-BB and VEGF were significantly decreased post-
operatively.  The result was supported by a significant decrease of VEGF concentrations of a 
cohort of 29 PC cases post-operatively when analysed by ELISA.  These data suggest that the 
processes are cancer specific and that pancreatectomy decreases the ratio of pro- to anti-
angiogenic factors and shifts the angiogenic switch towards “off”.  The validity of this hypothesis 
is further strengthened by the significant impact of pancreatectomy on the assays of invasion, 
angiogenesis, TF bearing MP, procoagulant activity and CD 14 bearing MP.  It was noted that the 
maximum serum chemotactic activity (AsPC1 cells motility) and HDMEC angiogenesis (total 
length and total number) was induced by the baseline serum of the patients with cancer (group 
B) and was significantly greater than that of the control groups.  Following resection there was a 
significant decrease in the induction of AsPC1 cell motility and HDMEC capillary formation by the 
post-operative sera in the cancer patients (Group C).  There was no such effect of resection 
either in the group III patients (precancerous pancreatic cases, control group) or in the group IV 
patients (chronic cholecystitis, control group).   
 
Flow cytometry was used to evaluate TF bearing MP (which might has a role in the pro-
coagulant, cell invasion and angiogenic activities) and CD 14 bearing MP (which might has a role 
in cell invasion activity).  A one stage PT assay was used to evaluate the procoagulant activity.  
The work presented here shows that there was significant increase in the number of TF bearing 
MP, number of CD 14 bearing MP and procoagulant activity in PC cases compared with the 
control group III (Precancerous pancreatic lesions).  Furthermore there was significant decrease 
of TF bearing MP, procoagulant activity and CD 14 bearing MP post-operatively.  This novel 
finding supports the author’s hypothesis that cell invasion, angiogenesis and haemostatic 
condition in PC patients are cancer specific, driven by the cancer and that removal of the cancer 
reverses them towards normal.  Although it seems that these three indices have different 
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signalling pathways, the current study suggests that there is a clinical correlation between them.  
The potential biological links between the coagulation pathways and molecules driving the cancer 
process have been discussed in the introduction and published recently (Echrish et al. 2011).  
Furthermore, it seems to be the tumour enhance incidence of the thrombosis and the 
hypercoagulability drives tumour progression.   
 
In the few cases studied, ELISA did not show a significant difference in MP activity from that of 
the control.  Furthermore, TF (measured by ELISA) of PC cases in the current study did not differ 
significantly from that of control group III and IV, and this indicates that not only TF activity but 
also TF antigen may also be affected by frozen storage.  MP activity is generally considered to be 
a good indicator of procoagulant activity, however in this thesis the MP activity ELISA was not 
used, as it emerged during this work that this test was unreliable.  The other possibility is that 
ELISA is an insensitive technique to measure TF antigen and MP activity.  As mentioned 
previously in section 8.6.1, this suggestion was supported recently by data presented at the 5th 
ISTH 2011, casting doubt on the discriminating ability of the ELISA technique, and it was 
reported that flow cytometry is both a more sensitive and precise method (conf reference 2 and 
3).   
 
Several studies postulated the relationship between the TF expression on the tissue and the 
intra-tumour MVD representing endothelial markers (Khorana et al., 2007 , Guan et al., 2002, 
Nakasaki et al., 2002).  However none of the published studies have correlated the tumour TF 
with the serum angiogenic activity or correlated tumour TF expression with all three biological 
indices (haemostasis, angiogenesis and cell invasion).  In the current study, 62% of group B 
(cancer patients) showed positive TF expression which was positively correlated with the 
procoagulant activity; furthermore the number of TF bearing MP of TF positive cases was higher 
than negative cases (p= 0.06).  This result tended towards significance and is hypothesised that 
these would become significant if further cases are studied.  Moreover there were several lines 
of evidence to show that TF expression on the tissue is significantly correlated with high 
angiogenic activity.  These include the significant correlation between tumour TF expression and 
the total length and number of capillaries when HDMEC were treated with serum.  Furthermore, 
the VEGFR 2 expression on positive TF cases was significantly higher than that of TF negative 
cases (p=0.01), and the MVD of positive TF expression cases was higher than that of negative 
TF expression cases; the latter relationship was tendeding towards significance (p= 0.07).  
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Furthermore, the current study revealed that TF expression by tissue was significantly associated 
with angiogenesis and procoagulant activity measured in serum and plasma respectively.  
Therefore the high PC procoagulant activity and angiogenesis activity described previously, could 
in large part be due to TF expression on the tumour with TF potentially  representing the link 
between them.   
 
It has been reported previously that tumour VEGF expression was significantly associated with 
MVD (Khorana et al., 2007, Khorana et al., 2005, Niedergethmann et al., 2002, Seo et al., 2000,  
Ikeda et al., 1999).  The current study revealed that VEGF was expressed in 20 malignant cases 
out of 21 (95%).  In a total of 21 immunohistochemical VEGF positive cases, 62% expressed TF, 
62% expressed VEGFR 2.  The VEGF expression associated with MVD of cases of high VEGF 
expression cases (grade II and III) VEGF was significantly higher than that of low VEGF 
expression cases (grade I and negative expression).  Furthermore, the total number of HDMEC 
capillaries (gel capillaries) of high VEGF expression cases was significantly higher than those with 
low expression.  To summarise the results: haemostasis, cell invasion, angiogenesis are cancer 
specific and the removal of the PC reverses them toward the normal.  These indices are 
significantly associated with each other and the link between them could be in part through the 
TF on the tumour; both TF and VEGF seem to be correlated with angiogenesis.   
 
As most soluble TF is MP dependent, targeting of MP might play an important role in the control 
of the tumour.  It has been reported that some conventional treatments (chemotherapy) can 
inhibit MP formation; i.e. both taxol and other vinca alkaloids, conventional chemotherapeutic 
medicaments not only inhibit cell division, but additionally will decrease MP release (Iero et al., 
2008, Wright 2008, Cheng et al., 2005, Jordens et al., 2005). Interestingly these agents have 
been classified as non specific anti-angiogenic molecules (Kerbel and Kamen 2004).  
Furthermore, the correlation between TF-MP and the procoagulant state have led to the 
commencement of a randomised trial. In this trial the usefulness of prophylactic enoxaparin (a 
type of low molecular weight heparin) was investigated in patients with pancreatic, lung, and 
colorectal cancer with elevated plasma TF microparticles.  Patients with high levels of circulating 
MP activity are randomised to anti-coagulation vs. no anti-coagulation (web reference 8).  
Moreover, it has been postulated that recombinant nematode (Ancylostoma caninum) 
anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor TF/FVIIa complex with 
novel anti-thrombotic activity (Zhao et al. 2009).  In addition to its anticoagulant activity it also 
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inhibits angiogenesis, primary and metastatic tumour growth in mice (Hembrough et al., 2003).  
Furthermore, in a randomised phase II trial, chemotherapy with and without PCI-27483 
(FVIIa/TF inhibitor, 1.2 mg/kg two times daily) was investigated.  The study is ongoing 
(Ramanathan et al. 2011).   
 
Work in this thesis has strengthened the concept of TF having an important role in angiogenesis 
together with VEGF. There are numerous targeting strategies of the VEGF pathway but the 
possibility is raised that dual anti-TF and anti VEGF strategies, in combination with 
chemotherapy, will have a more potent role in the treatment of PC; this hypothesis would need 
to be tested in a clinical trial.  Furthermore the results support the suggestion that the tumour 
might increase the hypercoagulability and the hypercoagulabilty might increase the tumour 
progression.   
 
Future Work  
The microarray work of the current study has demonstrated further molecules that may be 
involved in PC angiogenesis, such as angiopoitin-1, PDGF-AA, PDGF-AB/PDGF-BB and VEGF. One 
strategy would be to elucidate whether invasion and angiogenesis of the serum is prevented by 
blocking of these soluble factors using the in vitro experiments described herein.  Furthermore, 
although the result of the current study strengthened the data on the correlation of TF on 
angiogenesis and the VEGF/VEGFR pathway, it raises the idea that there may other molecules 
that also effect invasion. For this reason there may be more work to be done on other factors 
such as Ephrin, E-cadherin, IL-6 and IL-8 all of whom have shown to have potential activity in 
cell invasion and angiogenesis.  Following further testing in vitro it would then necessary to 
move to in vivo testing having correlated the effects of the combination of tumour attributes 
(invasion, angiogenesis and promotion of procoagulant activity) with specific markers.  These 
can be targeted specifically in vivo.   
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Appendix-A 
Patient Information Sheet for Pancreatic Cancer Patients Undergoing Whipple’s 
operation  
A Study of the Effect of Resection of Localised Pancreatic Cancer on Tissue-Factor 
Promoted Pathways of Thrombosis and Angiogenesis Markers 
Introduction 
You have been invited to take part in a research study.  Before you decide, it is important that 
you understand why the research is being done and what it will involve.  Please take time to 
read the following information carefully and discuss it with friends, relatives and your GP if you 
wish.  Ask us if there is anything that is not clear or if you would like more information.  Take 
time to decide whether or not you wish to take part.  Consumers for Ethics in Research (CERES) 
has published a leaflet called Medical Research and You.  This leaflet gives more information 
about medical research and looks at some questions you may want to ask.  A copy can be 
obtained from a doctor or nurse inviting you to take part or from CERES, PO Box 1365, London 
N16 OBW. 
 
What is the Purpose of the Trial? 
You have been diagnosed as having cancer of the pancreas, which is localised and can hopefully 
be removed.  If this is successful you may be offered more treatment called chemotherapy.  This 
will depend on the stage of the tumour and will only be accurately known after the pathologist 
has had a chance to study the tumour under the microscope.  Chemotherapy may be offered 
after surgery.  The aim of chemotherapy is to improve symptoms and to prevent or delay further 
complications of the cancer in your gut such as blockages.  Apart from the common symptoms of 
blockage of the gut and the bile system that this cancer causes, and which you may be 
experiencing, it can also have effects on the blood.  We and others have found that it increases 
the capacity of the blood to clot and to provide nutrients for cancer blood vessels.  All these 
effects promote the growth of secondary cancer and are collectively called ‘cancer promoting 
factors’.  To prove this we have designed a clinical study of these ‘cancer promoting effects’ 
before and after surgery and during and after chemotherapy.  We are studying two major groups 
of pancreatic cancer patients, those in which the surgeon can remove the tumour and those in 
which he cannot.  
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What will happen to me During the Trial? 
We would want to study the concentration of these ‘cancer promoting factors’ in your blood 
before and after surgery, and during and after chemotherapy if it is offered to you.  We 
therefore would like to ask your permission for some of your blood and for a small portion of the 
tumour to be used for research purposes. 
Before the operation, blood will be drawn for regular blood tests and at this point we would like 
to draw some more (about two-three tablespoons) for the study.  The surgeon will proceed with 
the operation as planned.  
About 4-6 weeks after the operation, by which time we think that healing is complete, and 
during a regular follow-up visit, we would like a further sample of blood of similar quantity as 
before the research.  If you are not offered chemotherapy this will be the end of the study for 
you. 
If you are offered chemotherapy a further two or three blood tests will be taken, depending how 
you are responding to treatment.  One blood test will be taken during chemotherapy, at around 
8-12 weeks when you would also be due a CT scan to assess the response of the cancer.  If your 
doctor decides to continue for a further 12 weeks a further blood test will be taken at 24 weeks 
of treatment at which point usually a break in the chemotherapy will follow.  About eight weeks 
into the break a further blood test will be required.  At this point, your involvement with the 
study finishes.  In the case, therefore, of you going on to chemotherapy, a total of five blood 
samples are required. 
 
Are There any Side Effects Associated with These Treatments? 
There should be no extra risks or side effects from the procedures as they will be part of the 
regularly planned tests that your doctors need before the surgery and to monitor your progress 
after the surgery and during and after chemotherapy. 
 
Are There any Other Extra Procedures? 
No extra procedures are planned.  The tissue will be taken from the tumour that has already 
been removed. 
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What are the Possible Benefits of Taking Part? 
No direct benefits to you are expected from this research.  The information we get from this 
study may help us to improve the future treatment of patients with pancreatic cancer. 
 
What if Something Goes Wrong? 
If you were harmed by taking part in this study, no special compensation arrangements exist.  
However, if you were harmed due to someone’s negligence, then you would have grounds for 
legal action.  Regardless of this, if you have any cause to complain about any aspect of the way 
you have been approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms are available to you. 
 
What if New Information Becomes Available? 
Sometimes during the course of a research project, new information becomes available about 
the treatment that is being studied.  If this happens, your research doctor will tell you about it 
and discuss with you whether you want to continue in the study.  If you decide to withdraw, 
your research doctor will make arrangements for your care to continue.  If you decide to 
continue in the study you will be asked to sign an updated consent form. 
 
Will my Taking Part in This Study be Kept Confidential? 
All information which is collected about you during the course of this research will be kept strictly 
confidential.  With your permission we will inform your GP of your participation in the study.  
Other than this, any information about you that leaves the hospital will have your name and 
address removed so you cannot be identified from it. 
 
Who is Organising and Funding the Research? 
This is a trial sponsored and funded by the NHS (HEYNHST). 
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What if I do not wish to Take Part or Change my Mind? 
You do not have to take part in this trial if you do not wish to do so.  If you decide to take part 
you are free to withdraw at any time.  In either case you do not have to give a reason for your 
decision and this will have no influence over your future medical care.  If you do decide to take 
part in this study you will be asked to sign a consent form. 
 
We would like to thank you for your attention so far and hopefully for your 
participation in this study.  Please feel free to ask your doctor any questions about 
the study or about any of the treatment described above.   
 
Please contact:  
Dr Anthony Maraveyas - Princes Royal Hospital.  
Telephone Number: 01482 676703.  
 
Dr Hussein Echrish – Biomedical Science Department, Hull University.  
Mobile Number: 07592271016. 
 
Please feel free to ask your doctors any questions about the study or about any of 
the treatments described above. 
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Note: There is a similar Patient Information Sheet for Pancreatic Cancer Patients 
Undergoing Bypass Operation with some modification in the paragraph on purpose of 
the trial (You have been diagnosed as having cancer of the pancreas, which is not localised and 
cannot be removed.  Your surgeon therefore has offered you bypass surgery to relieve the 
symptoms.  Chemotherapy may be offered after surgery.  The aim of chemotherapy is to 
improve symptoms and to prevent or delay further complications of the cancer in your gut such 
as blockages.  Apart from the common symptoms of blockage of the gut and the bile system that 
this cancer causes, and which you may be experiencing, it can also have effects on the blood.  
We and others have found that it increases the capacity of the blood to clot and to provide 
nutrients for cancer blood vessels.  All these effects promote the growth of secondary cancer and 
are collectively called ‘cancer promoting factors’.  To prove  this we have designed a clinical 
study of these ‘cancer promoting effects’ before and after surgery and during and after 
chemotherapy.  We are studying two major groups of pancreatic cancer patients, those in which 
the surgeon can remove the tumour and those in whom he cannot).  
 
There is a similar Patient Information Sheet for Patients Undergoing Laproscopic-
Cholecystectomy with some modification in the introductory paragraph and the 
purpose of the trial.   Introductory paragraph was (We would like to invite you to take 
part in a research study as a patient volunteer who does not suffer from cancer but has 
inflammation in the gall bladder or bile duct.  Before you decide, it would be much appreciated if 
you could read the following information to understand why the research is being done and what 
it involves. We are happy to explain anything that you do not understand.  Please take as much 
time as you need to read the information and make a decision).   
 
what is the purpose of the trial (The actual study is focused on a type of cancer of the gut 
called pancreatic cancer and we are studying changes in the patient’s blood that may cause the 
cancer to spread or to cause clots in the veins and the other vessels.  We are trying to evaluate 
these changes in patients with pancreatic cancer before and after surgery and before and after 
chemotherapy.  In order to establish the significance of these measurements it is essential that 
we also study patients that do not suffer from cancer but suffer from inflammation of the same 
organs that can be affected by this cancer and also individuals that are healthy and do not suffer 
from any inflammation.  This will allow us to compare the values and trends of the blood tests 
we are studying).  
265 
 
Appendix-B 
Consent Form for Patients Undergoing Whipple’s operation  
Title of project: A study of the effect of resection of localised pancreatic cancer on 
tissue–factor promoted pathways of thrombosis and angiogenesis markers.  
Name of the researcher: Hussein Echrish  
 
1. I confirm that I have read and understood the information sheet 
(dated..................................version ..................) for the above study.  I have had the 
opportunity to consider the information, ask questions and have these answered satisfactorily.  
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being affected.  
3. I understand that if I decide later to withdraw from the study, the blood samples taken 
from me and any analysis results will be destroyed and not included in the study.  
4. I understand that relevant sections of my medical notes and data will be collected 
during the study from regulatory authorities or from the NHS Trust, where they are relevant to 
my taking part in this research.  I give permission for these individuals to have access to my 
record.  
5. I agree to take part in the above study and give part of my tissue which is already 
resected by the surgeon.  
6. I agree to take part in the above study and give my blood for the purpose of this 
research.  
Signature of participant: ……..…..…………………………………………………………….. 
Full name of participant: ………….…………………………………………………………….. 
Date: ……………………………………………………………..…………………………………….. 
Signature of person taking data consent: ………….……………………………………… 
Full name: …………………………………………………………………………………………….. 
Date: ………………………………………………………………………..………………………….. 
Note: There is a similar consent form for patients Undergoing By-Pass Surgery, for 
patients Undergoing Laproscopic Cholecystectomy and for patients Undergoing 
Laproscopic Cholecystectomy.   
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Appendix-C 
Data Collection Form 
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